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Abstract 
A large number of infiltrating tumour-associated macrophages (TAM) is 
associated with a poor prognosis in many diverse cancers. In B-cell Non-
Hodgkin Lymphomas (B-NHL), the situation is less clear with conflicting reports 
on the clinical significance of the total number of macrophages. Comprehensive 
gene expression analysis of unsorted diagnostic biopsy specimens in the two 
most common B-NHL, Follicular Lymphoma (FL) and Diffuse Large B-cell 
Lymphoma (DLBCL), implies differential expression of macrophage genes 
between good and bad prognosis cases. The hypothesis being tested in this 
thesis is that macrophages play a fundamental role in the progression of B-
NHL. This functional significance may not be fully reflected simply by counting 
the numbers of macrophages, but rather by revealing the functional roles of 
TAM in lymphoma. 
In this thesis we critically review the clinical and laboratory evidence relating to 
lymphoma-macrophage interactions, before detailing our own laboratory 
investigations. The laboratory goal of this project is to establish proof-of-
concept, principally using mouse models, that TAM are partners in a lymphoma-
supporting microenvironment. A large number of diagnostic human biopsies of 
DLBCL were interrogated for evidence of correlations between macrophage 
numbers, phenotype, and tumour proliferation. Our subsequent experimental 
strategy was to manipulate the numbers and phenotype of TAM in a transgenic 
Myc-driven mature B-lymphoma transplanted to immune-competent hosts. The 
use of macrophage ablation with toxic liposomes, and with a transgenic host 
possessing drug-inducible macrophage-specific cell death, explored the impact 
of gross macrophage depletion in lymphoma. Adoptive transfer experiments 
investigated the impact of supplementary macrophages of different phenotypes. 
The administration of a colony-stimulating factor-1 receptor (CSF-1R) inhibitor 
was used to block the accumulation of TAM in growing lymphoma, and act as a 
pre-clinical model for this promising class of therapeutic agents. We detail the 
first reported use of CSF-1R inhibition in a model of B-NHL, and discuss the 
efficacy and consequences of this strategy. CSF-1R inhibition reduces 
circulating monocyte and TAM numbers and diminishes lymphoma growth.  
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 1 Macrophage Biology. 
1.1 Macrophage development. 
1.1.1 The traditional paradigm of macrophage development. 
The traditional and simplified paradigm of macrophage development is that 
haematopoietic stem and progenitor cells (HSPC) within the bone marrow give 
rise, via a common myeloid precursor cell, to monocytes (Fogg et al., 2006, 
Gordon and Taylor, 2005). Monocytes are released from the bone marrow and 
circulate throughout the blood and tissues of the lymphoid system. Monocytes 
migrate across endothelial barriers to enter tissues within which they 
differentiate into macrophages or dendritic cells (DC). A gradient of chemo-
attractive cytokines regulates this migration and differentiation, and so enables 
steady-state turnover of resident tissue macrophages, as well as rapid 
accumulation of macrophages in response to inflammation in the context of 
tissue damage, infection or malignancy.  
!
Figure 1 - The traditional and simplified scheme of macrophage development. 
 
The development of monocytes and macrophages is controlled principally by 
the cytokine colony stimulating factor-1 (CSF-1) and the recently discovered 
interleukin-34 (IL-34) (Lin et al., 2008), both acting on the CSF-1 receptor (CSF-
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1R). CSF-1R is expressed on early multipotent cells, mononuclear phagocyte 
precursors, monocytes, and macrophages (Sasmono et al., 2003, Dai et al., 
2002, Cecchini et al., 1994, Wiktor-Jedrzejczak and Gordon, 1996, Kondo et al., 
2000). CSF-1 has roles in both the development and function of monocytes and 
macrophages, as revealed by investigation of op/op mice, spontaneous mutants 
that lack a functional Csf-1 gene (Wiktor-Jedrzejczak and Gordon, 1996). The 
more severely compromised phenotype seen in CSF-1R deficient mice versus 
op/op CSF-1 deficient mice, strongly suggests that both CSF-1 and IL-34 
contribute to monocyte and macrophage development and function (Dai et al., 
2002).  
CSF-1R ligation contributes to several stages of monocyte lineage 
differentiation, as depicted in the figure overleaf, and the precise points that are 
critical is debated (Lenzo et al., 2012). Certainly, generation of common myeloid 
progenitors (CMP) from HSPC in the bone marrow is promoted by CSF-1R 
ligation, and depends upon the activity of PU.1, an E-twenty six (ETS) family 
transcription factor (Dakic et al., 2005, Iwasaki et al., 2005). CMP mature into 
granulocyte macrophage progenitor cells (GMP). GMP represent a critical stage 
at which pursuit of either a granulocytic or monocytic maturation is determined. 
The fate of such bipotent GMP cells depends upon the relative activities of 
different transcription factors. CCAAT/enhancer-binding protein alpha (CEBP!) 
is responsible for directing granulocytic differentiation by activating the zinc-
finger protein Gfi-1. Monocyte differentiation via a bone marrow resident 
macrophage dendritic cell precursor (MDP) stage is directed by PU.1, 
antagonising the actions of CEBP! (Zhang et al., 1997).  
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Figure 2 – Divergent monocyte and granulocyte differentiation pathways in the 
bone marrow. CSF-1R ligation promotes a monocyte fate at several stages, in 
cooperation with PU.1 transcription factor.  
CSF-1 dependent macrophage differentiation critically depends upon PU.1 
activation of downstream early growth response (EGR) transcription. The critical 
nature of PU.1 action in CSF-1R ligation induced monocyte differentiation is 
underlined by the fact that experimentally induced CSF-1R expression cannot 
rescue monocyte-macrophage differentiation in PU.1 deficient cells (DeKoter et 
al., 1998). Cells at the MDP stage lose Ly6G expression are committed to a 
monocyte or dendritic cell fate and have no granulocytic potential (Fogg et al., 
2006, Massberg et al., 2007, Jiang and Schwarz, 2010). Granulocytes maintain 
Ly6G expression but only express CSF-1R at very low levels (Sasmono et al., 
2007, Geissmann et al., 2008). Among CD11b positive cells in the blood it is 
only granulocytes that express Ly6G (Auffray et al., 2009). Monocytes are 
defined by CD11b expression and the absence of Ly6G expression, with 
variable expression of Ly6C, a GPI-anchored molecule also expressed by Ly6G 
positive granulocytes and subsets of NK cells (Auffray et al., 2009). In the 
following section we will discuss how variable expression of Ly6C appears to 
define functional subsets of monocytes in mice. 
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1.1.2 Monocyte subsets have distinct effector functions in both mice and 
humans. 
There is now a greater appreciation that monocytes are important immune 
effector cells in their own right, rather than simply being macrophage 
precursors.  Further, monocyte subsets have been identified that appear to be 
of distinct functional significance, and also developmental significance in terms 
of their potential maturation to resident tissue macrophages. In mice, two 
functional subsets of monocytes can be distinguished on the basis of surface 
expression of the Ly6C antigen, as depicted below in figure 3. 
!
Figure 3 - Monocyte subsets in mice. 
Ly6C+ monocytes are short-lived and termed “inflammatory” as they derive 
macrophages and DC in a variety of animal models of infection (Geissmann et 
al., 2003). These “inflammatory” monocytes produce high levels of tumour 
necrosis factor-alpha (TNF-#), reactive oxygen species (ROS) and nitrous oxide 
(NO), and are thus specialised to participate in acute inflammatory responses. 
Ly6C- monocytes can be distinguished by higher expression of the chemokine 
receptor CX3CR1 and the integrin LFA-1, and reduced expression of the 
chemokine receptor CCR2 and L-selectin (Wiktor-Jedrzejczak and Gordon, 
1996). In vivo studies reveal that they are functionally distinct from Ly6C+ 
inflammatory monocytes, possessing a prolonged half-life and a long-range 
crawling activity exhibited along the luminal surface of vascular endothelium.  
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This behaviour has given rise to the term “patrolling” monocytes, and it is this 
subset that appears to be recruited to sites of tissue damage and gives rise to 
resident tissue macrophages (Nahrendorf et al., 2007). An elegant example of 
this phenomenon has been observed in a myocardial ischaemia model, in 
which Ly6C- patrolling monocytes are recruited at a delayed phase after tissue 
injury, and increase their production of vascular endothelial growth factor 
(VEGF). Further evidence of the “wound healing” phenotype of “patrolling” 
monocytes has been gained by gene expression profiling of such cells in a 
model of Listeria monocytogenes infection, demonstrating similarities with the 
transcription profile of macrophages involved in wound healing (Steinman et al., 
1974, Auffray et al., 2007). The fact that DC can be generated in vitro by 
exposure of human and mouse monocytes to GM-CSF and IL-4 (Sallusto and 
Lanzavecchia, 1994, Geissmann et al., 2008) highlights the broad 
developmental potential of monocytes in vivo, that they are not committed to a 
macrophage fate.   
There is evidence for functional homologues of mouse monocyte subsets in 
humans. Cros et al. performed characterisation of human monocytes by surface 
marker expression, gene expression pattern and functional transfer studies, and 
were able to further elucidate distinct monocyte populations based upon earlier 
observations (Ziegler-Heitbrock, 1996) that surface expression patterns of 
CD14 and CD16 varied among human monocyte functional groups. They 
demonstrated that CD14+CD16- (classical) and CD14+CD16+ (intermediate) 
monocytes resembled Ly6C+ mouse “inflammatory” monocytes, and that a 
minority population (7%) of CD14dimCD16+ (non-classical) monocytes behaved 
in a manner similar to “patrolling” mouse monocytes, had attenuated 
inflammatory cytokine responses to lipopolysaccharide (LPS), toll-like receptor 
(TLR) 4 or TLR2 agonists, and were unable to present antigens to T-cells. 
Despite exhibiting a broadly anti-inflammatory phenotype in their steady state, 
CD14dim CD16+ monocytes could be stimulated to elicit a pro-inflammatory 
repertoire of TNF-#, IL-1 and chemokine ligand 3 (CCL3) in response to viruses 
and nucleic acids. A pathway involving TLR7/8 ligation, myeloid differentiation 
primary response gene 88 (MYD88) and mitogen-activated protein kinase 
kinase (MEK) activation is responsible for this phenomenon, closely paralleling 
the behaviour of “patrolling” monocytes in the mouse, which can also be 
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stimulated by TLR7 agonists. Experimental evidence of some functional 
equivalence with mouse monocyte subsets, whilst intriguing, leaves many 
crucial questions as yet incompletely answered. The significance of human 
monocyte subsets in disease, particularly in cancer, is poorly understood, and 
the potential for therapeutic benefit from manipulating the balance of human 
monocyte subsets remains to be demonstrated.!!
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1.1.3 Monocyte subsets may represent a developmental series. 
Not only is evidence emerging of monocytes with distinct functions, but also that 
these subsets may well have very different fates as either inflammatory or 
wound healing macrophages. Moreover, “inflammatory” and “patrolling” 
monocytes may, in certain circumstances, represent not just a functional 
classification, but also an important developmental series in relation to each 
other. Evidence for this being a potential maturation series comes from adoptive 
transfer experiments. Bone marrow Ly6C+ monocytes are able to move 
between the bone marrow and blood compartments, and eventually lose Ly6C 
expression (Varol et al., 2007, Yrlid et al., 2006). As will be discussed later in 
much greater detail, experiments with CSF-1R inhibition demonstrate that this 
strategy can block the maturation of Ly6C+ monocytes into Ly6C- monocytes, 
and so reduce the accumulation of mature resident tissue macrophages. 
However, contrary to this view, neither antibody mediated depletion of Ly6C+ 
monocytes nor a genetic defect (Feinberg et al., 2007, Alder et al., 2008, 
Scatizzi et al., 2006, Mildner et al., 2007) in Ly6C positivity (Kruppel-Like Factor 
4 knockout in haematopoietic cells) appears to abrogate the ability to form 
Ly6C- monocytes. It remains unclear as to whether this phenomenon 
represents an absence of, or a redundancy in, the Ly6C+ to Ly6C- monocyte 
maturation pathway. The developmental origin of resident tissue macrophages 
also appears to be more complex and diverse than was hitherto appreciated, 
seemingly varying between different tissue-specific resident macrophage 
populations. This insufficiently understood topic is an area of active research.   
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1.1.4 Local extra-medullary proliferation contributes to renewal and 
expansion of resident tissue macrophages. 
Evidence is accumulating that in certain circumstances resident tissue 
macrophages are able to proliferate in situ, and so obviate the need for 
monocyte recruitment and maturation to replenish or supplement their numbers. 
Constitutive egress and circulation in the blood of bone marrow resident HSPC 
(Wright et al., 2001) has been shown to enable accumulation of tissue-resident 
innate immune myeloid cells through local proliferation of HSPC in response to 
TLR agonists (Massberg et al., 2007). Specifically in relation to macrophages, 
this phenomenon has been described in the mouse brain (Mildner et al., 2007, 
Ajami et al., 2007) and epidermis (Chorro et al., 2009), tissues with limited 
potential for rapid trafficking of monocytes within which the postulated 
contribution of this proliferation is to populate tissue with macrophages during 
organogenesis (Davies et al., 2011) and then at a much lower rate to maintain 
tissue macrophage populations during normal homeostasis. A more recent 
study describes rapid bursts of proliferation of resident macrophages during 
Th2-type inflammation induced by parasitic infections (Jenkins et al., 2011). 
Davies et al. observed not only a proliferative burst of resident peritoneal 
macrophages during an episode of acute-resolving infection, but also that the 
accompanying peripheral monocytosis made only a negligible contribution to 
the peritoneal resident tissue macrophage accumulation. The authors theorized 
that self-sustenance by local proliferation of mature tissue macrophages “might 
represent a general paradigm and may not simply be restricted to tissue that 
has limited or controlled leukocyte access.” This certainly challenges the 
traditional paradigm of tissue macrophage numbers increasing during 
inflammatory processes due to recruitment of bone marrow generated 
monocytes. Further, that Jenkins et al. observed resident macrophage 
proliferation during Th2-type inflammation and under the control of IL-4 raises 
the prospect that the accumulation of tumour-associated macrophages (TAM) in 
a growing tumour, in which similar conditions prevail, might also be partly due to 
local macrophage proliferation.    
Human macrophage proliferation has been observed in the setting of renal 
pathology (Isbel et al., 2001, Yang et al., 1998). Although evidence of 
proliferation of physiological resident macrophages in humans has not yet been 
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published, we do know that human monocytes can proliferate (Cheung and 
Hamilton, 1992) and that they regulate cell cycle genes under the control of 
CSF-1 (Martinez et al., 2006). The significance of local macrophage 
proliferation to the accumulation of human TAM is unclear, although it is 
interesting to speculate that this process might also be governed by CSF-1, and 
so be susceptible to CSF-1R inhibition. !
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1.2 Macrophages have vital roles in embryology and 
homeostasis. 
Macrophages are involved in wound healing, tissue repair, iron metabolism, 
bone remodelling, graft-versus-host reactions, acute and chronic inflammation 
and cancer-related inflammation. These roles are mainly achieved by 
performing the cellular processes of phagocytosis, cytokine production and 
antigen presentation to variable extents at different times in different tissues. 
Aside from their roles in innate immunity, macrophages function as regulator 
and effector cells in both humoral and cell-mediated immune responses 
(Martinez et al., 2006). Upon phagocytosis, macrophages degrade proteins and 
process antigens for presentation by major histocompatability (MHC) molecules 
(Hume, 2008c), so T-cells can recognize the presented substances as ‘foreign’. 
When activated in an immune response, macrophages can acquire microbicidal 
and tumouricidal activities involving reactive-oxygen species and reactive 
nitrogen metabolites.  
Macrophages have the potential to orchestrate the tissue microenvironment, 
contributing to very many aspects of physiological homeostasis. During 
embryonic development, macrophages play an important role in scavenging 
dying cells and clearing areas of apoptosis, and thereby contribute to 
organogenesis (Hume, 2008a). 
Under normal physiologic conditions, host tissues exist in a homeostatic 
balance with cells of the innate and adaptive immune systems. Acute and 
transient insults usually produce an acute inflammatory response, which 
resolves with healing of normal host tissues. Malignant cells have the potential 
to elicit an unresolved chronic inflammatory response.  
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1.3 Macrophages participate in cancer-related inflammation, 
demonstrating opposing functions in different settings 
and diseases. 
A persistent population of malignant cells acts as a chronic inflammatory 
stimulus, exciting an ongoing and unresolved immune response, in which the 
normal homeostatic balance is not regained. Solid tumours consist of neoplastic 
cells, non-malignant stromal cells and migratory haematopoietic cells. In 1863 
Virchow noted leukocytes in neoplastic tissues and made a connection between 
inflammation and cancer (Balkwill and Mantovani, 2001). Deidier observed a 
positive correlation between infection and remission of malignant disease in the 
eighteenth century (Garay et al., 2007). We now appreciate that there are 
indeed common pathways of inflammation shared by responses to infection and 
to malignancy. 
Complex interactions between the different cell types in the malignant 
microenvironment regulate inflammation, tissue remodelling, tumour growth, 
progression, metastasis and angiogenesis (Sica and Bronte, 2007, Murdoch et 
al., 2008). The tumour microenvironment consists of an inflammatory 
component, and activation of the innate immune system appears to contribute 
to the progression of cancer (Sica and Bronte, 2007, Mantovani et al., 2008b). 
Plasticity of macrophage function is well described, and evidence suggests that 
TAM are involved in complex chemical cross talk with tumour cells and other 
cells of the tumour microenvironment (Mantovani et al., 1992, Hagemann et al., 
2004, Sica et al., 2000a). This interplay has the potential to modulate 
macrophage phenotype, which may in turn affect the ability of the tumour to 
thrive.  
In several carcinomas (breast, prostate, endometrium, bladder, kidney, and 
oesophagus) an abundance of TAM is associated with a poor prognosis 
(Tsutsui et al., 2005, Lissbrant et al., 2000, Ohno et al., 2004, Hanada et al., 
2000, Hamada et al., 2002, Koide et al., 2004). There is overwhelming evidence 
for macrophages as obligate partners in cancer progression; not only from 
association studies, but also from experimental cancer models showing that 
ablation of macrophage function, or inhibition of their infiltration, inhibits growth 
and metastasis (Lin et al., 2001). Such compelling evidence is incomplete in 
relation to B-NHL and is considered later. An abundance of macrophages in 
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colon and gastric carcinomas, and melanoma is associated with improved 
clinical outcome (Forssell et al., 2007, Ohno et al., 2003, Piras et al., 2005). As 
such, it is important not to assume a pro-tumoural role of macrophages in B-
NHL. Rather, it is necessary to study the functional consequences of 
manipulating interactions between macrophages and malignant B-cells in the 
laboratory. 
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1.4 Phenotypic diversity underlies the broad spectrum or 
roles played by macrophages in cancer. 
Macrophages display enormous variation in phenotype, with specialised 
populations seen in different tissues. This variation in phenotype of resident 
tissue macrophages with a common origin, which can to a certain extent be 
distinguished by the expression of cell surface markers, provides supporting 
evidence for the plasticity of macrophage phenotype. Well-described 
specialised resident tissue macrophages include Kuppfer cells (liver), 
osteoclasts (bone), microglia (brain), histiocytes (connective tissue) and 
alveolar macrophages (lung). The anatomical and temporal variation in 
macrophage phenotype is influenced by activation signals from the surrounding 
microenvironment and can be strongly regulated by bacterial lipopolysaccharide 
(LPS) and the products of T-lymphocytes, natural killer (NK) cells and tumour 
cells, in particular interferon-gamma (IFN-!) and a cytokine network involving IL-
4, IL-10, IL-12, and IL-13, as well as tissue oxygen tension and pH. 
Macrophage activation states have been described in terms of M1 or M2 
phenotype, emulating the Th1/Th2 paradigm, and in vitro data has established 
that peripheral blood monocyte-derived macrophages can be polarised into M1 
or M2 phenotypes. This has been extensively validated as an in vivo 
phenomenon for M1 macrophages, which are activated by IFN-! or by bacterial 
cell wall derived LPS, and predominate during acute inflammatory responses. 
1.4.1 M1 macrophage phenotype. 
M1 macrophages produce large quantities of pro-inflammatory cytokines, 
express high levels of MHC molecules, and are implicated in the killing of 
pathogens and tumour cells (Gordon and Taylor, 2005). It was already apparent 
in the early 1960s (Bennett et al., 1963, Old and Boyse, 1964) that peritoneal-
harvested macrophages from mice could be cytotoxic to tumour cells, and that 
this was augmented by exposure to certain stimulating agents such as starch, 
and by opsonising tumour-specific anti-sera. Macrophages harvested from the 
peritoneal cavity following the injection of inflammatory stimulants were found to 
have increased cytoplasm volumes and increased rapid spreading ability 
(North, 1969) hinting at phenotypic plasticity. In 1971 (Alexander and Evans, 
1971) it was recognised that exposure to LPS (and also to DNA) rendered 
macrophages cytotoxic, so describing what is now known as the M1 or 
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”classically activated” macrophage phenotype.  
 
!
Figure 4 - Features of M1 phenotype macrophages, activated by bacterial LPS. 
1.4.2 M2 macrophage phenotype. 
M2 macrophages behave in a “wound-healing” manner, and can also be 
described as “alternatively activated” (Gordon, 2003). M2 macrophages 
moderate the inflammatory response and can promote angiogenesis and tissue 
re-modelling (Murdoch et al., 2008, Mantovani et al., 2008a). Stimulation with 
IL-4 (Becker and Daniel, 1990, Stein et al., 1992) from CD4+ T-cells (De Nardo 
et al., 2009b), IL-13 for example from NK T-cells (Sinha et al., 2005), 
transforming growth factor-" (Flavell et al., 2010) (TGF-"), IL-10 (Sica et al., 
2000b, Wong et al., 2010)m! immune-complexes, glucocorticoid hormones, and 
agonists of certain TLR or the IL-1R, drives macrophages towards an M2 
phenotype (Mantovani et al., 2004b).  
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Figure 5 - Features of M2 phenotype macrophages. 
A window on the true complexity of in vivo conditions and subsequent 
macrophage phenotypes is provided by literature describing multiple subsets of 
M2 macrophages (Martinez et al., 2008, Biswas and Mantovani, 2010) and 
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specialised subsets seen in vascular disease (Gleissner et al., 2010). The 
tumour microenvironment appears to ‘educate’ TAM towards a tumour-
promoting M2 phenotype (Pollard, 2004), but the mechanisms underlying this 
phenomenon are not fully understood. Isolation of TAM from experimental 
tumours, and determination of their gene expression, provides further evidence 
that TAM develop an immunoregulatory phenotype (Biswas and Lopes de 
Faria, 2006, Ojalvo et al., 2009, Pucci et al., 2009). TAM show considerable 
variability, yet mainly display an IL-10high, IL-12low phenotype with expression of 
mannose receptor (MR/CD206) and scavenger receptor class A (SRA/CD204) 
(Mantovani et al., 2002), and approximate an M2 phenotype. Increased 
expression of MR appears to be a feature of M2 macrophages that is 
particularly common in TAM, and may have important roles in the progression 
of some types of tumour. MR is able to mediate phagocytosis in an actin-
dependent manner (Aderem and Underhill, 1999, Kruskal et al., 1992), and so 
contribute to clearance of apoptotic tumour cells without exciting a 
proinflammatory cytokine response. Similarly, MR participates in the removal of 
lysosomal hydroxylases and neutrophil derived myeloperoxidase, so limiting 
tissue damage and moderating elements of the acute inflammatory response 
(Shepherd and Hoidal, 1990, Stahl et al., 1980). High levels of secreted IL-10 
have been found in follicular lymphoma (FL), diffuse large B-cell lymphoma 
(DLBCL) and Burkitt lymphoma (BL) (Ogden et al., 2005, Voorzanger et al., 
1996). IL-10 in the tumour microenvironment seems to direct aspects of the M2 
phenotype through inhibition of macrophage nuclear factor-kappa B (NF-%B) 
signalling, leading to reduced production of IL-12 and attenuated anti-tumoural 
activity (Sica et al., 2000b), and IL-10 is itself subsequently produced as a 
hallmark of the M2-like TAM phenotype.  
The impact of macrophages may not simply be a reflection of their phenotype. 
The activation phenotype of TAM must be seen within the context of the whole 
tumour microenvironment. There is compelling in vitro evidence that not only is 
activation of TAM required to promote tumour growth, but that defects in the 
regulation of such activated macrophages might also be necessary. By 
observing immune synapses formed between natural killer (NK) T-cells and 
macrophages, Nedvetzki and colleagues (Nedvetzki et al., 2007) showed that 
macrophagelytic synapses developed between these cell types if the 
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macrophages were in a state of activation. This indicates a surveillance role for 
NK T-cells in eradicating activated macrophages and reflects important 
interactions between immune cell populations. Defects in this auto-regulation of 
activated macrophage numbers may contribute to tumour progression. 
Moreover, as a therapeutic approach, NK T-cells might be directed to eradicate 
TAM. As such, the functional significance of macrophage activation is likely to 
depend on many factors in addition to macrophage phenotype alone, in 
particular the function of other immune cells. This project aims to focus on the 
role of TAM in lymphoma, but will also consider the direction and composition of 
the overall immune response to this disease, and how this relates to features of 
the macrophage population.  
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1.5 Criticism of the M1-M2 model of macrophage phenotype. 
Whilst classification systems based upon function are useful when trying to 
understand macrophage biology, they are to a certain extent artificial 
distinctions, with discrete phenotypic subsets probably not existing as separate 
populations in complex and dynamic multi-cellular in vivo systems. Attempts to 
simplify macrophage phenotype further by interrogating populations for the 
presence of absence of M1 or M2 markers are fraught with the potential for 
making misleading assumptions, given that individual markers do not appear to 
correlate well with each other when analysed across large data sets, or in 
response to different stimuli (Gordon and Martinez, 2010, Mabbott et al., 2010). 
Multiple diverse cytokines and adhesive interactions with surrounding cells and 
the extracellular matrix influence macrophage phenotype. The specific 
composition of the activating signal leads to a variety of macrophage functions, 
which differ significantly. Macrophage phenotype appears to be very stimulus 
specific, and not stereotyped or binary in response to different stimuli, as might 
be erroneously assumed to be the case if misinterpreting the M1/M2 schema. 
This schema remains, nonetheless, a useful tool for descriptive purposes and 
laboratory testing of broad principles of macrophage phenotype.    
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1.6 Macrophages exhibit phenotypic plasticity that may be 
harnessed therapeutically in cancer. 
Macrophage plasticity of phenotype appears to extend to the ability, once 
activated, to switch phenotypes under certain conditions (Biswas and 
Mantovani, 2010). Arnold et al. found in mice that CX3CR1low Ly6C+ 
inflammatory monocytes recruited after skeletal muscle injury switched to a 
CX3CR1high Ly6C- anti-inflammatory macrophage phenotype on entering 
muscle tissue, postulated to support myogenesis (Arnold et al., 2007). 
Monocytes and macrophages were tracked first by ablating existing phagocytes 
with injection of toxic liposomes, followed by labelling newly formed 
monocyte/macrophages with fluorescent latex beads. In vitro studies showed 
that inflammatory macrophages began secreting TGF-"1 after ingestion of 
myocyte debris, and that inhibition of phagocytosis with cytochalasin D or 
recombinant Annexin V prevented the phenotypic switch. The specific 
components of the myocyte debris responsible for this phenomenon were not 
identified. Additionally, experiments with tissue-specific conditional gene 
knockout (Hagemann et al., 2008) and also with small molecule inhibitors (Fong 
et al., 2008) have demonstrated that inhibition of macrophage NF-%B activity 
has the potential to switch M2 to M1 phenotypes, providing both a proof-of-
concept for the plasticity of mature activated macrophage phenotype, and also 
a possible therapeutic strategy. A tantalising glimpse of what might be possible 
in humans has been provided by pre-clinical studies with human cells, 
investigating the therapeutic use of IFN-! to reverse the immune-suppressive 
phenotype of TAM (Duluc et al., 2009). TAM isolated using CD14+ magnetic 
beads from ovarian cancer ascites were of a M2-like phenotype. Subsequent 
publications identified that high levels of IL-6 and leukaemia-inhibitory factor 
(LIF) in ovarian cancer ascites primed monocytes to consume the high levels of 
CSF-1 also present and so mature in to M2-like TAM (Duluc et al., 2007, 
Jeannin et al., 2011). When exposed to IFN-! they recovered a M1-like 
phenotype with IL-10low IL-12high CD86+ expression, able to induce enhanced 
proliferation of CD4+ lymphocytes and enhanced cytotoxic function of CD8+ T-
cells, with reduced production of VEGF and matrix metalloproteinase 9 (MMP9). 
Peripheral blood mononuclear cell (PBMC) fraction derived monocytes from 
healthy donors cultured in ovarian cancer ascites with the addition of 
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supplementary IFN-! tended to an M1 rather than M2 TAM phenotype. 
Consistent with this is the observation from a phase III clinical trial of first-line 
chemotherapy for ovarian cancer with cisplatin and cyclophosphamide showing 
that the addition of seven sub-cutaneous injections of IFN-! during each of a 
maximum of six 28-day cycles was associated with prolonged progression-free 
survival (Windbichler et al., 2000). !
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1.7 Tumour cells recruit and activate monocytes towards a 
pro-tumoural phenotype.  
Owing to plasticity of function, resident tissue macrophages are able to 
contribute to tumour initiation and propagation by switching to a pro-tumoural 
M2-like phenotype. However, in a growing tumour, it appears as though the 
bulk of the TAM population derives from immature monocytes recruited from the 
circulation, which subsequently undergo maturation to specialised 
macrophages within the tumour microenvironment. This phenomenon has been 
observed and extensively studied in animal models of cancer such as the 
polyoma middle T oncoprotein (PyMT) induced mouse mammary tumour (Lin et 
al., 2006, Lin et al., 2001, Pollard, 2009, Wyckoff et al., 2007) and strikingly in 
orthotopic tumours in the transgenic ‘MacGreen’ model, in which cells of the 
monocyte/macrophage lineage express an enhanced green fluorescent protein 
(Sasmono et al., 2003). Similar patterns have been detected in human 
endometrial and breast cancers (Lewis and Pollard, 2006, Smith et al., 1995). 
Macrophages are recruited in the presence of CSF-1 (De Nardo et al., 2009a, 
Hamilton, 2008, Lin et al., 2001) synthesized by tumour cells. In humans, the 
greatest concentration of CSF-1 protein expression and of macrophages is 
found at the tumour invasion edge (Lin et al., 2001, Scholl et al., 1994, Smith et 
al., 1995), supporting the importance of this relationship in humans.  
Intimate cooperation between macrophages and tumour cells has been 
observed in a mouse model of breast cancer, such that tumour-derived CSF-1 
induces macrophage migration and secretion of epidermal growth factor (EGF), 
which in turn activates tumour cell migration (Wyckoff et al., 2004). This 
mechanism neatly links macrophage recruitment to tumour spread. In this case, 
as in the majority of cancers and cancer models studied, the CSF-1 receptor is 
restricted to monocyte/macrophages, and the EGF receptor to tumour cells. A 
similar reciprocal interaction has been described between human monocytes 
and human pancreatic cancer cells in vitro (Solinas et al., 2010). Exposure of 
PBMC-derived monocytes to tumour conditioned media (TCM) from 16 cancer 
cell lines representing ovarian, colon and pancreatic cancers, showed that TCM 
from two of the pancreatic cancer cell lines induced differentiation of monocytes 
to macrophages of an M2-like phenotype. Ligation of the CSF-1R with CSF-1 
was critical to this process, as demonstrated by blocking with anti-CSF-1R 
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antibodies. In addition to up-regulating several genes implicated in the 
organisation of the extra-cellular matrix (ECM), induction of migration-
stimulating factor (MSF) in TCM-exposed monocytes was found at a gene 
expression and protein level, and was found to promote increased tumour cell 
migration across a transwell chamber membrane. Elevated MSF levels have 
previously been reported in patients with breast cancer (Picardo et al., 1991), 
but not in healthy individuals or non-malignant adult cells (Schor et al., 1988), 
and administration of labelled anti-MSF antibodies in a mouse xenograft of 
oesophageal cancer showed localisation to tumour vasculature and produced a 
reduction in tumour mass (Hu et al., 2009).  !
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1.8 Links between malignant B-cell apoptosis, macrophage 
recruitment, activation and anti-tumour immune 
responses. 
CSF-1 is certainly not the only monocyte chemo-attractant. CCL2 is well 
described as a chemo-attractant for monocytes and macrophages, in health, 
inflammation and in cancer (Mantovani et al., 2004b, Mantovani, 1994, Loberg 
et al., 2006, Mantovani et al., 2004a, Loberg et al., 2007). CCL2 levels are 
raised in the blood of patients with non-haematological cancers (Bingle et al., 
2002, Mantovani et al., 1992) and this cytokine has more recently been 
implicated in an amplification loop with IL-6 resulting in increased survival and 
acquisition of pro-tumoural features of human monocytes and macrophages 
(Roca et al., 2009a). Human PBMC derived monocytes in vitro were treated 
with CCL2 and IL-6, and it was found that each was able to induce increased 
production of the other. Both were able to improve monocyte survival by up 
regulating the production of anti-apoptotic molecules including BCL2 and BCXL, 
inhibit elements of the caspase cascade, and up-regulate expression of CD14 
and MR, features of M2-like macrophages.  
The rapid removal of apoptotic cells by macrophage phagocytosis prevents 
potentially detrimental inflammatory reactions during physiological processes 
(Savill et al., 1993). Macrophages use CD14 to bind apoptotic cells prior to 
initiating phagocytosis (Devitt et al., 1998), and so in cancer-related 
inflammation, CD14 expression is a key element in suppressing anti-tumour 
immune responses that might otherwise be sparked by a failure of apoptosis. 
As previously discussed, MR is strongly implicated in the immune-suppressive 
phenotype of TAM. IL-6 is abundant in the tumour microenvironment and 
contributes to tumour cell proliferation and survival (Cavarretta et al., 2007, 
Tricot, 2000). Combined, these data suggest that CCL2 and/or IL-6 from tumour 
cells or other elements of the tumour microenvironment might drive the survival 
and alternative activation of TAM which in turn promote tumour proliferation 
through further IL-6 production, promote further TAM accumulation through 
CCL2 production, and limit anti-tumour immunity.  
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2 Macrophages in the tumour microenvironment. 
In this chapter we will broadly outline the major roles ascribed to TAM in 
supporting the survival, growth and spread of tumours. In a later chapter we 
critically review the literature specifically relating to such roles for TAM in B-
NHL. 
2.1 Angiogenesis. 
The majority of cancers and cancer models show increased tissue vascular 
density during transformation to the malignant state. Multiple cell types 
contribute to this “angiogenic switch” (Hanahan et al., 1996) of which 
macrophages are a major component (Zumsteg and Christofori, 2009). It 
appears that hypoxia plays a role in directing macrophages towards a pro-
angiogenic phenotype, and so promoting tumour progression. Studies from our 
own research group have found a relationship between the location of 
macrophages expressing CD163, an M2 phenotype marker (Mantovani et al., 
2004b), and neo-angiogenic vascular sprouts in human biopsies of poor 
prognosis Follicular lymphoma (FL) (Clear et al., 2010). 
Functional studies in mouse models of cancer provide further evidence for a link 
between macrophages and the “angiogenic switch.” Macrophage depletion is 
observed in CSF-1 constitutive genetic knockout mice, in which PyMT induced 
mammary tumours show vastly attenuated angiogenic switch (Lin et al., 2006). 
There is evidence from this model that VEGF production by TAM may be a key 
element in the “angiogenic switch.” Using transgenic VEGF-A op/op PyMT 
mice, VEGF over-expression at a benign stage in such macrophage-depleted 
mice produces increased angiogenesis and accelerates the transition to outright 
malignancy (Lin et al., 2007). Moreover, myeloid cell-specific ablation of the 
VEGF-A gene retards the “angiogenic switch” in mouse mammary tumour 
models (Stockmann et al., 2008).  
Hypoxia is a typical feature of growing tumours and, in addition to being 
positively correlated with the extent of TAM infiltration, promotes a pro-tumoural 
TAM phenotype and thus VEGF production. Hypoxia-inducible factor-1! (HIF-
1!) has a key role in controlling this response. Hypoxia stabilizes the #-subunit, 
preventing hydroxylation and subsequent degradation via the proteasome. 
Persistent !-subunits attach "-subunits in the nucleus before binding hypoxic 
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response elements of oxygen-sensitive genes, altering their expression 
(Semenza, 2002). In this way, hypoxia stimulates TAM to secrete pro-
angiogenic cytokines and enzymes, immunosuppressive agents and mitogens 
(Lewis and Murdoch, 2005). In vitro work has identified a distinct hypoxia 
induced pro-angiogenic human macrophage phenotype, with upregulation of 
VEGF, basic fibroblast growth factor (bFGF), CXCL8, cyclooxygenase-2 
(COX2), hepatocyte growth factor (HGF), VEGFR1, tissue factor and MMP12 
(White et al., 2004, Burke et al., 2003). In human breast cancer, TAM express 
VEGF almost exclusively in hypoxic areas, and upregulate VEGF on migrating 
to hypoxic regions (Lewis et al., 2000).     
Tumour cells expressing membrane bound CSF-1 (mCSF-1) appear capable of 
eliciting anti-tumour immune responses from macrophages in several non-
haematological cancer models (Graf et al., 1999, Jadus et al., 2003, Dan et al., 
2001, Williams et al., 2001a) but conversely a tumour growth-promoting effect 
in studies of lymphoma cell lines in vitro and in vivo (Wang et al., 2008). In 
these studies, the lymphoma cell lines Namalwa and Ramos were stably 
transfected to express mCSF-1, and showed increased in vitro proliferation 
when co-cultured with macrophages. Injected subcutaneously in irradiated 
BALB/c mice, these cell lines grew larger tumours than non-mCSF-1 over-
expressing controls, with more TAM and increased blood vessel density. This 
indicates that in B-lymphomas, TAM are more plentiful, pro-angiogenic and pro-
tumoural in the presence of mCSF-1.  
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2.2 Invasion and metastasis. 
Tumour cell migration, particularly in epithelial tumours, requires proteolytic 
destruction of the surrounding matrix to facilitate the escape of tumour cells 
from the confines of the basement membrane. Common to all spreading 
tumours is the need for subsequent proteolysis of surrounding dense tissue 
stroma. Macrophages are potent producers of many proteases, including 
cathepsins, MMPs, and serine proteases (Egeblad and Werb, 2002). Increased 
production of MMPs is a feature of the M2 macrophage phenotype and is 
typical of TAM (Coussens et al., 2000). Macrophage-specific depletion of 
cathepsins or urokinase plasminogen activator results in reduced tumour cell 
invasion and inhibition of metastasis in mouse mammary tumour models 
(Gocheva et al., Vasiljeva et al., 2006, Almholt et al., 2005). In a model of 
invasive colorectal cancer, immature myeloid cells producing both MMP9 and 
MMP2 were observed to accumulate at the tumour invasion front (Kitamura and 
Taketo, 2007). Breast cancer cell-lines show increased invasiveness on co-
culture with macrophages, due to TNF-! induced up-regulation of MMPs 
(Hagemann et al., 2004). As discussed earlier in more detail, M2-polarised 
macrophage-derived MSF is a potent stimulant of pancreatic cancer cell line 
migration in vitro (Solinas et al., 2010). 
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2.3 Immune-suppression. 
Macrophages are central to many immune responses and under certain 
circumstances, particularly during bacterial infection, are potent antigen 
presenting cells. However, within the tumour microenvironment, it appears that 
TAM adopt an immunoregulatory role, suppressing anti-tumour immune 
responses. Macrophages can inhibit cytotoxic T-cell responses through several 
mechanisms. For example, macrophages produce IL-10 that in turn induces 
monocytes to express the co-stimulatory molecule programmed death ligand-1 
and suppresses cytotoxic T-cell responses (Kuang et al., 2009). In human 
ovarian cancers, macrophages produce CCL22, a chemokine that influences 
the influx of regulatory T-cells (Tregs) that suppress cytotoxic T-cell responses. 
The abundance of Tregs in ovarian cancer predicts poor survival (Curiel et al., 
2004). In mammary tumour xenografts, a recruited macrophage population 
suppressed immune responses through synthesis of prostaglandin-E2 and 
transforming growth factor-beta (TGF-") (Torroella-Kouri et al., 2009). In human 
B-NHL and Hodgkin Lymphoma it appears that the role of Tregs might be 
different from that in ovarian cancer, with several studies describing an 
association between high numbers of infiltrating Tregs and a favourable 
prognosis (Tzankov et al., 2008, Lee et al., 2006).  
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2.4 Stimulation of tumour cell proliferation. 
M2 macrophages secrete a variety of growth factors that can stimulate the 
differentiation and proliferation of other cells. Macrophage-elicited platelet-
derived growth factor (PDGF) and TGF-"1 stimulate the differentiation of 
fibroblasts and myofibroblasts. It seems plausible that these and other growth 
factors might also promote the differentiation and proliferation of malignant 
cells, as has been postulated by Mantovani (Mantovani et al., 2004b). 
IL-6 is a growth signal that blocks apoptosis and is one of the effector signals of 
activated NF-kB in the promotion of neoplasia. IL-6 can be produced by 
activated macrophages, and signals through STAT3, which is in turn activated 
in many different cancers (Haura et al., 2005). This transcription factor regulates 
genes that mediate cell proliferation (such as Cyclin-D1 and c-Myc), promotes 
angiogenesis (through regulation of VEGF) and suppresses apoptosis (Bcl-xL) 
(Aggarwal et al., 2006). 
Studies involving deletion of IKK" from enterocytes or myeloid cells reveal 
distinct pathways through which NF-#B contributes to colitis-associated 
carcinogenesis (CAC) (Greten et al., 2004). In a mouse model of CAC induced 
by the carcinogen azoxymethane, in the context of dextran sulfate sodium salt-
stimulated inflammation, deletion of IKK" in enterocytes resulted in many fewer 
tumours compared to wild-type mice. This is thought to be a direct result of 
more apoptosis in pre-neoplastic enterocytes. IKK" deletion in myeloid cells, 
however, also led to a decrease in tumour size and this mechanism is thought 
to depend on decreased IL-6 production leading to slower tumour growth. IL-6 
receptor antagonism in the mouse model of CAC slowed tumour growth 
markedly but did not change the number of individual tumours that arose 
(Becker et al., 2004). These findings suggest that IL-6 has its most profound 
effect on tumour promotion and progression rather than initiation. In the context 
of lymphoma, Gilbert and Hemann describe a role for stromal derived IL-6 in 
sustaining malignant B-cells (by inducing anti-apoptotic BCXL) within a chemo-
resistant niche in a mouse model of B-lymphoma (Gilbert and Hemann, 2010). 
In their work, IL-6 knockout mice with lymphoma had prolonged survival 
following chemotherapy than wild type controls. 
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A proliferation inducing ligand (APRIL) is a cytokine of the TNF family (Hahne et 
al., 1998, Kalled et al., 2005, Kelly et al., 2000) that promotes the survival and 
proliferation of neoplastic B-lymphocytes (Planelles et al., 2004, Burjanadze et 
al., 2009, Planelles et al., 2008, Roosnek et al., 2009). Munari et al. reported 
that APRIL is produced almost exclusively by an M2-like subset of 
macrophages (CD68+CD163+) in primary samples of human gastric MALT 
lymphoma, and was not detectable from tissue macrophages in areas of normal 
healthy gastric mucosa (Munari et al., 2011). In vitro studies demonstrated that 
autologous PBMC derived macrophages produced APRIL when directly 
stimulated with either Helicobacter pylori (HP) or with patient-derived HP-
specific T-cells. HP eradication therapy leading to remission of gastric MALT 
lymphoma was associated with a reduction in APRIL producing macrophages.   
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2.5 Summary. 
The phenotype and role of TAM is not entirely consistent amongst cancers, and 
there is a need for detailed study of the specific features of TAM in B-lymphoid 
malignancies. Moreover, specialised macrophage subpopulations within each 
tumour appear to have very different roles in supporting tumour progression, 
and might represent attractive new therapeutic targets (Qian and Pollard, 2010). 
Even in the setting of cancer, the majority of monocytes and macrophages in 
the body remain involved in critical physiological roles. For this reason, 
identifying and specifically targeting macrophage subpopulations is likely to be 
crucial in any attempt at macrophage-directed anti-cancer therapy.  
There is a wealth of recent evidence strongly indicating a pivotal role for the 
CSF-1R in monocyte development and the accumulation of resident tissue 
macrophages and TAM. As will be critically reviewed in the following chapters, 
CSF-1R inhibition might offer the opportunity to target the accumulation of TAM 
in a growing tumour, without impacting significantly on the ability of the host to 
mount vital acute inflammatory responses. 
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3 Critical roles for the CSF-1R. 
3.1 CSF-1R ligation promotes the formation, survival, 
maturation and proliferation of monocytes and 
macrophages. 
The majority of mononuclear phagocytes express the macrophage colony-
stimulating factor receptor, CSF-1R, a type III integral membrane protein 
tyrosine kinase also known as CD115, or in humans, M-CSF. Ligation of the 
CSF-1R results in non-covalent receptor dimerization, and phosphorylation of 
intracellular tyrosine kinase residues. These act as docking sites for a variety of 
signalling molecules, activating downstream pathways (Jacquel et al., 2009). 
Phosphatidylinositol 3-kinase (PI3K) / protein kinase B (AKT) and mitogen 
activated protein kinase (MAPK) pathways are critically involved in CSF-1R 
ligation dependent monocyte to macrophage maturation (Gobert Gosse et al., 
2005). mRNA encoding the CSF-1R is expressed in such a highly restricted 
manner in the monocyte-macrophage lineage in mouse and man (Ovchinnikov 
et al., 2010, Bonifer and Hume, 2008) that the promoter region has been used 
to generate CSF-1R-EGFP transgenic mice to enable in vivo imaging of this cell 
type (Sasmono et al., 2003). Circulating levels of CSF-1 rise with pregnancy 
(Pollard et al., 1987, Bartocci et al., 1986), infections, cancer, and chronic 
inflammation (Chitu and Stanley, 2006, Sweet and Hume, 2003, Hamilton, 
2008). CSF-1 controls the formation, proliferation, differentiation, adaptation 
and survival of mononuclear phagocytes (Chitu and Stanley, 2006, Sweet and 
Hume, 2003).  In vitro studies have confirmed that GM-CSF, IL-3 and IFN-# act 
with CSF-1 to further promote the proliferation and maturation of macrophages 
from bone marrow cells. In mice, macrophages undergo cell death in the 
absence of CSF-1 (Irvine et al., 2006, Williams et al., 1990).  
A second ligand for the CSF-1R, IL-34, was recently described (Lin et al., 2008) 
and a partial redundancy of function of either ligand may explain the extreme 
derangement of phenotype of mice with CSF-1R mutations compared to the 
op/op mutated mice with isolated CSF-1 deficiency in which total circulating 
monocyte numbers are maintained (Dai et al., 2002). Studies of the impact of 
CSF-1 deficiency in these mice is limited, however, as macrophage deficiency 
is present during embryogenesis, resulting in gross developmental 
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abnormalities of the central nervous system, pancreas, mammary glands and 
reproductive organs (Chitu and Stanley, 2006, Dai et al., 2002). Although 
binding the same receptor, the finding that some anti-CSF-1R monoclonal 
antibodies block the binding of CSF-1 but not of IL-34 strongly indicates that the 
two ligands bind at different sites on the CSF-1R (Chihara et al., 2010).  
!
Figure 6 - The CSF-1R, its ligands and downstream events. 
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3.2 The CSF-1R is a conceptually attractive therapeutic target 
in cancer.  
Transcriptional profiling of human monocytes and macrophages in vitro has 
revealed that CSF-1 induces monocyte to macrophage differentiation. In vitro 
work with mouse and human cells indicates that when CSF-1 is the sole 
activating stimulus for monocyte-derived macrophages, then macrophages are 
polarised away from an antigen presenting phenotype and towards 
immunosuppression (Hume, 2008b, Hume, 2008c) and promoting tumour cell 
migration (Solinas et al., 2010), and hence are M2-like (Martinez et al., 2006, 
Svensson et al., 2011). However, CSF-1 stimulated macrophages are not of a 
pure M2 phenotype, and respond to IL-4 supplementation with further 
immunosuppressive changes in gene expression (Gordon and Martinez, 2010, 
Martinez et al., 2006, Svensson et al., 2011, Rehli et al., 2005). A potential role 
for CSF-1R ligation in directing monocyte subset differentiation and maturation 
towards immune-suppressive macrophages is outlined in the figure below. As 
we will detail in the following chapter, CSF-1R ligation is implicated in the 
maturation of Ly6C+ monocytes to Ly6C- monocytes, and so in the formation of 
TAM. 
!
Figure 7 - Monocyte subsets as a potential developmental series under the 
control of CSF-1R ligation.  
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CSF-1 supplementation in mice produces an increase in numbers of mature 
resident tissue macrophages (Hume et al., 1988, Munn et al., 1990), and in 
non-human primates produces an increase in the anti-inflammatory CD16 
positive (non-classical) monocytes (Munn et al., 1990). Increased CSF-1 serum 
levels have been found in several malignancies, including breast carcinoma, 
ovarian cancer, and endometrial carcinoma, cancers in which high macrophage 
numbers are associated with poor prognosis (Kacinski, 1997). The expression 
of epithelial CSF-1 and CSF1-R in metastases of ovarian carcinoma was shown 
to be associated with poor clinical outcome (Chambers et al., 1997). In several 
other tumour types, a CSF-1 response gene signature is observed in the 
primary tumour and corresponding metastases, correlating with increased 
angiogenesis (Espinosa et al., 2011), higher tumour grade and worse prognosis 
(Webster et al., 2010, Sharma et al., 2010, Espinosa et al., 2009). As such, 
CSF-1 and its receptor present rational targets for cancer therapies aiming to 
ablate or modify TAM. A detailed understanding of the physiological and 
pathological roles of the CSF-1/CSF-1R axis is required to predict the 
consequences of therapeutic interference.  
The CSF1-R is itself expressed by some tumour cells (Pollard, 2009, Condeelis 
and Pollard, 2006, Wyckoff et al., 2007, Steidl et al., 2011), raising the 
possibility that CSF-1R inhibition in these cancers may produce some direct 
anti-tumour effects. It remains to be seen whether CSF-1R expressed by 
malignant cells is fully functional and sensitive to ligation with CSF-1 or IL-34, 
and whether inhibition of CSF-1R on malignant cells has any therapeutic 
benefits. !
! %%!
3.3 Exploring CSF-1R inhibition. 
As outlined earlier, Hume and co-workers have developed the ‘MacGreen’ 
mouse, in which an enhanced green fluorescent protein (EGFP) reporter gene 
is driven by the Csf-1r promoter (Sasmono et al., 2003). This model enables 
visualisation of the participation of CSF-1R positive cells in tumour progression 
and metastasis (Wyckoff et al., 2007) and enables assessment of the number, 
phenotype and fate of CSF-1R positive cells upon administration of an anti-
CSF-1R antibody (MacDonald et al., 2010). This work sheds further light on the 
consequences of inhibition of CSF-1R, confirming that signalling through the 
CSF-1R is required for maturation of mononuclear phagocytes into resident 
tissue macrophages. The administration of a novel CSF-1R blocking antibody 
selectively reduced the CSF-1R+Ly6C- ‘patrolling’ monocyte precursors of 
resident tissue macrophages. CSF-1R+Ly6C+ ‘inflammatory’ monocytes were 
correspondingly increased, supporting other evidence for their position as 
developmental precursors of ‘patrolling’ monocytes and ultimately mature tissue 
macrophages (Sunderkotter et al., 2004, Tacke et al., 2006). 
CSF-1R blockade had no effect on CSF-1R+Ly6C+ inflammatory monocyte 
recruitment in LPS-induced lung inflammation, wound healing, peritonitis and 
severe acute graft-versus-host disease. However, CSF-1R blockade reduced 
the numbers of TAM in syngeneic tumour models of mesothelioma and lung 
carcinoma, although this had no impact on tumour growth. This work indicated 
that CSF-1R ligation and subsequent maturation to a CD11b+Ly6C- status is a 
necessary step in TAM development from immature monocytes. 
These data indicate that CSF-1R signalling is required only for the maturation of 
Ly6C- resident-type monocytes and tissue macrophages from Ly6C+ 
precursors, and may not be absolutely required for monocyte production itself, 
or for effective function of inflammatory monocytes. Alternatively, it may be that 
CSF-1R inhibition in this model was partial, with sufficient residual activity to 
permit monocyte production but not maturation to TAM. In a study of graft-
versus host disease (GvHD) following allogeneic bone marrow transplantation 
modelled in mice, treatment with CSF-1 expanded the numbers of suppressive 
macrophages, which correlated with a reduction in severity of GvHD 
(Hashimoto et al., 2011) thus one could hypothesize that the reverse effect 
might be seen with CSF-1R inhibition. Indeed, MacDonald et al. demonstrated 
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this using anti-CSF1R monoclonal antibody (MacDonald et al., 2010) with a 
reduction in accumulated macrophages and increased severity of acute GvHD. 
Growth of transplantable tumours in op/op CSF-1 deficient mice is markedly 
impaired (Nowicki et al., 1996). Moreover, experimental CSF-1 blockade via 
antisense oligonucleotides and siRNA, or inhibiting CSF-1R receptor signalling, 
significantly suppresses tumour growth (Aharinejad et al., 2004, Kubota et al., 
2009, Priceman et al., 2010). Likewise, as mentioned earlier, spontaneous 
mammary cancer development in the PyMT model is altered in a op/op CSF-1 
null background, with no effect on tumour growth but a delay in the 
development to invasive, metastatic carcinomas (Lin et al., 2001). Prolonged 
use of the anti-CSF-1R antibody M279 in an established tumour selectively 
reduced numbers of tissue macrophages, with no significant effect on the ability 
to mount an inflammatory monocytosis in response to a variety of triggers 
(MacDonald et al., 2010). The depletion of resident macrophages was notable 
despite the fact that tumours were established prior to starting treatment. There 
was, however, no discernable effect on tumour growth. 
Taken together, current evidence from genetic models, treatment with CSF-1 
and treatment with CSF-1R inhibitors indicates that the non-redundant function 
of CSF-1R signalling is to promote the differentiation of monocytes from bone 
marrow precursors, and possibly to direct monocyte maturation towards the 
formation of resident tissue macrophages (Hume and Macdonald, 2012). 
By extrapolation, one might postulate that CSF-1R inhibition could selectively 
reduce TAM numbers in a mouse model of lymphoma, while not significantly 
attenuating the ability to generate neutrophilia and a Ly6C+ monocytosis and so 
mount successful acute inflammatory and anti-infective immune responses. 
Moreover, the contrasting dynamics of TAM accumulation and physiological 
macrophage turnover suggest that a brief period of CSF-1R inhibition-induced 
attenuation of monocyte production, survival, trafficking and maturation might 
preferentially reduce TAM accumulation without significantly reducing 
physiological tissue macrophage numbers. TAM accumulate rapidly in growing 
tumours, yet turnover of physiological resident tissue macrophages is relatively 
slow, in terms of several weeks rather than days. 
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Figure 8 - CSF-1R inhibition might induce a maturation block and relative 
reduction in "patrolling" monocytes and TAM. 
MacDonald et al. reported a several-fold increase in CSF-1R expression by 
Ly6C- compared to Ly6C+ monocytes (MacDonald et al., 2010). This, and 
subsequent differential effects on monocyte subsets of CSF-1R inhibition were 
not reproduced in similar work using a different sub-class of IgG anti-CSF-1R 
antibody (Lenzo et al., 2012). This is an area of active research and warrants 
investigation in any new studies with a CSF-1R inhibitor. !
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3.4 Blocking the intracellular tyrosine kinase domain may be 
the most effective strategy to inhibit the CSF-1R. 
CSF-1 is cleared from the circulation by receptor-mediated endocytosis 
(Bartocci et al., 1987). CSF-1R blockade by monoclonal antibodies causes a 
massive elevation in circulating CSF-1 concentration, as is also observed in 
CSF-1R knockout mice (Dai et al., 2002). As the antibody concentration 
subsides, there is an enhanced CSF-1 signal and rebound monocyte 
production. This may also occur if CSF-1R bearing cells are killed, for example 
by toxic liposomes or macrophage directed toxic transgenes (Hume, 2011). As 
such, intermittent or brief CSF-1R inhibition with antibody might cause a 
paradoxical increase in monocyte production. This does not occur with the 
administration of small molecule CSF-1R kinase inhibitors (unless they are 
cytotoxic) (Irvine et al., 2006). A better understanding of the physiological roles 
of the CSF-1/CSF-1R axis has been obtained by studies using selective 
inhibitors of CSF-1R kinase activity (Conway et al., 2005, Conway et al., 2008, 
Manthey et al., 2009), and drug-inducible CSF-1R dependent cell suicide 
(Burnett et al., 2004). These are both strategies that we have explored in a 
mouse model of lymphoma. 
!
Figure 9 - CSF-1R inhibition strategies. 
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3.5 CSF-1 R inhibition in lymphoma. 
A case report provides some support for pursuing CSF-1R inhibition in 
lymphoma, detailing elevated plasma CSF-1 levels with CSF-1 positive-staining 
abnormal lymphocytes in a splenectomy specimen from a patient with DLBCL in 
whom the plasma CSF-1 levels and peripheral blood monocyte percentage fell 
after chemotherapy (Nakayama-Ichiyama et al., 2010). In the model of 
lymphoma we have used (to be described later) the major disease sites, as 
determined by lymphoma bulk, appear to be lymph nodes and spleen. In the 
physiological steady state, Hume and co-workers found that in healthy mice, the 
majority of splenic and nodal macrophages were unaffected by anti-CSF-1R 
antibody treatment, and so may not be derived from CSF-1R dependent 
monocytes. However, various macrophage subpopulations exist within these 
tissues, and splenic marginal zone macrophages and nodal sub capsular sinus 
macrophages do express the csf-1r-EGFP transgene at high levels, and were 
depleted in antibody-treated animals in keeping with findings from previous 
work in which the development of splenic marginal zone macrophages was 
dependent upon CSF-1 (Takahashi et al., 1994). Moreover, the accumulation of 
TAM was not investigated, which may well be CSF-1R dependent. Further, one 
must take in to account the potential reduced efficacy of anti-CSF-1R 
antibodies, as used in this work, compared to the potentially more potent small 
molecule inhibitors of the intracellular tyrosine kinase domain of the CSF-1R 
that are not compromised in their action by disrupting receptor mediated 
endocytosis.   
We obtained compound AZ268 from AstraZeneca; a novel, orally administered, 
small molecule CSF-1R tyrosine kinase inhibitor that is not yet commercially 
available and is under ongoing investigation. We studied its effects on a mouse 
model of lymphoma in C57BL/6 mice. We were particularly interested in the 
effects on different monocyte and macrophage populations in the blood and 
lymph nodes, and the impact on lymphoma progression.  
Having introduced macrophage biology we will now discuss NHL, before 
outlining our approach to studying the role of macrophages in NHL.!
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4 B-cell Non-Hodgkin Lymphomas. 
4.1 Background to B-NHL. 
B-NHL is characterised by abnormal clonal accumulations of B-lymphocytes. 
The stage of development at which B-cell maturation is arrested varies, as does 
the presence, nature and balance of abnormalities in proliferation and 
apoptosis. This was reflected in the early classification of B-NHL into disease 
entities largely on the basis of dynamics, as well as macroscopic and 
microscopic features of malignant cells and their infiltration of tissues and 
organs (National Cancer Institute, 1982). The wide variation in clinical 
behaviour of B-NHL is a consequence of the multitude of genetic and epigenetic 
abnormalities underlying these conditions. As we expand our knowledge and 
understanding of these underlying abnormalities and the critical molecular 
events consequent on them, the classification of these diseases is developing 
to become more relevant to pathophysiology rather than gross clinical features. 
This is reflected in the latest document from the world heath organisation 
(WHO) updating the classification of lymphoid malignancies (Campo et al., 
2011). The population age-adjusted incidence of lymphoma diagnoses rose 
from the 1970s to the 1990s, and appears to be stabilising more recently, with 
NHL now being the 7th most common malignant diagnosis in the USA (Jemal et 
al., 2010). More widespread and accurate cancer diagnosis and reporting, and 
earlier diagnosis of asymptomatic indolent forms and stages of lymphoma has 
contributed to this rise, although there is evidence for a genuine underlying 
increase that is only partly explained by the rise of HIV-related lymphomas 
(Friedberg and Fisher, 2008, Hartge et al., 1994). !
4.1.1 Staging of B-NHL. 
The extent of disease is determined by imaging of enlarged lymph nodes and 
extranodal sites, and by bone marrow biopsy. Routine sampling of cerebro-
spinal fluid is undertaken in lymphomas that are commonly disseminated at 
diagnosis; including Burkitt lymphoma (BL) and high risk diffuse large B-cell 
lymphoma (DLBCL). Conventional imaging by computed tomography may be 
supplemented by metabolic scanning, such as fluorodeoxyglucose-positron 
emission tomography (FDG-PET), and tissue biopsy to confirm the presence of 
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B-NHL in enlarged nodes or extranodal sites. FL, DLBCL and BL are usually 
staged using the Ann Arbor system. 
4.1.2 The Ann Arbor system for staging B-NHL. 
This staging system, first developed in 1971 principally for Hodgkin lymphoma 
(Carbone et al., 1971), depends upon both the location and extent of 
lymphoma, as well as the presence of specific systemic symptoms attributable 
to it. Stage I indicates only one affected region, Stage II two separate regions 
both above or both below the diaphragm, and Stage III involving sites above 
and below the diaphragm. Stage IV indicates infiltration of sites outside of 
lymph nodes or spleen, commonly the bone marrow, abdominal or thoracic 
viscera. The Ann Arbor stage at diagnosis is incorporated into prognostic 
scoring algorithms in FL and DLBCL. 
4.1.3 B-NHL arise by dysregulated expression of oncogenes during 
aberrant maturation of B-lymphocytes. 
B-NHL are derived from either committed lymphoid progenitor cells or from 
more mature B-lymphocytes that acquire chromosomal translocations through 
errors in the immunoglobulin (IG) gene remodelling processes during normal B-
cell differentiation, usually involving immunoglobulin heavy chain (IGH) genes 
juxtaposed to a variety of oncogenes (Willis and Dyer, 2000). 
Histology Translocation Upregulated 
Gene 
Frequency (%) 
FL t(14;18)(q32;q21) BCL2 70-95 
 t(3;14)(q27;q32) BCL6 10-15 
DLBCL t(3;14)(q27;q32) BCL6 30-35 
 t(14;18)(q32;q21) BCL2 20-30 
 t(8;14)(q24;q32) MYC 10 
BL t(8;14)(q24;q32) MYC 70 
 t(2;8)(q12;q24) MYC 8 
 t(8;22)(q24;q11) MYC 22 
Table 1 - Common chromosomal translocations in B-NHL (Tomita, 2011). 
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In B-NHL, the majority of oncogenes targeted by translocations are regulators 
of proliferation, apoptosis, development and differentiation. In FL, the 
characteristic chromosomal translocation, t(14;18), establishes a premalignant 
cell that must acquire secondary mutations to be capable of generating 
malignant lymphoma. FL cells invariably show somatic hypermutation (SHM) of 
both IGH alleles, suggesting that the immortalized B-cells with BCL2 over-
expression must have pursued an ongoing differentiation pathway, with transit 
through the germinal centre. SHM can also target BCL6, MYC and other 
oncogenes in germinal centre-derived B-NHL (Shen et al., 1998, Pasqualucci et 
al., 2001).  
DLBCL and BL are derived from more mature germinal centre-derived 
lymphocytes and although there is evidence for secondary mutations in most 
cases, lymphocytes with MYC rearrangements that deregulate self-renewal 
pathways may not require such events, and are able to act as lymphoma-
originating cells able to drive malignancy. MYC is a transcription factor that is 
mutated and deregulated in a large proportion of B-cell lymphomas of different 
subgroups through various genetic mechanisms (Haluska et al., 1986, Neri et 
al., 1988). Unlike other lymphoma oncogenes, forced expression of Myc in 
lymphoid cells in mice is sufficient to generate B-cell lymphoma (Adams et al., 
1985), yet translocations juxtaposing MYC and IG genes can be detected in 
non-malignant conditions including HIV in humans and normal B-cell 
differentiation in mice (Muller et al., 1995, Roschke et al., 1997). Myc activation 
is a necessary step for lymphoma to develop in Bcl2 transgenic mice (Strasser 
et al., 1990).  
In this thesis we shall consider the two most common B-NHL; FL and DLBCL, in 
greatest detail. In addition we will discuss BL, owing to its molecular and 
dynamic parallels with the chosen mouse model of lymphoma, and other 
lymphomas and lymphoma models in so far as there is relevant literature to 
inform discussion. We shall introduce the basic features that distinguish each 
lymphoma, before critically appraising the literature in relation to evidence for 
the roles of TAM in each disease.  
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4.1.4 B-NHL and their relationship to TAM. 
Most mature B-NHL are incurable. This is despite most cases showing 
significant malignant-cell death when initially treated with cytotoxic 
chemotherapy. There is growing evidence that crosstalk between malignant B-
cells and surrounding stromal and immune cells contributes to B-NHL survival, 
growth, and resistance to chemotherapy. One could speculate that if a 
lymphoma stem cell population exists (Martinez-Climent et al., 2010), then it too 
might be subject to similar support from its microenvironment. It is conceptually 
very attractive to explore combining traditional cytotoxic approaches with novel 
strategies to disrupt the permissive signals provided by elements of the 
lymphoma microenvironment (Burger et al., 2009). An early study comparing 
CD68+ macrophage infiltration between normal lymphoid tissue, FL, mantle cell 
lymphoma (MCL), DLBCL and BL found that grade of tumour and proliferation 
rate by Ki67 expression showed a positive correlation with macrophage density 
(Hermann et al., 1998). The more aggressive and proliferative diseases of BL 
and DLBCL contained significantly more macrophages than the more indolent 
FL, MCL and normal lymphoid tissue. The authors speculated that a functional 
relationship might exist between the extent of macrophage infiltration and the 
biologic grade of lymphoma. Our own laboratory work will consider this 
question. !
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4.2 Diffuse large B-cell lymphoma. 
DLBCL is the most common of all adult lymphomas, accounting for 28% of all 
lymphoid malignancies and 40% of B-NHL (Morton et al., 2006). DLBCL is 
approximately 50% more common in men than women, and has a peak 
incidence in the 60-70 year age group (Hartge and Devesa, 1992). DLBCL has 
an aggressive natural history, with an untreated median survival of less than 
one year (Fisher et al., 2004). Combination chemotherapy containing 
anthracyclines, such as cyclophosphamide, doxorubicin, vincristine and 
prednisolone (CHOP) is potentially curative (Fisher et al., 1993). Addition of the 
chimaeric (mouse-human) anti-CD20 monoclonal antibody (mAb) rituximab to 
this regime improves overall survival by 10-15% (Coiffier et al., 2002). 
4.2.1 Prognostication in DLBCL. 
The international prognostic index (IPI) predicts survival based on 5 factors; 
age, disease stage, serum lactate dehydrogenase (LDH), performance status 
and number of extra-nodal sites of disease (International NHL Prognostic 
Factors Project, 1993). Owing perhaps to the biological heterogeneity even 
within the risk groups, the IPI score does not influence decisions regarding 
initial therapy. In an attempt to understand the complex and heterogeneous 
biology of DLBCL better, comprehensive genome-wide expression profiling 
exercises have investigated how prognosis relates to the molecular features of 
the disease at diagnosis (Alizadeh et al., 2000, Shipp et al., 2002, Rosenwald et 
al., 2002). 
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4.2.2 Gene expression profiling reveals biological heterogeneity and 
highlights roles for the microenvironment in DLBCL. 
Two biologically and clinically distinct molecular groups have been identified 
(Rosenwald et al., 2002, Alizadeh et al., 2000). Germinal centre B-cell (GCB) 
subtype probably arises from normal GCB-cells and has an improved prognosis 
with CHOP chemotherapy compared with the activated B-cell (ABC) subtype 
(Wright et al., 2003) which may arise from post-GC B-cells that have 
experienced a block during plasma cell differentiation (Lenz et al., 2008). 
Supervised analysis has enabled the construction of models to predict 
outcomes in DLBCL, based on the expression of subsets of highly 
discriminatory genes (Shipp et al., 2002, Rosenwald et al., 2002). Shipp et al. 
identified a 13-gene predictive model, and Rosenwald et al. a 17-gene 
predictive model. There was no overlap of the genes in these two models, 
which were derived using different microarray platforms and different statistical 
algorithms. Immunohistochemical surrogates of the gene expression profile-
derived ABC/GCB schema might provide more practical clinical applications. 
The classic Hans algorithm (Hans et al., 2004) uses staining for BCL6, CD10 
and MUM-1. Newer, expanded versions of this appear to provide greater 
accuracy when predicting individual patient outcomes (Meyer et al., 2011b, 
Choi et al., 2009). Of note, a recent trial of rituximab plus chemotherapy 
demonstrated the validity of the ABC/GCB schema by gene expression 
profiling, yet this has not been matched by concordance with 
immunohistochemical surrogate algorithms (Gutierrez-Garcia et al., 2011).    
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4.2.3 Tumour-associated macrophages in DLBCL. 
In DLBCL, variable representation of macrophage gene expression has been 
discovered amongst different subsets of the disease (Monti et al., 2005). Whole 
genome arrays and multiple clustering statistical methods describe 3 distinct 
subsets of DLBCL: Oxidative Phosphorylation, B-Cell Receptor/Proliferation, 
and Host Response. Although there were no differences in 5 year overall 
survival (OS) among the subsets, as distinct biological entities they may have 
importance not only in identifying pathogenetic mechanisms, but also identifying 
and exploiting subset specific rational targets. The Host Response group was 
enriched for several genes of critical importance in monocyte/macrophage 
development and function, including CD14, CD163, B-lymphocyte activator 
macrophage expressed (BLAME), APRIL and CSF-1R. These biopsies also 
had increased expression of T/NK receptor and activation pathway 
components, the complement cascade, inflammatory mediators, CD2+/CD3+ 
cells and S100+/gamma interferon induced lysosomal transferase positive 
(GILT+) CD1a-/CD123- DCs. This study highlights the heterogeneity not just 
between different B-cell lymphomas, but also within them, and that with 
relevance to this thesis, TAM may have different and even opposite roles in 
different lymphoma subtypes, as well as at different times, locations within 
tumours, and in response to different therapies. 
Lenz et al. studied the gene expression signatures of pre-treatment biopsies of 
a training group of 181 patients with DLBCL treated with CHOP (or similar) 
chemotherapy, and applied their findings in a validation group of 233 patients 
treated with rituximab plus CHOP (Lenz et al., 2008). They looked for survival-
associated gene expression signatures, refined by hierarchical clustering and 
grouping of co-ordinately expressed genes and identified the two signatures 
most predictive of favourable and unfavourable prognosis. By sorting the 
malignant from the non-malignant components of the tumour on the basis of 
CD19 expression, they established that the non-malignant components were 
responsible for the two signatures, termed Stromal-1 and Stromal-2. The 
Stromal-1 signature predicted a favourable prognosis and contained genes 
associated with extra-cellular matrix (ECM) deposition and organisation as well 
as infiltration with mononuclear phagocytes. The Stromal-2 signature predicted 
an unfavourable prognosis and contained genes associated with angiogenesis. 
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This work highlights the discriminating nature of different stromal responses. 
With both the Stromal-1 and Stromal-2 signatures being feasibly linked to TAM 
function, it also supports the concept that TAM populations might be performing 
different and prognostically opposing functions in different tumours. 
Other gene expression profiling enterprises have yielded reproducible 
prognostic signatures, notably the work of Lossos et al., that developed a 
predictive model based upon the expression of only 6 genes from formalin fixed 
paraffin embedded (FFPE) samples (Lossos et al., 2004). They examined 
expression using quantitative real time polymerase chain reactions (qRT-PCR) 
of 36 candidate genes drawn from earlier genome-wide association studies 
from other groups, correlating this information with clinical features and 
outcomes in 66 diagnostic biopsies from the pre-rituximab era. This model was 
applied to the data set from Lenz et al. and found to ‘perform well’, 
distinguishing risk groups ‘nearly as well’ as the model of Lenz et al., but with 
the added advantage of being logistically and financially more feasible as a 
potential routine clinical tool (Alizadeh et al., 2009). Nonetheless, despite its 
limitations as a potential routine clinical tool, as a hypothesis forming paper, the 
work of Lenz et al. is of great value, illuminating complex biological subtypes of 
DLBCL and suggesting important interactions with the microenvironment.  
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4.2.4 Counting tumour-associated macrophages in DLBCL. 
CD68 is considered a pan-macrophage marker in humans. It is a glycoprotein 
found in lysosomes, phagosomes and neutrophil granules (Pulford et al., 1989, 
Pulford et al., 1990, Saito et al., 1991), and so although highly expressed in 
macrophages, may be detectable at lower concentrations in a variety of cells 
containing these organelles, such as mast cells and neutrophils, but also in 
some malignant cells (Gloghini et al., 1995, Lau et al., 2004). 
Several studies report enumeration of CD68+ macrophages in diagnostic 
biopsies of previously untreated DLBCL. Hasselblom et al. counted CD68+ 
macrophages in samples from 176 patients, none of whom received rituximab, 
some received radiotherapy, and all received anthracycline based therapy 
(Hasselblom et al., 2008). No correlations were found between macrophage 
numbers and OS, progression free survival (PFS), proliferation as assessed by 
Ki67 staining, ABC versus GCB subtype, or any clinical factors, other than age. 
The only statistically significant correlation was that patients over the age of 60 
years had more CD68+ macrophages than younger patients.  
Abundant expression of secreted protein, acidic and rich in cysteine (SPARC) in 
the microenvironment is reported to correlate with favourable prognosis in some 
patients with DLBCL (Meyer et al., 2011a). SPARC is a glycoprotein that can 
modulate the ECM, integrin activity, adhesion, growth factor signalling and 
apoptosis (Bradshaw et al., 2003, Raines et al., 1992, Sangaletti et al., 2003, 
Weaver et al., 2008). SPARC can be expressed in variety of cells, including a 
subset of tissue-injury associated macrophages (Lenz et al., 2008, Reed et al., 
1993). Meyer et al. investigated SPARC and CD68 staining by 
immunohistochemistry in pre-treatment biopsies of 262 patients with DLBCL, 
subsequently administered rituximab plus CHOP (or similar) chemotherapy. 
CD68 staining alone was not predictive of any survival measure. The presence 
of any SPARC positive cells in the microenvironment correlated with longer OS, 
and those with high numbers of SPARC staining cells had longer event free 
survival (EFS) than those with fewer.  On subgroup analysis, this was found to 
be almost entirely due to a strong prognostic effect in ABC-type DLBCL, with no 
effect seen in GCB-type DLBCL. Moreover, SPARC gene expression was 
represented within the Stromal-1 signature of favourable prognosis DLBCL 
(Lenz et al., 2008), reinforcing its association with good risk disease. Combined, 
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these data suggest that TAM with different phenotypes are present in different 
biological subtypes of DLBCL with different biology, and might be associated 
with contrasting roles. The identification of TAM-specific features associated 
with pro- or anti-tumour phenotypes might ultimately aid the selection of 
patients who would benefit most from novel therapies targeted against TAM.  
The number of macrophages was enumerated in 112 patients with newly 
diagnosed DLBCL, subsequently treated without rituximab, to examine the 
prognostic significance when biopsies were assigned to a high or low 
macrophage group, using CD68 and a single cut-off value (Cai et al., 2011). 
They found no difference in the CR rate, and the median OS was not reached 
for the low CD68 group. 
From our own research group, Coutinho et al. report that a high number of 
CD68 positive macrophages correlates with a good prognosis in terms of OS, 
PFS and disease-free survival (DFS) in diagnostic biopsies of 218 patients, 
67% of whom did not receive rituximab (Coutinho et al., 2011). Numbers of 
CD163 positive cells did not have any correlation with clinical outcomes, and 
subgroup analysis of rituximab treated versus non-rituximab treated patients is 
awaited.   
The 2 year OS of 101 cases of newly diagnosed DLBCL treated subsequently 
with a rituximab containing regimen was assessed examining the total numbers 
of macrophages, using CD68, and also the numbers of macrophages on which 
a marker of M1 phenotype (HLA-DR) or M2 phenotype (CD163) was also 
present (Wada et al., 2012). The presence of a large total number of CD68 
positive macrophages was associated with a worse outcome than a low number 
of CD68 positive macrophages. The presence of a large number of M2 
macrophages correlated with a worse overall survival than those with a low 
number of M2 macrophages. There was no such prognostic difference between 
high and low numbers of M1 macrophages, and the investigators found that the 
number of M1 macrophages was similar to the number of M2 macrophages in 
each individual biopsy. We suggest that this study was perhaps ambitious in 
hypothesizing that the in vitro phenomenon of pure M1 and M2 phenotypes 
might be sufficiently faithfully replicated within a human tumour, and particularly 
that biologically distinct phenotypes could be distinguished using only a single 
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marker in each case. Given the expected immune-suppressive milieu of the 
tumour microenvironment, one might expect to be unable to detect any 
macrophages of a truly M1-like phenotype.  
A smaller study of 43 patient samples of untreated primary central nervous 
system lymphoma (PCNSL) investigated not only macrophage phenotype, but 
also its links with the activation state of the malignant cells, as measured by 
STAT3 staining (Komohara et al., 2011). This was on the basis of earlier studies 
demonstrating the significance to tumour progression of malignant cell STAT3 
activation in DLBCL (Stewart et al., 2009, Ding et al., 2008) and other cancers 
(Cheng et al., 2003, Yu et al., 2007) and its correlation with the number of 
tumour-infiltrating M2 phenotype macrophages in ovarian cancer (Takaishi et 
al., 2010). Interrogating FFPE samples with the M2 macrophage phenotype 
markers CD163 and SRA/CD204, they report that increased PCNSL malignant 
cell STAT3 correlates with a denser infiltration with CD163 positive (but not 
SRA/CD204 positive) macrophages. In vitro co-culture without direct cell-cell 
contact demonstrated an up-regulation of STAT3 in lymphoma cell lines in the 
presence of healthy donor PBMC-derived macrophages that had been matured 
with GM-CSF and polarised with tumour-conditioned media. No correlation with 
prognosis was seen with quantification of staining for CD68, CD163, 
SRA/CD204, or STAT3. However, this study is of interest in identifying a 
possible mechanism and bi-directional relationship whereby secreted 
substances present in tumour-conditioned media are able to direct macrophage 
phenotype that subsequently impacts upon tumour cell activation state.  
Co-culture of monocytes promotes the survival of normal B-cells and primary 
human DLBCL B-cells. DLBCL cells also show increased proliferation with 
monocytes, further enhanced by supplementary B-cell activating factor of the 
TNF family (BAFF) or IL-12 (Mueller et al., 2007). This process is reinforced by 
the fact that macrophages can activate B-cells through the B-cell receptor 
(BCR), stimulating their release of CCL5, a leukocyte chemo-attractant included 
in the Host Response signature of DLBCL (Monti et al., 2005). Mueller et al. 
speculate that blocking CCL5 might provide a therapeutic strategy to attenuate 
monocyte/macrophage recruitment in DLBCL, and so reduce malignant B-cell 
survival and proliferation in this disease. 
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4.3 Follicular lymphoma. 
FL is a malignancy of germinal centre B-lymphocytes that accumulate to 
varying extents in the lymphoreticular, haematopoietic and extranodal 
compartments. Affected lymph nodes contain a mixture of small regular 
lymphoid cells (centrocytes) and larger more irregular lymphoid cells 
(centroblasts), within a variably conserved lymph node follicular architecture. 
This conservation of normal lymph node architecture, with attendant T-cells and 
FDC meshwork, hints at the importance of supporting non-malignant cells to the 
survival of FL, corroborated by the need for CD40L stimulation to maintain in 
vitro culture of primary FL (Ghia et al., 1998). FL is graded from I to III 
depending on the number of centroblasts seen per high power light microscope 
field.  
Malignant B-lymphocytes of FL express characteristic cell surface markers 
including the pan-B-cell markers CD19, CD20, CD22, as well as monoclonal 
light chains, CD10 (in 60%), but not CD5. The chromosomal translocation 
(14;18) is identified in 70-95% of FL (Rowley, 1988, Horsman et al., 1995) and 
20-30% of DLBCL (Weiss et al., 1987, Lipford et al., 1987), and causes 
rearrangement and over-expression of the anti-apoptotic protein BCL2, such 
that in contrast to non-malignant B-cells without high affinity for antigen, they do 
not undergo apoptosis but rather proliferate in germinal centres. In FL, BCL2 
expression can be readily identified in histological sections, and is thought to 
contribute to the pathophysiology of the accumulating malignant clone.  
With an annual incidence of about 3 new cases per 100 000 of the English 
population, FL contributes 2% to all malignancies diagnosed in the UK each 
year. The median age at diagnosis is 60 years, with an equal sex distribution.   
The worldwide incidence of all types of NHL, including FL, has been increasing 
at a rate of between 1-4% each year since the 1970's, resulting in almost a 
doubling in overall incidence in this time. Such analyses have also confirmed a 
striking geographical variation in FL, being more common in Western nations 
(Muller et al., 2005). The incidence of FL is particularly low in China and Japan. 
In the USA, the incidence is 2-3 times higher in Caucasians than in African 
Americans, suggesting that genetic factors may be significant, in addition to 
environmental modifiers, which remain unidentified.  
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4.3.1 Clinical features of FL. 
FL presents most commonly with palpable lymph node enlargement in the neck, 
axillae or groins. Rarely, cases are observed to spontaneously regress (Gattiker 
et al., 1980, Krikorian et al., 1980, Horning and Rosenberg, 1984, Kumar et al., 
2004), but sustained spontaneous remissions are extremely rare, and the vast 
majority eventually develop progressive lymph node enlargement. Untreated, 
FL usually progresses to infiltrate the bone marrow, resulting in compromised 
haematopoiesis of all cell lines. The natural history of this disease concludes 
with eventual death from bone marrow failure; infection, bleeding and 
consequences of anaemia, or less commonly from the mass effect of enlarged 
malignant lymph nodes.  
For each affected individual, FL typically behaves in a variably indolent fashion, 
with months or years of clinically imperceptible change or very gradual 
asymptomatic progression, interrupted by episodes of obvious clinical 
progression. Approximately 2% of patients with FL each year experience clinical 
“transformation” to a more aggressive and rapidly progressive disease termed 
transformed FL (tFL), which is histologically identical to DLBCL. tFL has a very 
poor prognosis (Acker et al., 1983) and is commonly a terminal event. Data 
collected prospectively over 25 years in our centre, relating to 325 diagnoses of 
FL demonstrated a 28% risk of transformation to histologically proven 
tFL/DLBCL over a 10-year period. These individuals had only a 1.2 yr median 
survival from transformation (Montoto et al., 2007). 
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4.3.2 Therapy for FL. 
Localised disease, though relatively rare, can be cured with radiotherapy (Chen 
et al., 1979, Paryani et al., 1983, Vaughan Hudson et al., 1994, Wilder et al., 
2001, Mac Manus and Hoppe, 1996). Widespread FL is almost always 
incurable with conventional chemotherapeutic approaches, yet is described as 
an indolent malignancy, with a median survival of about 12-14 years from 
diagnosis (Hoppe et al., 1981, Fisher et al., 2005). The clinical course of FL is 
highly variable. This presents major clinical challenges.  Some patients may 
never require treatment, even after more than 20 years, whilst others succumb 
to aggressive disease in less than 2 years. It remains difficult to predict 
accurately individual patient survival from diagnosis.  
Until the introduction of combined chemo-immunotherapy incorporating the 
monoclonal anti-CD20 antibody rituximab, evidence suggested that medical 
intervention had no significant impact on overall survival in FL (Hoppe et al., 
1981, Brice et al., 1997, Ardeshna et al., 2003, Young et al., 1988). 
Chemotherapy was reserved for symptomatic or bulky disease to induce 
regression to a once-more asymptomatic stage. The goal of therapy was to 
maintain the best quality of life and treat only when symptoms dictated. Any 
alteration to this approach required demonstration of improved survival with 
early therapy, or identification of criteria that defined patients at sufficiently high 
risk to merit early therapy (Gribben, 2007). The advent of rituximab challenges 
this approach. There is now a robust body of evidence indicating that rituximab 
in combination with chemotherapy improves the proportion of patients achieving 
a complete remission, prolongs PFS and OS (Marcus et al., 2005, Forstpointner 
et al., 2004, Hiddemann et al., 2005, Schulz et al., 2007). There is also 
evidence that single agent rituximab given as long-term maintenance therapy 
prolongs PFS in first remission (Salles et al., 2011) and after remission re-
induction for relapsed FL (van Oers et al., 2010). 
The aim of current management is to achieve and maintain the best possible 
response to therapy for the longest period, and to prolong survival. First-line 
treatment options for stage III or IV follicular lymphoma include single-agent or 
combination chemotherapy regimens based on alkylating agents, with or 
without steroids, and in combination with rituximab. There is no consensus as to 
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the best timing or combination of therapy in FL, and patients should always be 
considered for entry into clinical trials. 
There is compelling evidence for an effective immune response to FL in 
patients who successfully undergo allogeneic haematopoietic stem cell 
transplantation (HSCT). A graft-versus-lymphoma (GvL) effect has been 
demonstrated in vivo, with remissions occurring in response to donor 
lymphocyte infusions (DLI) in patients with relapsed FL following allogeneic 
HSCT (Morris et al., 2004). Allogeneic HSCT incurs a significant morbidity and 
mortality, and appropriate patient selection and timing of transplantation is 
critical in this indolent malignancy. However, FL remains incurable by both 
conventional and novel therapies, and young patients will likely die of their 
disease far short of the population average life expectancy. tFL in particular, 
has a poor prognosis despite the benefits to some selected patients of high 
dose chemotherapy supported by autologous HSC rescue (Foran et al., 1998, 
Kasamon et al., 2011, Eide et al., 2011, Bastion et al., 1997, Chen et al., 2001, 
Williams et al., 2001b, Oliansky et al., 2010). Ongoing studies are addressing 
whether there is a role for allogeneic HSCT in young patients and those with 
rapidly progressive, relapsed or refractory disease (Toze et al., 2004). 
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4.3.3 Prognostication in FL – the follicular lymphoma international 
prognostic index. 
The most rigorously validated and universally adopted prognostic scoring index 
available is the FL international prognostic index (FLIPI). This is a 5-factor index 
based on clinical characteristics and routine blood test results at diagnosis, and 
was established by retrospective analysis of 4167 patients diagnosed between 
1985 and 1992 and treated without rituximab (Solal-Celigny et al., 2004). Age, 
stage, number of nodal sites, haemoglobin concentration, and serum LDH, 
defines 3 prognostic groups. In patients with a good prognosis (0-1 adverse 
factor), the 10-year OS is 71%, falling to 36% with 3 or more adverse factors. 
Subsequent work has established the continued validity of the FLIPI score to 
patients treated with rituximab (Buske et al., 2006). Although prognostically 
useful, so far the clinical impact of the FLIPI score has been very limited, 
informing tactical decisions but not directing the optimal specific therapy for 
each patient group. The FLIPI has benefit in communicating risk to patients, 
and in comparing populations in clinical trials and laboratory analysis of patient 
samples. 
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Prognosis No. of adverse 
factors 
10-year survival (%) 
Good 0 or 1 71 
Intermediate 2 51 
Poor 3 or more 36 
 
Table 3 - Relationship of FLIPI score to survival. 
 !
Variable Adverse Factor 
Age > 60 years 
Stage > 2 
Affected nodal sites > 4 
Lactate 
Dehydrogenase 
>Upper limit of 
normal 
Haemoglobin < 12mg/dL 
Table 2 - Adverse prognostic variables of the FLIPI scoring system. 
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4.3.4 Gene expression profiling in FL reveals the prognostic influence of 
the cellular microenvironment. 
A seminal study strongly implicated a critical role for the tumour 
microenvironment in the prognosis of FL (Dave et al., 2004). Diagnostic lymph 
node biopsies were collected from 191 patients diagnosed with FL at a variety 
of international centres including our own and divided into a training set and a 
test set, balanced for institution and length of survival. RNA gene expression 
was determined using Affymetrix U133A and U133B human whole genome 
microarrays. A complex statistical approach was used to determine survival 
associated gene expression signatures, in this way avoiding the analytical 
limitations of multiple comparisons of large individual gene expression data 
sets. In the training set, the Cox model was used to determine genes 
associated with survival, and these genes were arranged by hierarchical 
clustering with respect to their prognostic association. Genes that had 
correlated expression were grouped into survival-associated gene-expression 
signatures.  
Each individual biopsy in the training set was then assigned a “signature 
average” relating to its own gene expression. The whole training set was 
interrogated to find associations between survival and expression of different 
combinations of multiple survival signatures. A binary model of one good 
prognosis signature and one poor prognosis signature was found to be highly 
predictive of survival in the training set. The two signatures were respectively 
termed “immune response 1” (IR1) and “immune response 2” (IR2). This model 
was then positively validated in the test set of diagnostic biopsy specimens.  
In an attempt to derive functional information from the statistical associations, 
the authors attributed cells of origin to genes in each signature. This was 
pursued by FACS of cell suspensions obtained from four fresh biopsy 
specimens, into CD19 positive (malignant) and CD19 negative (non-malignant) 
populations, and each subpopulation profiled for gene expression. Further 
analysis of the non-malignant cell population was attempted by comparison of 
gene expression in the FL biopsies with gene expression of monocytes purified 
from peripheral blood lymphopheresis samples from normal donors, magnetic 
sorted for CD14, a monocyte/macrophage marker, and a receptor for LPS.  
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Of note, the IR1 signature included genes encoding T-cell markers and genes 
highly expressed in macrophages, and IR2 included genes preferentially 
expressed in macrophages and DC. Interestingly, the IR1 and IR2 signature 
averages, and expression of individual component genes, were higher in the 
CD19 negative, non-malignant cells than the CD19 positive malignant cells. 
This suggested that gene expression of the non-malignant cells contributed 
more to prognostic discrimination at diagnosis, than did gene expression in the 
malignant B-lymphocytes. The authors speculated that the nature of the 
infiltrating immune cells was the predominant feature of the tumour that 
predicted length of survival, and that the relative contribution of immune cell 
gene expression, rather than absolute levels, was critical. With hindsight, this 
would appear to have been a highly prescient suggestion, given the 
inconsistent findings of subsequent studies simply attempting to relate absolute 
numbers of infiltrating macrophages to prognosis in FL. They suggested that an 
understanding of the nature of “trophic signals” provided by the 
microenvironment in FL might provide new targets for therapy. In this respect, 
their work provides an appropriate rationale for our own studies, attempting to 
elucidate the nature and significance of TAM in B-NHL. It is interesting to note 
that genes ascribed to monocytes and macrophages were present in both the 
IR1 and IR2 signatures, perhaps providing further clues that simply the 
abundance of these cells is not likely to be prognostic, but rather that 
determining their differing gene expression and phenotypes might be more 
illuminating. 
Several criticisms have since been raised regarding this work. In particular, it 
has been suggested that more extensive positive selection of immune cell 
subtypes would have yielded crucial missing information (Naresh, 2005). 
Additionally, the same authors contend that the identification of gene 
expression signatures was of limited use compared to the identification of 
smaller sets of highly discriminatory genes and their associated molecules that 
might translate into useful clinical applications in diagnostic 
immunohistochemistry. Whilst acknowledging the validity of such statements, 
we feel that the over-riding strength of Dave’s work is in hypothesis generation, 
and so directing future studies. The experimental and statistical design does not 
appear to have been formulated to answer questions about the specific roles of 
individual genes or even cellular subtypes beyond discriminating the 
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contributions of CD19 positive or negative or CD14 positive populations. Other 
criticisms of the techniques employed by Dave et al. are perhaps more valid. It 
is now recognised that a minority population of malignant B-lymphocytes in FL 
express CD19 at very low levels or not at all (Masir et al., 2006). Conceivably 
this might diminish the accuracy of conclusions drawn from using CD19 
selection to separate malignant from non-malignant cells. Furthermore, the 
assessment of gene expression in fresh biopsy specimens was limited to only 
four samples, from which conclusions were drawn regarding the whole data set. 
Additionally, attribution of genes expressed in FL biopsies to 
monocyte/macrophages was based on the assumption that this directly 
paralleled gene expression in circulating monocytes collected from normal 
healthy donors. Our knowledge of monocyte diversity, macrophage phenotypic 
plasticity, and the particular activation status observed in tumour-associated 
macrophages, informs that such assumptions are unlikely to be entirely valid.   
Tibshirani re-examined the statistical findings, and suggested that the results 
were rather fragile (Tibshirani, 2005). On swapping the training and test sets 
and reapplying the same formulae, they found that the same model did not 
emerge, and indeed that by these means, no such model could be significantly 
associated with survival. Dave and colleagues disputed the appropriateness of 
the statistical methods employed by Tibishirani, and defended their original 
methods, model and findings. Regardless of who is correct, the work of Dave 
and colleagues heralded much work investigating correlations between the 
numbers of non-malignant cells and prognosis in FL. Our own project aims to 
build on this, and contribute to the nascent field investigating functional 
interactions in the lymphoma microenvironment. 
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4.3.5 Counting tumour-associated macrophages in FL. 
Several independent groups have counted macrophages in specimens of FL, 
and searched for correlations with clinical features and outcomes. There is no 
clear consensus regarding the prognostic importance of numbers of 
macrophages in FL. There are wide variations between studies regarding 
patient selection, immunohistochemical staining protocols, and cell counting 
methods. !
Farinha and colleagues investigated 99 young patients with FL, all below the 
age of 61 years (median age 44yrs), treated uniformly, and without rituximab 
(Farinha et al., 2005). Therapy consisted of 6-agent combination chemotherapy 
plus steroids, followed by involved region radiotherapy. The median OS in this 
group was 16.3 years. The vast majority of patients, 87 in total, were classified 
as having few macrophages by CD68 immunohistochemistry, with less than 15 
positive cells per high power field, and had a median OS of 16.3 years. 12 
patients had more than 15 positive cells per high power field, with a median OS 
of 5.0 years (p=<0.01). This statistically significant p-value suggested that a 
large number of macrophages correlated with a poor prognosis in FL. A 
subsequent study assessed 60 frozen FL lymph nodes for macrophage 
numbers by IHC and the expression of 35 candidate “indicator” genes of 
immune response by qRT-PCR. A high number of CD68+ macrophages 
correlated with a shorter OS, as did high levels of CCR1 gene expression, a 
marker of monocyte activation (Byers et al., 2008). 
Wahlin and colleagues quantified infiltrating immune cells in pre-treatment 
biopsies in 70 FL patients at the extremes of survival, using both 
immunostaining and flow cytometry (Wahlin et al., 2010). An abundance of 
interfollicular CD68+ macrophages correlated with poor prognosis. An 
abundance of CD4+ cells also correlated with poor outcome (especially when 
follicular). Staining with programmed death-1 (particularly follicular) and CD8+ 
cells correlated with good prognosis (particularly when interfollicular). Follicular 
FOXP3+ cells correlated with good prognosis. This study supports the 
conceptually attractive proposition that the overall composition, balance and 
location of immune infiltrating cells are critical. The authors urged caution in 
interpreting the results relating to macrophage numbers and prognosis owing to 
the fact that this was not a primary objective in their study hypothesis, and that 
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the patient cohort was heterogeneous in respect to therapy, with 30% receiving 
rituximab at some point. 
Alvaro and colleagues interrogated 211 diagnostic biopsies of an older patient 
group than Farinha (Alvaro et al., 2006b). These patients were not treated with 
exactly the same regimens, and 5 received rituximab. They found that CD68+ 
cells were predominantly located in the interfollicular regions, and that an 
abundance of such macrophages was associated with features of good 
prognosis, including normal bone marrow at diagnosis, and earlier stage 
disease (I or II), but was not significantly, independently correlated with OS. 
Interestingly, their study focused on the discovery of different immune-cell 
signatures by immunohistochemistry. They identified an “immunosurveillance 
pattern” rich in T-lymphocytes and macrophages associated with “favourable 
clinical behaviour”, and an “immune-escape pattern” rich in CD57+ T-cells, 
associated with a higher frequency of adverse manifestations such as bone 
marrow infiltration by lymphoma. The authors state that their work does not 
provide conclusive evidence regarding such associations, rather a further guide 
toward future research questions. 
In our own centre, no correlation was found between numbers or location of 
CD68+ cells and survival amongst a large number of diagnostic biopsies from 
patients who never received rituximab (Lee et al., 2006). Similarly, Glas and 
colleagues studied biopsies of patients with FL who never received rituximab. 
Using the same cut-off criteria as Farinha, they found that CD68+ cells (and 
regulatory T-cells) were not differentially present with respect to risk of 
transformation and survival (Glas et al., 2007).  
Alvaro and colleagues, studying the same samples as discussed above (Alvaro 
et al., 2006b) attempted to derive information regarding the activation status of 
macrophages in FL (Alvaro et al., 2006a). Double immunofluorescence with 
CD68 and signal transducer and activator of transcription-1 (STAT-1) was 
performed.  STAT-1 staining co-localised exclusively with CD68 and was 
prognostic of shorter OS. The authors stated that patients with STAT-1 
expression and low infiltration of macrophages have reduced OS and more 
frequent progression than those without STAT-1 expression. As such, it would 
appear as though the presence of a low number of macrophages, but with a 
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high proportion expressing STAT-1, correlated with a poor prognosis. However, 
STAT-1 expression alone was not prognostic for survival, but became 
significant on multivariate analysis with the FLIPI score. These findings might 
support the notion of macrophage activation status and phenotype being more 
important than numbers alone, but remain to be independently validated in a 
separate data set. !
Work from our group has provided evidence for a functional association 
between TAM and angiogenesis within poor prognosis FL (Clear et al., 2010). 
In an attempt to gather functional information from FFPE sections of FL, the 
proximity of macrophages to tiny neovascular angiogenic sprouts was 
investigated. There was evidence for both a greater angiogenic activity in the 
poor prognosis group, and also a correlation between increased angiogenic 
sprouting and abundant CD163+ macrophages in the interfollicular regions. It 
has been suggested that CD163 might be a marker of macrophage activation 
towards a pro-tumoural M2 phenotype, particularly as evidenced by whole 
genome transcriptome analysis of M2 polarised human macrophages (Martinez 
et al., 2006). 
Recent elegant co-culture experiments with human tissue highlight interactions 
between mesenchymal stromal cells (MSC), monocytes, macrophages and 
malignant cells in FL (Guilloton et al., 2012). MSC produce anti-inflammatory 
mediators that direct an IL-10 high macrophage phenotype (Cutler et al., 2010, 
Nemeth et al., 2009, Choi et al., 2011). MSC from patients with FL (FL-MSC) 
had distinct gene expression profiles than from age-matched healthy donors 
(HD-MSC), up-regulating CCL2. CCL2 is known to act as a monocyte chemo-
attractant, and may also have roles in driving the M2 macrophage phenotype 
(Roca et al., 2009b, Qian et al., 2011, Shi et al., 2011). HD-MSC were found to 
up-regulate CCL2 on co-culture with malignant B-lymphocytes derived from FL 
infiltrated lymph nodes. CCL2 administration had no direct effect on FL B-
lymphocyte survival in vitro, but that their survival was promoted by FL-MSC 
alone, macrophages alone and synergistically by FL-MSC and macrophages. 
FL-MSC directed co-cultured monocytes towards a pro-angiogenic and LPS-
unresponsive phenotype with increased IL-10 release, less TNF-!, more IL-6 
and more VEGF.  Functional studies indicated that FL-MSC secreted more 
CCL2 and recruited monocytes more efficiently than HD-MSC, a difference that 
was abolished by the depletion of CCL2. As such, a tripartite relationship was 
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revealed such that MSC recruit and modulate monocytes to create a favourable 
niche for the survival of malignant B-lymphocytes. 
A recent publication illuminates a mechanism through which monocytes and T-
cells cooperate via IL-15 and CD40L to promote the growth of human normal 
and FL B-cell populations (Epron et al., 2012). Cells of the 
monocyte/macrophage/DC lineage are known to be the major producers of IL-
15 and do so maximally in the presence of the Th1 cytokine IFN-# (Rochman et 
al., 2009). Soluble IL-15 alone has no direct effect on B-cell survival or 
proliferation in vitro (Do and Min, 2009). Epron et al. found that IL-15 was over-
expressed in purified TAM from FL biopsies, and that STAT5 was over-
expressed in FL malignant B-cells. In vitro, CD40L signalling triggered an up-
regulation of STAT5 expression in FL B-cells, and favoured SRC-dependent 
phosphorylation of STAT5 in response to IL-15. Monocytes and lymphoid 
derived macrophages could trans-present IL-15 to normal B-cells, and in 
cooperation with T-cell derived CD40L, favour B-cell proliferation. This work 
suggests a role for Th1 activated monocytes and macrophages in 
lymphomagenesis. 
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4.3.6 Counting tumour-associated macrophages in relation to therapy in 
FL. 
Evidence has accumulated to suggest strongly that the direction and magnitude 
of correlation between macrophage numbers at diagnosis and outcomes might 
be dependent upon the subsequent therapies administered. In particular, 
exposure to, or lack of exposure to, rituximab, appears to be relevant within 
several studies, such that exposure to rituximab might circumvent an adverse 
prognostic influence of macrophages.  
Taskinen and colleagues counted CD68+ macrophages in 141 patients with FL 
using the same criteria as Farinha (Taskinen et al., 2007). 96 received rituximab 
initially or at relapse, 45 did not. In those not receiving rituximab, a high number 
of macrophages predicted shorter PFS (17 months versus 41 months). 
However, following rituximab therapy, many macrophages correlated with 
prolonged PFS (57 months versus 17 months).  
In a smaller study, Kelley and colleagues found by sub-set analysis of 69 
patients treated at the outset for a diagnosis of FL (rather than managed 
expectantly), that high numbers of CD68+ cells correlated with shorter OS in 
those not receiving rituximab (Kelley et al., 2007). This association was lost in 
those receiving rituximab.  
Canioni and colleagues counted CD68+ cells in 194 patients with FL enrolled to 
a trial assessing the addition of rituximab to a combination regimen of 
chemotherapy and interferon-! (Canioni et al., 2008). In those not receiving 
rituximab, low numbers of intra- or interfollicular macrophages correlated with 
longer event free survival (EFS). This association was critically dependent on 
the counting thresholds used, and was entirely absent in those treated with 
rituximab. It should be noted that follow up was relatively short (42.9 months), 
with no differences in OS discovered in this time.  
A retrospective analysis was reported of the prognostic value of total, 
intrafollicular and extrafollicular CD68 TAM numbers in patients treated in 3 
separate trials conducted by the South Western oncology group (SWOG), 2 of 
which exposed patients to rituximab (Sweetenham et al., 2010). All had long 
follow-up. In the first trial 103 patients received ProMACE-MOPP (Methotrexate, 
doxorubicin, cyclophosphamide, etoposide - Mechlorethamine, vincristine, 
prednisolone, procarbazine) and were randomized to receive no further therapy 
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or IFN-#. In the second study, patients received R-CHOP and 30 were eligible 
for this analysis, and in the third, 47 were eligible from a study using I131 
Tositumimab plus CHOP chemotherapy. The numbers of infiltrating 
macrophages had no correlation with OS in any of the studies, nor did the 
numbers of Tregs. 
A relatively small study of 50 patients with previously untreated FL who were to 
begin therapy, found that an abundance of intrafollicular CD68+ macrophages 
heralded a shorter OS and 3 year PFS than low numbers of intrafollicular 
CD68+ macrophages (Andjelic et al., 2012). 38 of these patients were not 
treated with rituximab, and subgroup analysis revealed that the prognostic 
significance of CD68+ macrophages held for this group, but not for the 12 
patients treated with rituximab. It was not stated whether such small numbers in 
the rituximab treated group provided sufficient statistical power to demonstrate 
a reasonably expected difference.    
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4.4 Burkitt lymphoma. 
There are 3 clinical variants of BL with similar histology; endemic, sporadic, and 
AIDS-associated. Epstein-Barr virus (EBV) appears to be an important co-factor 
in the development of BL (Rowe et al., 2009), possibly blocking apoptosis (Kelly 
et al., 2009a, Vereide and Sugden, 2011). It is usually present in endemic 
cases, variably in AIDS-associated, and infrequently in sporadic cases in 
Europe and North America (Jaffe and Pittaluga, 2011).  
The malignant cells in BL are medium-sized with uncleaved, round nuclei with 
multiple nucleoli and deeply basophilic, vacuolated cytoplasm. BL has a mature 
B-cell phenotype with surface IgM expression and is a highly aggressive 
disease with frequent involvement of extranodal sites and occasionally a 
leukaemic phase. BL cells express BCL-6 and CD10, reflecting a GC B-cell 
origin. In addition, they have detectable surface IgM, CD19, CD20, CD22 and 
CD79a. Ki67 staining is almost, if not entirely, universal amongst malignant B-
cells in BL, giving a doubling time of approximately 25 hours. BL cells are 
negative for CD5, CD23 and TdT (Blum et al., 2004). 
Taking all three groups together and worldwide, BL is most common among 
children, and in the developing world, as endemic BL. This disease is 
commonest in equatorial Africa between ages 4 and 7 years where it 
constitutes 70% of all childhood lymphoma diagnoses (Parkin and International 
Agency for Research on Cancer., 1998) and manifests with frequent 
involvement of the jaw and kidneys (Blum et al., 2004). In wealthy nations, the 
standard of care for children with BL is dose-intensive multi-drug chemotherapy 
with central nervous system (CNS) prophylaxis, giving long-term survival to 60-
90% of patients (Reiter et al., 1999, Cairo et al., 2007, Patte et al., 2007). AIDS-
associated BL, unlike other HIV-related NHL, frequently occurs with CD4 counts 
above 200 cells/µl (Davi et al., 1998) and has a similar clinical presentation to 
sporadic BL.  
The majority of adult patients with BL in the developed world are aged over 40 
years, are HIV negative and have sporadic BL. Usually having large abdominal 
tumour masses, they account for about 3% of all adult lymphomas in England 
and Wales. Adults with sporadic or AIDS-related BL typically present with large 
abdominal nodal masses with extranodal spread commonly detected in the 
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bowel, although other organs can be infiltrated (Blum et al., 2004). Bulky and 
rapidly growing disease results in a typical biochemical picture of raised serum 
LDH and uric acid concentrations. Bone marrow involvement is detected in 30-
38% and CNS infiltration in 13-17% of adults with sporadic BL (Mead et al., 
2002, McMaster et al., 1991, Soussain et al., 1995). BL can be staged using the 
Ann-Arbor system. 
There have been no randomized trials to inform choice of therapeutic regime in 
adults with BL. It is fairly clear from comparisons of different treatment series 
that the underlying principles should be prompt therapy with intensive courses 
of chemotherapy including fractionated alkylating agents and cell-cycle specific 
agents that cross the blood-brain barrier (Linch, 2012). The outcomes from 14 
treatment series have recently been analysed (Kelly et al., 2009b). All patients 
received dose-intensive multi-drug regimes, yet OS was found to be worse in 
this group than in younger patients, but had improved with the passage of time, 
with 6 out of 7 studies published since 2000 giving 2 year OS of over 60%. One 
of these series incorporated rituximab (Thomas et al., 2006), and reported a 3 
year OS of 89%. A more recent retrospective analysis of 23 adults with non-HIV 
related B-NHL with proliferation indices >95% (including 14 with typical sporadic 
BL) reports 83% OS at a median follow up of 34 months after treatment with 
rituximab plus intensive combination chemotherapy with CNS penetration 
(Mohamedbhai et al., 2011). Despite these improved figures with rituximab, 
there remains a need for additional novel therapies for those patients who do 
not achieve a complete remission (CR), or who relapse, as there is currently no 
satisfactory salvage strategy, and the majority of these patients will die of BL. 
The largest published series of allogeneic HSC transplants for BL reports 71 
patients from the European group for blood and marrow transplantation (EBMT) 
registry data aged 4 to 48 years treated either in first CR or at relapse (Peniket 
et al., 2003). Only 20% of these patients had chemoresistant disease at 
transplant. OS correlated with chemosensitivity, and not with the presence of 
acute GvHD, and matched patients undergoing high dose therapy with 
autologous stem cell rescue had a similar relapse rate and superior OS. A 
single case report describes only transient regression of relapsed BL with the 
onset of GvHD following withdrawal of immunosuppression and administration 
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of IFN-! after allogeneic HSC transplant (Grigg and Seymour, 2002). Together, 
these data do not provide convincing evidence for a strong GvL effect in BL. 
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4.4.1 Biology of BL in relation to tumour-associated macrophages. 
Diagnosis of BL is complicated by cases of typical immunophenotype but 
variant morphology, cases of typical morphology without evidence of MYC 
rearrangement, and cases of DLBCL with MYC rearrangement. Gene 
expression profiling has revealed that BL has a signature that is clearly distinct 
from DLBCL, is similar in adults and children, and a small proportion of 
intermediate cases exist with signatures showing features of both BL and 
DLBCL (Dave et al., 2006, Hummel et al., 2006). This has not yet been adopted 
as a routine diagnostic tool.  
BL is characterised by high rates of MYC-driven proliferation (Milner et al., 
1993) and apoptosis (Evan et al., 1992, Shi et al., 1992) with abundant TAM 
producing a “starry sky” appearance to histological sections, within which can 
be found apoptotic bodies containing tumour cell debris (Gregory et al., 1991). 
Macrophage phagocytosis of apoptotic cell debris serves to regulate anti-
lymphoma immune responses (Savill et al., 2002) by swiftly removing tumour 
antigens without exciting an acute inflammatory response and so failing to 
generate adaptive immune responses against apoptotic cell-derived antigens 
(Albert et al., 1998, Ronchetti et al., 1999). Moreover, the mechanisms 
underlying macrophage clearance of apoptotic cell debris activate anti-
inflammatory wound healing processes within macrophages, likely to further 
promote tumour growth and repel anti-tumour immunity (Ogden et al., 2005). 
With relevance to our project, macrophage ablation might, therefore, result in 
failure to clear apoptotic tumour cell debris, attenuate the anti-inflammatory 
macrophage phenotype and allow a more robust anti-tumour immune response 
to mount.  
CX3CL1 released from apoptotic lymphocytes is able to attract monocytes and 
macrophages expressing CX3CR1 (Truman et al., 2008). CX3CR1 deficiency 
reduces macrophage recruitment to the germinal centres of lymphoid follicles. 
Induction of apoptosis with UV radiation enhances the chemo-attraction of 
macrophages in vitro, as does exposure to cell-free supernatants of cultured 
malignant BL cells.  
It has been shown that macrophages support BL growth in vitro (Levens et al., 
2000). More recent work sheds light on some of the responsible mechanisms. 
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TAM depletion in lymphoma might conceivably contribute to reduced tumour 
progression through the removal of lymphoma cell survival factors such as 
BAFF, and decreased macrophage-phagocytosis and removal of apoptotic cells 
resulting in enhanced anti-lymphoma immunity. BAFF is known to promote the 
survival of normal and malignant B-cells in vitro (Schneider et al., 1999, Moore 
et al., 1999, Novak et al., 2002, Novak et al., 2004, He et al., 2004). Tumour 
and macrophage derived IL-10 appears a crucial cytokine in this regard, with IL-
10 activated macrophages in vitro demonstrating enhanced ability to engulf 
apoptotic cells and increased production of BAFF, which is further augmented 
by co-culture with malignant B-cells of BL (Ogden et al., 2005). Ogden et al. 
describe that the microenvironment in BL is rich in IL-10. Enhancement of BL 
cell survival by IL-10 activated TAM is mediated by macrophage-derived BAFF, 
and diminished by blocking BAFF or its receptor. Whilst blockade of BAFF, 
APRIL and IL-10 diminished the growth of BL populations in vitro, residual 
growth suggests roles for other pathways not identified by this work.  
In a later chapter we shall review further evidence for links between malignant 
B-cell apoptosis and TAM when discussing our use of a Myc-driven mouse 
model of lymphoma. !
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4.5 Lessons from T-cell lymphomas. 
In this section we shall critically review several publications relating to the role 
of TAM in mouse models of T-cell lymphoma. Whilst not relating specifically to 
mature B-NHL, they provide interesting and informative pointers as to the 
interactions between TAM, malignant lymphocytes, and other partners in the 
lymphoma microenvironment. 
Some of the very earliest evidence for the potential anti-lymphoma effects of 
TAM derives from work with T-cell lymphoma cell-lines and mouse models. 
L5178Y, a T-lymphoblastic lymphoma (Fischer, 1958) arising after carcinogenic 
methylcholanthrene exposure of DBA/2 inbred mice, was found to be sensitive 
to macrophage ingestion in vitro. Peritoneal macrophages, harvested after 
injection with the irritant agent thioglycollate, phagocytosed L5178Y cells more 
than control macrophages (Evans, 1971). More recent in vitro studies revealed 
that direct cell contact with L5178Y cells primes naïve macrophages to be 
sensitive to subsequent stimulation by LPS to a tumour cell cytotoxic phenotype 
(Buhtoiarov et al., 2007). This phenomenon is not seen with a B-cell lymphoma 
line (Daudi) and appears dependent on CD40:CD40L interactions.  
The in vivo growth of transplanted EL4 T-cell lymphoma was retarded in mice 
deficient for the M2 phenotype marker SRA, compared to wild type controls. 
This correlated with increased expression of the M1 macrophage phenotype-
associated genes NO and IFN-# in SRA deficient tumour tissues (Komohara et 
al., 2009) and increased production of these proteins by in vitro cultured 
macrophages from SRA deficient mice, suggesting important roles for SRA in 
modulating macrophage phenotype, and that lymphoma growth might be 
sensitive to these changes. Attempts to understand the true nature of the 
lymphoma microenvironment require an appreciation of the complex 
interactions between different immune cell populations. Interactions between 
Tregs and TAM are likely to be complex and bidirectional regardless of which 
cell type (if either of these) is the prime orchestrator of lymphoma-related 
immune responses, therapeutic perturbations of which would be likely to have 
significant impacts on the entire tumour microenvironment. It has been 
proposed that Tregs are able to suppress monocyte and macrophage activation 
and cytokine production whilst up regulating their expression of inhibitory 
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molecules (Mahajan et al., 2006, Taams et al., 2005, Kryczek et al., 2006, 
Tiemessen et al., 2007). Treg depletion is known to induce macrophage 
accumulation in secondary lymphoid organs (Kim et al., 2007). A virally induced 
T-cell lymphoma in mice (RMA-S) has been studied from the perspective of the 
interactions between Tregs, IFN-# and TAM in a multicellular immune response 
to lymphoma (Galani et al., 2010). Depletion of Tregs with anti-CD25 mAb led to 
tumour rejection, dependent on T-cells, NK cells and IFN-#. This phenomenon 
was also abrogated by neutralizing IFN-#. IFN-# was produced by T-cells and 
NK cells in the absence of Tregs. This correlated with an increase in TAM 
numbers of an M1-like phenotype, overexpressing MHCII and producing high 
levels of pro-inflammatory cytokines, and inhibiting tumour proliferation. This 
supported their hypothesis that in an unmanipulated situation, Tregs prevent the 
accumulation and anti-tumour activities of TAM. This work did not outline in 
detail the phenotype of the TAM present in the unmanipulated Treg non-
depleted scenario, although co-culture with RMA-S cells of identical numbers of 
TAM from the Treg deplete setting produced far more suppression of tumour 
proliferation than TAM from the unmanipulated setting, suggesting that in 
unmanipulated lymphoma, TAM might cooperate with Tregs in suppressing 
anti-tumour immune responses.    
Laboratory studies with Dalton’s lymphoma, a T-cell lymphoma manifesting with 
prominent ascites, indicates anti-lymphoma effects of M1-like macrophages, 
and the fact that macrophage plasticity allows this phenotype to be achieved in 
vivo, in this case with the intraperitoneal (ip) administration of a proton pump 
inhibitor (PPI), pantoprazole (Vishvakarma and Singh, 2010). This intervention 
led to enhanced TAM recruitment, with more features of an M1-like phenotype, 
compared to controls given ip PBS, with increased production of nitrous oxide, 
IL-1, TNF-! and IL-2R. The macrophages recruited following PPI administration 
had different properties ex vivo than control macrophages; with increased 
phagocytosis of yeast cells, and decreased survival of co-cultured lymphoma 
cells. Adoptive transfer of TAM from PPI treated mice retarded the growth of 
lymphoma and prolonged survival of host mice. Macrophages from healthy 
mice did not adopt these M1-like features when exposed to PPI either in vivo or 
in vitro. PPI treated lymphoma cells produced less IL-4, IL-10 and TGF-", and 
more IFN-#. Together, these data suggest an indirect effect whereby PPI 
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administration alters lymphoma cell biology, impacting on macrophage 
phenotype, and thus feeding back as an effective anti-lymphoma reaction. 
Features of tumour cell biology impact on macrophage phenotype, which in turn 
may influence tumour growth and survival, yet this itself may be a simplified 
interpretation. The true in vivo interactions involving a multitude of other 
immune and stromal cells are likely to be labyrinthine in their complexity. 
There is evidence for a potential cooperative anti-tumour partnership between 
macrophages and cytotoxic T-cells, coming from a mouse study using EG7 T- 
lymphoma cells (Asano et al., 2011). Fluorescently labelled, x-irradiated, killed 
tumour cells were injected to the footpads of mice, and fluorescence was 
observed to accumulate within CD11b+F4/80+MHC+CD169+ macrophages. 
Inoculation with dead tumour cells induced tumour antigen specific CD8 T-cell 
activation that was severely impaired in mice depleted of CD169+ 
macrophages, using the CD169 diphtheria toxin receptor (CD169-DTR) 
transgenic mouse. Mice were protected from subsequent injection with live EG7 
tumour cells if they had undergone prior dead EG7 cell immunization, unless 
they were CD169 depleted at the time of immunization, in which case the 
tumour established and grew. This work showed a critical role for CD169+ 
macrophages in anti-tumour immunity, by cross-presenting dead cell associated 
antigens to CD8+ T-cells. CD169 is the sialic acid binding receptor, 
sialoadhesin, which is expressed by activated macrophages in states of chronic 
inflammation including malignancy, chronic viral infections, and autoimmune 
disease (Hartnell et al., 2001). Expression of CD169 by TAM appears therefore 
to indicate a favourable anti-lymphoma immune endeavour, optimization of 
which might be an effective therapeutic strategy.  
Other studies point to the variably tumouricidal relationship between 
macrophages and T-cells in lymphomas, serving to highlight how the complex 
balance of the dynamic multi-cellular and cytokine-rich tumour 
microenvironment can impact on macrophage phenotype and so favour or 
suppress tumour growth and survival. Vicetti Miguel et al. described how 
cytotoxic T-lymphocyte (CTL) induction of NO production by TAM is critical for 
tumour elimination in a mouse model of T-cell lymphoma (Vicetti Miguel et al., 
2010). Tumours transferred to and growing in the skin were sensitive to the 
transfer of tumour antigen specific CTL, whereas those developing in the 
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relatively immune privileged site of the anterior chamber of the eye appeared 
resistant. Examining the CD11b+ populations in each site, the authors found 
that CD11b+Ly6G-F4/80+ cells were the dominant population in the skin, and 
that NO production by these cells following CTL injection was critical for tumour 
regression. In the eye, the majority population of CD11b+ cells were Ly6G-
F4/80- cells and failed to produce tumouricidal NO. When NOS2+ activated 
TAM were injected to the eye, they still failed to elicit tumouricidal activity, 
suggesting perhaps an over-riding influence of the surrounding milieu that 
inhibited the enzymatic activity of the potentially tumouricidal macrophages. 
This work suggests a role for CTL in the induction of tumouricidal activity in 
TAM for the effective elimination of lymphomas, and highlights that such a 
relationship may also be influenced by other, as yet poorly understood and in 
the case of this study unidentified, factors in the tumour environment. One 
might reasonably speculate that the CD11b+Ly6G-F480- population dominant 
within the eye might be myeloid cells of an immune suppressive phenotype, so 
attenuating tumouricidal immune activity, although this was not explored further 
in the paper.   
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4.6 Macrophages and rituximab. 
4.6.1 Macrophages cooperate with rituximab and other anti-CD20 
monoclonal antibodies in malignant B-cell killing. 
In DLBCL and FL, gene expression profiling implicates different groups of 
macrophage genes in different biological subtypes of disease (Monti et al., 
2005, Lenz et al., 2008, Dave et al., 2004). As summarised in tables 4 and 5, 
the literature does not provide evidence for an entirely consistent and 
reproducible association between overall TAM numbers and PFS, EFS or OS in 
FL or DLBCL. As outlined previously, there is evidence suggesting that 
macrophage phenotype is related to the biology and response to therapy in FL, 
DLBCL and BL (Wada et al., 2012, Meyer et al., 2011a, Komohara et al., 2011, 
Alvaro et al., 2006a, Clear et al., 2010, Ogden et al., 2005). Particularly in FL, 
there is evidence that a large number of TAM has opposing prognostic 
associations depending upon the therapy subsequently administered. 
Specifically, several publications suggest that a large number of TAM confers a 
poor prognosis in patients with FL treated without rituximab, and a good 
prognosis in those treated with rituximab (Taskinen et al., 2007, Kelley et al., 
2007, Canioni et al., 2008, Andjelic et al., 2012), although one large study did 
not find this pattern (Sweetenham et al., 2010). It is intriguing to speculate that 
macrophages might confer a favourable prognosis when rituximab is 
administered in B-NHL through cooperating in rituximab-induced killing of 
malignant B-lymphocytes. Most evidence for this phenomenon comes from 
observations in FL, and studies with another indolent B-cell malignancy, chronic 
lymphocytic leukaemia (CLL).  
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Author Number 
of 
samples 
Treated 
with 
rituximab  
Relative 
prognostic 
impact of many 
CD68+ cells 
Phenotypic data and 
relation to prognosis 
Hasselblom 
(2008) 
176 No Nil None 
Meyer 
(2011) 
262 Yes Nil CD68+/SPARC+ good 
prognosis  
Komohara 
(2011) 
43 Not stated Nil CD163 & tumour 
STAT3 
CD68+/CD163+ Nil 
CD68+/CD204+ Nil 
Cai  
(2011) 
112 No Nil None 
Coutinho 
(2011) 
218 67% No Good prognosis CD163 Nil 
Wada 
(2012) 
101 Yes Bad prognosis CD68+/CD163+ bad 
prognosis 
 
Table 4 - Summary of available data in relation to immunohistochemical 
enumeration of macrophages in DLBCL. 
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Author Number 
of 
samples 
Treated 
with 
rituximab 
Relative 
prognostic 
impact of many 
CD68+ cells 
Phenotypic data 
Farinha 
(2005) 
 
99 No Bad prognosis None 
Alvaro 
(2006) 
211 98% No Nil Few CD68+ with 
high proportion 
STAT1+ = bad 
prognosis 
Lee 
(2006) 
 
59 No Nil None 
Glas 
(2007) 
 
58 No Nil None 
Taskinen 
 (2007) 
141 32% No 
68% Yes 
Bad prognosis 
Good prognosis 
None 
Kelley 
(2007) 
69 51% No 
49% Yes 
Bad prognosis' 
Nil 
None 
Canioni 
(2008) 
194 No 
Yes 
Bad prognosis 
Nil 
None 
Byers 
(2008) 
 
60 No Bad prognosis None 
Wahlin 
(2010) 
 
70 70% No Bad prognosis'  None 
Sweetenham 
(2010) 
180 57% No 
53% Yes'' 
Nil 
Nil 
None 
Andjelic 
 (2012) 
50 76% No 
24% Yes 
Bad prognosis 
Nil 
None 
Table 5 - Summary of published data in relation to immunohistochemical 
enumeration of macrophages in FL. 
' = data refers to interfollicular CD68+ cells 
'' = 17% rituximab, 36% I131 Tositumamab (total 53%) 
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4.6.2 Rituximab and the mechanisms of action of anti-CD20 monoclonal 
antibodies. 
Rituximab in combination with chemotherapy has improved response rates, 
PFS and OS in FL, DLBCL, BL and MCL. Rituximab is thought to exert its 
effects partly through direct lymphoma killing, and partly through immune 
mediated mechanisms, in which activatory immunoglobulin G fragment C 
receptor (Fc#R) expressing macrophages play a prominent role (Beers et al., 
Glennie et al., 2007). Relapse and resistance to rituximab are prominent clinical 
challenges in B-NHL and so there is great interest in developing new anti-CD20 
antibodies with even better efficacy in even more patients. There are three 
major mechanisms by which rituximab operates:  
i) Direct cell death: mAb binding induces growth inhibition and apoptosis.  
ii) Complement-dependent cytotoxicity (CDC).  
iii) Antibody-dependent cellular cytotoxicity (ADCC).  
ADCC is of greatest relevance when considering the potential role of TAM-
rituximab interactions in B-NHL, as this mechanism crucially involves the 
cooperation of Fc#R expressing macrophages and NK-cells. Interaction 
between the Fc portion of bound anti-CD20 mAbs and the Fc#R of 
macrophages or NK cells precipitates cell-killing. As such, the efficacy of ADCC 
in this instance might be influenced by engineered modifications to the Fc 
region of anti-CD20 antibodies, and host variations in the conformation or 
number of Fc#R, and indeed the number of macrophages/NK cells present in 
the tumour microenvironment to display the Fc#R and effect B-cell killing. 
Moreover, there are different classes of anti-CD20 mAb with different 
properties. The binding epitope of a given anti-CD20 mAb to B-cell surface 
CD20 dictates these functional differences, giving a classification as type I or 
type II mAb (Glennie et al., 2007, Chan et al., 2003, Cragg and Glennie, 2004). 
Type I mAbs such as rituximab are potent inducers of CDC with low level 
induction of direct cell death. Type II mAb are potent inducers of direct cell 
death and poor inducers of CDC (Cragg and Glennie, 2004). Also, Type II mAb 
have been found to persist for longer in complex with CD20 at the B-cell surface 
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(Beers et al., 2010), putatively exposing for longer the Fc region to immune 
effector cells capable of performing ADCC.  
In support of macrophages having a crucial role in rituximab’s mechanism of 
action in B-NHL, macrophage ablation with toxic liposomes abolished the 
therapeutic benefit of a mAb against CD20 in a mouse model of lymphoma 
(Minard-Colin et al., 2008). A fascinating insight has been provided by in vitro 
work with malignant B-lymphocytes, demonstrating that M2-like macrophages 
phagocytose rituximab-opsonised malignant B-cells more efficiently than M1-
like macrophages, leading the authors to suggest that M2-like TAM actually 
switch from a tumour promoting to a tumour-inhibiting function with the addition 
of rituximab (Leidi et al., 2009).  
The phenotype of TAM appears to impact on their ability to bind and 
phagocytose malignant B-cells that have been opsonised with rituximab (Leidi 
et al., 2009). Human macrophages matured from PBMC with CSF-1 showed 
two to three times the phagocytic activity of those matured with GM-CSF. 
Binding and phagocytosis was further enhanced by supplementary IL-10, and 
attenuated by IL-4. This is consistent with earlier reports that phagocytosis of 
apoptotic cells is part of the wound healing macrophage phenotype (Mantovani 
et al., 2004b, Lewis and Pollard, 2006) and that CSF-1 or IL-10 are potent 
inducers of phagocytic activity in macrophages (Akagawa, 2002, Verreck et al., 
2004, Xu et al., 2006, Ogden et al., 2005) and IL-4 a suppressor of phagocytic 
activity (Mantovani et al., 2004b, Martinez et al., 2006). Phagocytosis in these 
assays was correlated with expression of the three Fc# receptors CD16 
(Fc#RIII), CD32 (Fc#RII), CD64 (Fc#R1), and was completely inhibited by 
excess human immunoglobulin, demonstrating a critical role for Fc#R in this 
phenomenon. Polymorphisms in the activatory Fc#RIIIa/CD16a have been 
described as correlating with response to rituximab (Cartron et al., 2002, Weng 
and Levy, 2003, Farag et al., 2004). Two variants at position 158 of human 
Fc#RIIIa exist; a common low-affinity form 158F and less common higher affinity 
form 158V which is present in a homozygous state in approximately 15% of 
patients (Cartron et al., 2004), which in the case of FL correlates with better 
response rates and PFS when treated with rituximab-containing regimens 
(Cartron et al., 2002, Weng and Levy, 2003). Therapeutically, there is interest in 
increasing the affinity of mAb interactions with innate immune effector cell 
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Fc#RIIIa. One strategy might be to alter key structural elements of anti-CD20 
mAb through glycoengineering and defucosylation (Mossner et al., 2010).  
One prominent example of this approach is the development of GA101, the first 
Fc-engineered type II humanized IgG1 anti-CD20 mAb. GA101 has improved 
direct and immune effector cell mediated cytotoxicity with increased affinity of 
binding to Fc#RIII on macrophages and NK cells. It has demonstrated improved 
anti-tumour activity in human lymphoma xenografts, with greater B-cell 
depletion in lymphoid tissues in non-human primates, and is now being 
administered to patients through several phase I-III clinical trials in B-NHL and 
B-CLL (Sehn et al., 2012, Salles et al., 2012). 
It is not simply the presence of Fc#R on macrophages (and NK cells) that is 
important, but of course their interactions with bound mAb, and the degree of 
involvement of inhibitory FcR, both on the target cells and effector cells (Clynes 
et al., 2000, Uchida et al., 2004, Nimmerjahn and Ravetch, 2007, Beers et al., 
2008).  
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4.6.3 Malignant-cell Fc receptors also play a crucial role in rituximab 
action. 
Important mechanistic insights into the roles of TAM in anti-CD20 mAb therapy 
of B-cell malignancies have perhaps begun to explain both individual rituximab 
resistance, and the differential sensitivity of B-cell lymphomas and leukaemias 
to anti-CD20 mAb. In 48 primary CLL samples, the presence of the inhibitory 
Fc#RIIb on normal and malignant B-cells was found to promote rituximab 
internalisation, reduce subsequent macrophage phagocytosis, and reduce its 
clinical efficacy (Lim et al., 2011). This built on previous work with mice showing 
that internalization of anti-CD20 monoclonal antibodies by target B-cells 
reduced their phagocytosis by macrophages (Beers et al., 2010). In human CLL 
studies, maximal phagocytosis of rituximab was restored in vitro by blocking 
Fc#RII on CLL B-cells with AT10 fragment antigen-binding (Fab) fragments. 
Fc#RII expression levels between different B-cell lymphoma/leukaemia 
diseases correlates with their observed responsiveness to rituximab therapy, 
with FL and DLBCL expressing less Fc#RII and being more sensitive to 
rituximab than CLL and MCL. These observations strengthen the case that 
TAM function is of critical importance in B-lymphoma treated with rituximab or 
other anti-CD20 mAb.  
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5 Current clinical priorities in B-NHL. 
The ultimate ambition remains to cure all B-NHL patients, with the minimum 
treatment related toxicity. Realistically, this is likely to be achieved in a stepwise 
fashion, and by identifying, and addressing in turn, key clinical priorities: 
1) Prognostication:  
Can we identify more accurately those patients in whom early aggressive 
or novel therapies are warranted, and those who can be safely observed 
without therapy, or treated with conventional regimens, without missing a 
“window-of-opportunity” to modulate the natural history of the disease? 
2) Promoting regression:  
Temporary “spontaneous” regression of FL is commonly observed, often 
lasting many months, and very rarely a long-term complete remission 
occurs without any therapy. One might reasonably speculate that this 
represents an effective host immune response against FL. A similar, but 
allogeneic, tumouricidal immune response is seen with successful 
allogeneic haematopoietic stem cell transplantation. Exploiting immune 
phenomena could provide an effective, prolonged, and well-tolerated 
means of controlling FL in particular. 
3) Preventing progression of indolent B-NHL:  
Can we indefinitely prolong the “plateau phase” of FL during which the 
disease is present but seemingly dormant? 
4) Effective treatment of transformation and chemoresistance:  
It is a typical feature of FL that initial chemosensitivity is progressively 
lost with each relapse. Death usually occurs after several relapses, 
following the advent of chemoresistance. When this is accompanied by 
transformation to a highly proliferative and clinically aggressive 
lymphoma, then survival is usually brief, even if high dose chemotherapy 
is used. An urgent challenge is to develop novel effective therapies to 
overcome chemoresistance and successfully treat transformed FL. 
Similar challenges are presented by the more aggressive B-NHL, in 
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those patients who experience primary refractoriness to therapy, or 
relapse with chemoresistant disease.  
5) High efficacy, low toxicity:  
Traditional approaches to relapse, chemoresistance or transformation 
have relied on increasing the doses of combination chemotherapy. If 
highly myelosuppressive doses are used, this may be combined with 
autologous haematopoietic stem cell rescue. However, with an ageing 
population, and prolonged survival in this disease since the advent of 
rituximab, then effective therapies must be tolerable to many patients of 
advanced age, and so also to those with common medical co-
morbidities, such as heart disease, airways disease, renal disease and 
the complications of diabetes mellitus.    
In the following chapter we shall consider the available strategies to target or 
manipulate macrophage populations in vivo, both in the laboratory and 
potentially in the clinic. This will be with the aim of establishing the nature of 
lymphoma-macrophage interactions, and the feasibility and impact of 
therapeutic intervention. An improved understanding of the innate immune 
response to lymphoma may well help address the priorities we have highlighted 
in this chapter. Improved biomarkers and novel therapeutic targets for 
immunotherapy have the potential to improve the management of B-NHL. 
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6 Targeting macrophages in cancer. 
The preceding chapters outline the extensive research undertaken to describe 
and better understand the roles of TAM, and the molecular mechanisms that 
contribute to these roles. Successfully translating this knowledge into effective 
clinical applications is an enormous challenge. Even in the setting of an 
individual with malignant disease, very many of the macrophages in the body 
are likely to be performing beneficial, physiological functions. Furthermore, 
within and surrounding tumours themselves, different macrophage populations 
are described with various phenotypes, only some of which may be considered 
maladaptive. The plasticity of macrophage phenotype adds a further layer of 
complexity, such that the challenge includes not only targeting the right 
macrophages in the right place, but also at the right time. Whilst certain 
functional characteristics of TAM appear common in different tumours, distinct 
differences are well described, and so optimal approaches are likely to differ 
depending upon the specific cancer diagnosis. Targeting macrophages in the 
laboratory has been achieved in a variety of ways, each of which have major 
limitations when considered as therapy in humans, yet have enabled a greater 
understanding of TAM biology. The objectives of any laboratory or clinical 
approach to target TAM should be to remove pro-tumoural influences, 
introduce, maximise and maintain tumouricidal effects, whilst preserving 
physiological macrophage functions in normal tissues.  
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6.1 Liposomes and other nanoparticles. 
In the 1980s, a “macrophage suicide” technique was developed, whereby 
cytotoxic liposome-encapsulated bisphosphonates were delivered into cells, 
exploiting the preferential engulfment of nanoparticles by phagocytes. 
Intracellular accumulation of bisphosphonate leads to apoptosis, primarily of 
monocytes and tissue macrophages (van Rooijen et al., 1996). The most 
effective bisphosphonate for this purpose is clodronate (dichloromethylene 
bisphosphonate) (Van Rooijen and Sanders, 1996). Liposomal clodronate (LC) 
has been extensively used to try and demonstrate proof-of-concept in mouse 
models of cancer (Zeisberger et al., 2006, Gazzaniga et al., 2007, Hiraoka et 
al., 2008, Miselis et al., 2008), to establish a functional relationship between the 
presence of TAM and tumour progression. LC has been evaluated as therapy in 
dogs with a spontaneous histiocytic neoplasm (Hafeman et al., 2010). Two of 
five dogs demonstrated tumour regression with an intravenous schedule of 0.5 
ml/kg over 60 minutes, repeated once or twice, at 2 weekly intervals. The 
authors believe that direct tumour cell killing was at least partly responsible for 
the clinical response observed in this situation, rather than only that mediated 
by macrophage depletion.  Nonetheless, this work showed that such a short 
course of LC was feasible and well tolerated in larger mammals. Encouraging 
results have recently been published with a mouse model whereby macrophage 
ablation with LC given prior to radiotherapy inhibits relapse of a melanoma 
model (Meng et al., 2010). Identification of such critical therapeutic windows for 
macrophage ablation, perhaps to augment responses to chemotherapy or 
radiotherapy, offers the prospect of optimising anti-tumour effects while 
minimising detrimental effects to physiological processes. Consequently, there 
have been calls for urgent clinical trials of LC in humans (Meng et al., 2010, 
Hafeman et al., 2010, Steidl et al., 2010). However, this relatively unselective 
macrophage ablation technique destroys many physiological tissue 
macrophages, and in its unrefined form is likely to be very limited in its human 
application. 
Systemic delivery of un-encapsulated bisphosphonates has been common 
clinical practice for many years, intended to inhibit osteoclast-mediated bone 
resorption in the setting of osteoporosis, multiple myeloma and cancer 
metastasising to bone. Intriguingly, recent data strongly suggest that the effects 
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of systemic bisphosphonates go beyond simply reducing bone resorption or 
metastasis, also appearing to modulate overall cancer progression. In a clinical 
trial of 1803 pre-menopausal women with oestrogen-responsive early breast 
cancer, the addition of the intravenous bisphosphonate zoledronic acid, 
improved disease free-survival (Gnant et al., 2009). In addition to fewer bone 
metastases there were reductions in loco-regional recurrence, distant 
recurrence and disease in the contralateral breast, implying anti-tumour effects 
extending beyond the bone microenvironment.  Similarly, the Medical Research 
Council Myeloma IX Study of 1960 patients reports a survival benefit from 
zoledronic acid, distinct from that associated with prevention of skeletal-related 
events, again implying anti-cancer properties by mechanisms that remain 
unclear (Morgan et al., 2010). The contribution of macrophages to this effect 
remains to be established as direct anti-cancer cell effects may also operate. In 
vivo work in a mouse model of mesothelioma has indicated that systemic 
zoledronic acid might impair myeloid cell differentiation to tumour-associated 
macrophages (Veltman et al., 2010), and further work is needed to clarify and 
confirm this mechanism of action.  
In vitro studies with lung cancer cell lines and mouse alveolar macrophages 
suggested that empty endotoxin-free poly(isobutylncyanoacrylate) nanoparticles 
are able to induce tumouricidal activity in macrophages with an associated 
increase in Th1 cytokines in the co-culture supernatant (Al-Hallak et al., 2010). 
Silica nanoparticles, under investigation as gene delivery vectors to the CNS, 
induce inflammatory and potentially tumouricidal phenotypic changes in rat 
brain resident macrophages (Choi et al., 2010) increasing the production of 
reactive oxygen and nitrogen species, and down-regulating TNF-! gene 
expression.  Nanoparticles with additional functionality can be engineered with 
surface ligands to enhance binding to target cells, be they cancer cells or TAM. 
An alternative approach has been to try to exploit the tumour homing capacity 
of macrophages as a method of targeting delivery of anti-cancer therapeutics to 
notoriously hard to reach hypoxic areas of tumours (Holden et al., 2010). Such 
work has demonstrated the technical feasibility of immobilising nanoparticles 
containing such agents that would otherwise be toxic to macrophages if directly 
exposed, on the surface of chemically modified macrophages. It is hoped that 
with further development of this technique, engineered macrophage-
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nanoparticle hybrids might be adoptively transferred and migrate to the centre 
of tumours, driven by hypoxic stimuli.  
Building on the concept of delivering drugs to macrophages through liposomes 
has been the development of mifamurtide (Mepact(, Takeda).  Mifamurtide is 
liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-
PE). It is a liposome packaged synthetic glycopeptide, which also occurs 
naturally as a component of bacterial cell walls, and is capable of activating 
macrophages to an inflammatory M1-like potentially tumouricidal phenotype, 
with production of IL-1, IL-2, IL-6, IL-12 and TNF-! (Nardin et al., 2006). This 
imaginative strategy has proven an effective anti-cancer therapy in 
osteosarcoma. Intravenous delivery results in accumulation of mifurmatide 
particles in the pulmonary vasculature, exactly the site most at risk of micro 
metastasis and relapse in this disease. In an adjuvant setting with multi-drug 
chemotherapy, Mifurmatide reduces mortality by 70-78% and has been 
approved for use by the Food and Drug Administration, European Medicines 
Agency and the National Institute for Health and Clinical Excellence. 
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6.2 Systemic macrophage apoptosis in MaFIA mice.  
MaFIA (Macrophage Fas-induced apoptosis) mice are a transgenic strain 
(C57BL/6J-Tg (Csf1r-EGFP-NGFR/FKBP1A/TNFRSF6) 2Bck/J) developed to 
facilitate inducible in vivo macrophage depletion (Burnett et al., 2004). This 
model enables laboratory investigation of the consequences of systemic 
macrophage depletion. We have used this model to investigate macrophage 
depletion in a transplantable mouse lymphoma. The CSF-1R promoter is used 
to express a drug-inducible suicide gene, that when activated by a specific 
synthetic compound, leads to macrophage-lineage specific Fas-mediated 
apotosis via tumour necrosis factor receptor superfamily member 6 (TNFRSF6, 
also known as apoptosis-mediating surface antigen FAS). This model was 
developed following work to create a suicide construct with the cytoplasmic 
domain of FAS lined to two copies of FK506-binding protein (FKBP) (Spencer et 
al., 1996). The modified transgene insert in this case contains a mutant human 
FK506 binding protein 1A, which preferentially binds the dimerization drug 
AP20187. AP20187 was developed by Ariad Pharmaceuticals to be otherwise 
inactive, and to not affect endogenous FKBP. Administration of the drug causes 
cross-linking of Fas-receptors, leading to activation of the caspase-8 pathway 
and apoptosis of cycling and resting cells (Ashkenazi and Dixit, 1998). The 
MaFIA transgene also contains an otherwise non-functional membrane 
insertion unit of the low affinity nerve growth factor receptor ($LNGFR) (Thomis 
et al., 2001). Owing to the absence of the promoter gene in relevant HSPC, 
monocyte production is recoverable and the effect is reversible once dimerizer 
administration is halted. The 11.1 kb MaFIA transgene was introduced into 
C57BL/6 donor eggs and the resultant male mice bred with C57BL/6 mice until 
pure breeds of both sexes were obtained. Owing to the presence of normal 
numbers and subsets of monocytes, macrophages and DC during 
organogenesis, MaFIA mice have no developmental abnormalities. In this way, 
Burnett et al. used genes coding for the CSF-1R promoter, EGFP, and the 
$LNGFR-FKBP-Fas suicide construct to generate this model of systemic, drug-
inducible macrophage cell death, in which macrophages express EGFP, and 
cell death occurs independently of cell cycle dynamics. 
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Data on the impact of intraperitoneal administration of dimerizer to healthy 
MaFIA mice indicates widespread and majority, but sub-total, macrophage 
depletion with variations between different tissues (Burnett et al., 2004). Daily ip 
injections of 10 mg/kg for 5 consecutive days to MaFIA mice (‘treated mice’) 
was compared to an identical schedule in wild type mice, and vehicle control 
injections in MaFIA mice. Macrophage depletion was evident in ‘treated mice’ 
from 24 hours after the third injection. 24 hours after the last of the 5 injections, 
EGFP positive cells were quantified by flow cytometry. Compared to vehicle 
control treated MaFIA mice, ‘treated mice’ had reductions of over 90% in the 
bone marrow and peritoneum, and over 70% in the blood, spleen, lungs and 
thymus. No significant reductions were seen in lymph nodes or brain. 
Macrophage numbers started to rise in the bone marrow and spleen, 7 days 
after the last injection.  
‘Treated mice’ lost 18.1% (+/- 6.7%) of their total body weight. The authors 
postulated that this was due to macrophage loss, as weight loss was not seen 
in any of the control groups. ‘Treated mice’ also displayed splenomegaly, lymph 
node enlargement and thymic atrophy. Prominent extramedullary 
haematopoiesis was evident in the spleen, yet lymph node architecture 
appeared normal, although expanded in overall cell number. The failure to 
achieve macrophage depletion in lymph nodes was hypothesised to be due to 
poor tissue penetration of the ip administered dimerizer. 
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6.3 Cellular adoptive transfer. 
Given that some of a growing TAM population is probably recruited from 
circulating monocytes, it is reasonable to suppose that supplementary 
populations of injected monocyte/macrophages might preferentially accumulate 
within tumours. Without manipulation, these cells might contribution to the TAM 
population and so encourage tumour growth. Manipulation of 
monocyte/macrophages either in vitro or subsequently in vivo might provide the 
potential to deliver classically activated macrophages with anti-cancer 
properties. This is a strategy we employ in a mouse model of lymphoma in later 
chapters. Alternatively, or in addition, these macrophages might be used as 
vectors to express genes within the tumour, such as for inflammatory cytokines, 
or pro-drug conversion genes to optimise local delivery of active 
chemotherapeutics (Griffiths et al., 2000). 
Studies in mice have demonstrated the therapeutic potential of macrophage 
adoptive transfer. In 1974, Isaiah Fidler and colleagues studied the ability of 
syngeneic macrophages to inhibit pulmonary metastases in C57BL/6 mice 
bearing a progressively growing B16 melanoma (Fidler, 1974). Their work 
demonstrated that peritoneal macrophages, harvested after thioglycollate-
induced inflammation, reduced the number of pulmonary metastases. This 
activity was dependent upon the macrophages being specifically treated in vitro 
and then injected intravenously. Whilst unable to describe the macrophage 
phenotype in language with which we are now familiar, it was clear that the 
tumour-cytotoxic activity of the macrophages was influenced by their prior in 
vitro exposure to sensitising agents during maturation. Those exposed to rat 
lymphocytes sensitised to tumour in vivo in addition to tumour supernatants 
were highly active in preventing pulmonary metastases, compared to those 
exposed only to tumour supernatants, which had no effect. Later work 
described that the subsequent tissue distribution in a normal host mouse of 
transferred macrophages was determined by the method used to elicit and 
activate them from the donor peritoneum (Wiltrout et al., 1983). It is much 
clearer now that macrophage subtype and phenotype is likely to be crucial in 
successfully populating and influencing growing tumours.   
Similarly successful adoptive transfer of macrophages with tumour regression 
has been repeated and refined in other mouse models of cancer (Hagemann et 
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al., 2008, Ben-Efraim et al., 1994). Human studies in the late 1980s 
demonstrated that macrophage adoptive transfer is feasible and safe in patients 
with cancer (Lacerna et al., 1988, Stevenson et al., 1987).  Greater than 3x109 
autologous monocyte-derived macrophages, sensitised in vitro with IFN-# or 
LPS, or in vivo with GM-CSF, can be safely infused by iv, ip or intrapleural 
routes. Systemically delivered macrophages are first retained in the lungs 
before pooling in the liver and spleen, concentrating at sites of metastases 
(Andreesen et al., 1998). Macrophages delivered ip remain within this cavity for 
more than 7 days and accumulate at sites of major tumour growth. In one study 
of patients with ovarian or gastric cancer, ip macrophages significantly reduced 
the volume of malignant ascites in 3 out of 7 patients, but without impacting on 
tumour mass (Andreesen et al., 1990). Unfortunately these results proved to be 
exceptional, with the majority of early human in vivo studies showing little or no 
measurable benefit in a variety of cancers (Lacerna et al., 1988, Faradji et al., 
1991b, Faradji et al., 1991a, Lopez et al., 1992, Eymard et al., 1996, 
Hennemann et al., 1995). One reason for this failure of effect, despite 
successful transfer, might be an overwhelming ability of the tumour to 
manipulate the phenotype of transferred macrophages, so down-regulating their 
tumouricidal and pro-inflammatory functions. This might be overcome by 
transfecting macrophages with critical pro-inflammatory cytokines. In vitro and 
in vivo studies in mice support the feasibility of this approach with respect to 
IFN-!, IL-4, IL-6, TNF-!, also showing increased tumouricidal activity (Nishihara 
et al., 1995). Immunotherapy approaches using adoptive transfer of ex vivo 
IFN-# activated macrophages shows that they can be manufactured on a large 
scale, cryopreserved and safely administered to patients with cancer (Baron-
Bodo et al., 2005), and in concert with rituximab in B-CLL participate in ADCC 
killing mediated by Fc#RI on macrophages (Lefebvre et al., 2006).  
 
! (("!
7 Experimental rationale. 
This project is hypothesis driven, namely, that TAM form part of a lymphoma-
supporting microenvironment, and might themselves be rational and effective 
targets in these diseases. Of course, it would be simplistic to postulate that 
macrophages might act as sole and prime orchestrators of the tumour 
microenvironment. Nonetheless, manipulation of their number or phenotype 
might critically alter the overall balance of cancer-related immunity, and so be 
sufficient to significantly alter tumour progression.  
We interrogated human diagnostic biopsies of DLBCL to investigate 
correlations between macrophage numbers, phenotype and lymphoma growth 
rates. We then aimed to establish proof-of-concept for a cooperative 
relationship between macrophages and lymphoma by performing varied and 
sometimes opposing manipulations of macrophage populations in mice 
harbouring a growing population of malignant mature B-cells. Our experimental 
rationale was to inject a known and consistent number of lymphoma cells in to 
the venous circulation of mice of the same age and sex. Using techniques that 
will be detailed later, we manipulated macrophages in these mice, measuring 
the impact on lymphoma progression. We ablated macrophages in two different 
ways, also looking to see if there is a dose-response relationship between 
macrophage ablation and lymphoma progression. We then supplemented 
macrophages, and investigated whether supplementary macrophages of 
different phenotypes had different impacts. Subsequently, we investigated the 
effects of attempting to preferentially reduce the number of TAM by inhibiting 
the CSF-1R. We also investigated the impact of macrophage depletion on 
responses to chemotherapy.  
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Figure 10 - Approaches to manipulate macrophages in a mouse model of 
lymphoma. 
 
 
! (($!
8 Experimental approach. 
8.1 Demonstrating functional interplay between macrophages 
and malignant lymphocytes in mouse models. 
Our primary purpose of using a mouse model of lymphoma is to investigate the 
functional relationships between lymphoma and macrophages. Direct 
interactions between lymphoma cells and macrophages in isolation can readily 
be studied using in vitro co-culture techniques. Lymphomas consist of 
malignant lymphocytes interspersed with stromal cells and infiltrating immune 
cells, of which macrophages form a minority population. Mouse models allow a 
more faithful reproduction of the complex multicellular interactions occurring in 
nature.  
By manipulating quantitative and qualitative aspects of the macrophage 
population, mouse models allow us to observe the effects on other cellular 
populations, as well as on the total lymphoma mass. In this way, we have been 
able to test our hypothesis that TAM form part of a complex lymphoma-
supporting microenvironment. As such, not only might features of the TAM 
population (number and phenotype) correlate with outcomes, but also might 
present novel therapeutic targets in this disease. 
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8.1.1 Mouse models of B-NHL. 
Several mouse models have been developed to simulate different aspects of 
the various lymphoid malignancies. Human lymphoma xenografts have the 
advantage of utilizing the true human malignant cells, yet are far from suitable 
for our purposes, as they require a significantly immune-suppressed host. In a 
variety of genetically engineered models, mice eventually develop lymphoid 
malignancies. These models are particularly valuable for studying the role of 
specific introduced genetic lesions in lymphoid tumourigenesis. The variable 
frequency, timing, and lineage of malignancy in these transgenic models would 
create significant challenges for standardisation of experimental conditions. 
Furthermore, introduced genetic lesions affecting lymphoid populations 
necessarily alter the immune microenvironment of transgenic mice. We wanted 
to work with a B-lymphoid malignancy that could be readily transplanted to 
immune-competent hosts, enabling standardised in vivo study of the 
interactions between macrophages and malignant B-cells.  
A proposal for the classification of lymphoid neoplasms in mice has been 
compiled to aid communication about mouse models of human lymphoid 
diseases (Morse et al., 2002). This work attempts to pair mouse lymphoma 
models with human equivalent counterparts, based upon features of histology, 
cell surface or cytoplasmic antigens, and genetic lesions. The authors found it 
very difficult to make the case that any diseases in the two species were true 
homologues. “Follicular lymphoma” models that have been developed thus far 
tend to consist of mixed centroblasts and centrocytes rather than almost entirely 
centrocytes, and arise predominantly in the spleen rather than lymph nodes, 
thus not replicating the characteristic follicular architecture of human FL. 
Raffergerst and colleagues discovered that an established MHC class II 
transgenic mouse line that had been developed as a model for autoimmunity 
(Ito et al., 1996), eventually developed spontaneous lymphoid tumours 
(Raffegerst et al., 2009). This chimaeric HLA-DR4-H2-E (DR4) homozygous 
transgenic mouse develops very diverse haematological cancers, equally 
distributed in frequency between T- and B-cell lymphomas. A disease with 
features of FL develops after 18 months in under half of mice over-expressing 
BCL2 under the control of Vav, the panhaematopoietic promoter (Egle et al., 
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2004). The authors were not successful in transplanting this lymphoma even to 
immune-compromised hosts. 
The observation that DLBCL can derive from germinal centre B-cells with 
dysregulated expression of BCL6 led to the development of transgenic mice 
with constitutive BCL6 expression in B-cells, under the control of the 
immunoglobulin Iµ promoter (Cattoretti et al., 2005). This model produces 
mature B-lymphomas in the majority of mice by 20 months, yet unfortunately 
cannot be transplanted successfully to immune-competent hosts (oral 
communication from Professor R. Dalla-Favera). Other potentially suitable 
models of DLBCL include one with dysregulated Tcl1 expression (Hoyer et al., 
2002) that is reported as being transplantable, and another with deletion of the 
pro-apoptotic molecule BAD (Ranger et al., 2003). We chose to work with a 
lymphoma derived from the Eµ-myc/bcl-2 mouse. The principal advantages 
included the very extensive characterisation and successful ongoing use 
(Gilbert and Hemann, 2010) of this model in the literature over the past 26 
years, its ease and reproducibility of transplantation to normal hosts, and local 
laboratory experience.  
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8.2 Background – the Eµ-myc transgenic mouse. 
The Eµ-myc lymphoma was developed on the basis of work in the early 1980’s 
(Brinster et al., 1983, Storb et al., 1984, Grosschedl et al., 1984, Rusconi and 
Kohler, 1985) and has since been extensively characterised (Adams et al., 
1985, Leder et al., 1986, Harris et al., 1988). Eµ-myc tumours are considered to 
be a good model of human NHL (Adams et al., 1985) with the highly 
proliferative nature drawing parallels with BL (Gilbert and Hemann, 2010, Cory, 
1986). The Eµ-myc model of B-NHL has been extensively used to characterise 
in vivo responses to anticancer drugs (Schmitt et al., 2000, Schmitt et al., 2002). 
In this model, transgenic mice harbour the Myc proto-oncogene coupled to the 
immunoglobulin µ enhancer, resulting in tissue-specific constitutive Myc 
overexpression in the lymphocyte lineage. Dysregulated MYC expression drives 
many human cancers including BL, and some cases of aggressive DLBCL and 
possibly transformed FL, in which the acquisition of quantitative or qualitative 
abnormalities in the expression of MYC have been reported to occur at 
transformation (Yano et al., 1992, Lossos et al., 2002) with one large series 
reporting increased expression of MYC in 14 of 20 paired samples of FL at 
transformation to tFL (Davies et al., 2007). Eµ-myc mice develop a polyclonal 
B-cell hyperplasia progressing to a monoclonal lymphoma, and die within a few 
months of birth. Tumour histology reveals effacement of normal lymph node 
architecture, with monotonous appearing intermediate sized lymphocytes with 
round to oval nuclei, small indistinct nucleoli and a rim of basophilic cytoplasm. 
Numerous apoptotic bodies are present, giving a “starry-sky” appearance 
(Minard-Colin et al., 2008). 
Phenotypically, Eµ-myc mice with lymphoma display massive lymph node 
enlargement, splenic enlargement, and infiltration of malignant lymphocytes in 
the liver, bone marrow and blood. As such, these mice develop a disseminated 
lymphoma with associated leukaemia. As first described, isolated tumour cells 
were all monoclonal B-lymphoblasts (Adams et al., 1985), but theoretically the 
Eµ-enhancer is active at several stages of B-cell maturation. The stage of B-cell 
maturation of the dominant clone varies between individual mice, and in some 
cases over time. Some display characteristics of pre-B cells (B220+, CD19+ 
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IgM-), others mature B-cells  (B220+, CD19+, IgM+, CD5-), and some have 
been documented to progress from pre-B to B-cell phenotype.  
Isolated Eµ-myc malignant B-cells are capable of reproducing disseminated 
lymphoma in genetically matched, non-transgenic recipient mice, such that the 
reconstituted malignancy is histopathologically indistinguishable from the 
primary lymphomas (Schmitt et al., 1999, Bearss et al., 2000). For the purposes 
of our work, this offers the advantage of being able to transplant lymphoma into 
immune competent hosts. We believe that used in this way we are able to 
orthotopically model aspects of tumour growth and dissemination in a whole 
organism multicellular environment. However, with the intravenous transplant of 
established tumour populations, this model is unlikely to provide useful 
information regarding the roles of monocytes and macrophages in de novo 
lymphomagenesis. As such, our studies focus on the role of lymphoma-
associated macrophages in cancer-induced inflammation, rather than their 
potential role in inflammation-induced cancer formation. There are well-
documented links between specific chronic infections, chronic inflammation, 
and subsequent development of lymphomas, epitomised by Helicobacter pylori-
associated gastric mucosa associated lymphomas (Isaacson, 1993, 
Wotherspoon et al., 1991, Nakamura et al., 1997). Indeed, there is compelling 
evidence for the recruitment and action of macrophages and other myeloid cells 
being of critical importance in animal models of tumourigenesis. In a colitis 
induced carcinogenesis model, blocking the actions of the chemokine CCL2 
reduced macrophage recruitment and tumourigenesis (Popivanova et al., 
2009). In gastric carcinogenesis, macrophage recruitment under the control of 
bacterial infection and prostaglandin E2 induced CCL2 expression was found to 
be a non-redundant step. We considered these aspects beyond the scope of 
this thesis.    
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8.3 The Eµ-myc/bcl2 mouse – a chemoresistant model. 
There is an urgent clinical need to identify improved strategies to treat 
aggressive MYC driven lymphomas in humans, and more specifically in their 
common chemoresistant phase which is often associated with defective 
apoptosis regulated by the BCL2 protein family. 
Whilst the majority of B-NHL diagnoses are not MYC driven, nor do they over-
express BCL2, those that harbour either or both mutations often represent the 
very worst prognosis groups with conventional therapies. Bento et al. presented 
hypothesis-forming data supporting this view from a small number of diagnostic 
patient biopsies of DLBCL. MYC and BCL2 alterations at diagnosis appear to 
identify a high-risk population for whom conventional therapy is inadequate 
(Bento et al., 2011, Aukema et al., 2011). Cuccuini et al. (Cuccuini et al., 2011) 
investigated the presence of MYC and BCL2 rearrangements by break apart 
FISH in 156 of 396 analysable patient samples from the collaborative trial in 
relapsed aggressive lymphoma (CORAL) study. This study recruited patients 
with relapsed and/or refractory DLBCL. 24 patients (16%) had MYC 
rearrangements of which 21 (87.5%) also had BCL2 rearrangements. The 
outcome of MYC-rearranged patients was significantly worse regardless of 
which chemotherapy regime they received, in terms of both PFS and OS. It is 
also well documented that cases of t-FL, although not commonly having 
translocations over-expressing MYC, represent a highly proliferative BCL2 over-
expressing lymphoma with very poor outcomes to conventional chemotherapy, 
even at high doses. As such, it is for these groups of poor prognosis patients 
that novel therapies must most urgently be developed and must demonstrate 
efficacy in pre-clinical models if they are to be of maximal clinical utility. The Eµ-
myc/bcl2 lymphoma models several aspects of these poor prognosis groups 
and would appear a rational choice of model in which to investigate novel 
therapeutic approaches.   
The BCL2 gene is normally expressed in pre-B cells, is quiescent in resting B-
cells, is expressed in proliferating B cells, and down-regulated in differentiated 
B-cells. Lymphomas with the t(14;18) display inappropriately elevated levels of 
BCL2-Ig fusion RNA for their mature B-cell stage of development (Graninger et 
al., 1987, Seto et al., 1988). This situation can be mirrored by the manipulation 
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of the Eµ-myc lymphoma. Defined cancer genotypes can be created ex vivo 
using a mouse stem cell-virus based retroviral vector to transduce a gene of 
interest into Eµ-myc lymphomas (Schmitt et al., 2000). In this case, insertion of 
the Bcl2 gene leads to over-expression of BCL2 by malignant B-lymphocytes in 
the Eµ-myc/bcl2 mouse.  
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8.4 Eµ-myc/bcl-2, chemoresistance and macrophages. 
The validity of the Eµ-myc/bcl-2 model has been established by therapeutic 
studies, with Bcl2 insertion and over-expression conferring chemo-resistance to 
a wide range of agents. Specifically, when compared to parental Eµ-myc 
lymphomas, Eµ-myc/bcl-2 is resistant to treatment with the alkylating agents 
cyclophosphamide (Mason et al., 2008) and maphosphamide, the 
topoisomerase II inhibitor adriamycin, the microtubule inhibitor docetaxel 
(Schmitt et al., 2000), and the HDAC inhibitor vorinostat (Lindemann et al., 
2007). Furthermore, Eµ-myc/bcl-2 mice have been used successfully as a 
model for testing BCL2 antagonists (Mason et al., 2008).  
We hypothesised that macrophage depletion might improve the response to 
genotoxic chemotherapy in lymphoma. Two studies exemplify different ways in 
which this might occur. Gilbert and Hemann found that microenvironmental 
signals, including IL-6, helped create a chemo-resistant niche in which 
lymphoma cells were able to survive genotoxic stress and subsequently 
generate systemic relapse (Gilbert and Hemann, 2010). Given that TAM are 
abundant in the tumour microenvironment and can produce IL-6, this work 
supports the concept of prior-ablation of TAM to maximise the effect of 
genotoxic chemotherapy. Ahn et al., using a xenograft of human 
hypopharyngeal carcinoma, demonstrated that tumour re-growth following 
radiation therapy was highly dependant on subsequent macrophage-induced 
angiogenesis (Ahn et al., 2010). Tumour re-growth was attenuated by inhibiting 
macrophage repopulation of irradiated tumours using an antibody against 
macrophage-1 antigen (CD11b/CD18). This study suggests that macrophage 
depletion following cytotoxic therapy might slow or prevent relapse. We 
investigated the impact of macrophage depletion both prior to and following 
chemotherapy, and used the nitrogen mustard derivative and pro-drug 
cyclophosphamide (Arnold et al., 1958), one of the key components of therapy 
for FL, DLBCL and BL (Bishop et al., 2000). Advanced Eµ-myc/bcl-2 
lymphomas respond to 200-300 mg/kg single ip doses of cyclophosphamide, 
but always relapse (Mason et al., 2008), unlike Eµ-myc lymphoma in which 
long-term survival can be induced (Schmitt and Lowe, 2001). This partial 
response provides a scenario in which a measurable benefit might be observed 
should macrophage ablation improve responses.!
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8.5 Eµ-myc/bcl-2, apoptosis, senescence and macrophages. 
Similar to Eµ-myc transgenic mice, Eµ-myc/bcl-2 tumours have a 
lymphomyeloid progenitor phenotype (Strasser et al., 1990, Strasser et al., 
1996), such that it is vital that the lineage and maturation stage of any given 
population is fully characterised.  Eµ-myc/bcl-2 mice die with enlarged spleens, 
livers and lymph nodes, and lymphoblasts in the blood and bone marrow 
(Mason et al., 2008). 
There is further evidence to suggest that a Myc driven mouse model of 
lymphoma might yield relevant and interesting insights specifically in relation to 
lymphoma-macrophage interactions. A recent review, focusing on Myc driven 
cancers, discusses the links between oncogene action, tumour cell apoptosis, 
immune-cell response and senescence induction as a mechanism of potential 
tumour suppression (Lee et al., 2011). Myc stimulates aberrant proliferation and 
cell growth, and as a countermeasure to this uncontrolled expansion, evokes 
apoptosis, seemingly as a safeguard. Equally, autophagy or senescence have 
been identified as cell-autonomous safeguard strategies in such circumstances 
(Schmitt, 2003). In the relatively apoptosis resistant Eµ-myc/bcl2 mouse, 
Schmitt et al. found that inactivation of senescence (by genomic deletion of the 
senescence related histone methyltransferase suv39h1) promoted B-lymphoma 
development.  
 The mechanism identified is that Myc-induced apoptosis attracts and activates 
macrophages which produce TGF-" that can induce terminal cell-cycle arrest 
(senescence) in Myc-driven lymphoma cells without causing a pro-
inflammatory, and, therefore, potentially pro-tumourigenic cytokine response 
(Reimann et al., 2010). Genetic inactivation of senescence accelerated Myc-
driven lymphomagenesis, as did neutralization of TGF-" action. When 
exogenous TGF-" was administered to lymphoma cells in vitro there was a 
dose dependent slowing of proliferation until growth stopped and features of 
senescence appeared, except in the suv39h1 knockout mice. Lymphoma cells 
themselves did not secrete TGF-". This was found to be macrophage derived, 
in response to apoptosis. If apoptosis is blocked, there are fewer macrophages 
and less senescence. Liposomal clodronate macrophage depletion further 
reduced senescence. One can reasonably postulate that macrophage depletion 
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in the premalignant stage might promote lymphomagenesis in situations of Myc 
and Bcl2 overexpression. An adequate macrophage response in this model 
may therefore have a role to play in the suppression of lymphomagenesis, 
despite possibly having lymphoma growth promoting effects in established 
malignancy. Qualifying this theory, the authors themselves state that the cells 
and cytokines delaying lymphomagenesis via senescence do not necessarily 
continue to operate as “tumour constraints during later steps of cancer 
progression.” They recognise the evidence that both TAM and TGF-" have 
potentially pro-tumoural effects in established malignancies. We used 
lymphoma cells from the same Myc and Bcl2 over-expressing transgenic mice. 
By transplanting cells of an established mature B-cell lymphoma, we modelled 
the interactions between macrophages and established lymphoma, in contrast 
to the work described above that focused on lymphomagenesis in the 
transgenic mice.  
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8.6 Experimental strategy. 
We chose to propagate and repeatedly use a batch of malignant cells isolated 
from the lymph nodes of a single Eµ-myc/bcl-2 mouse. This enabled us to 
characterise the lineage and maturation stage of the tumour cells, and keep this 
constant throughout our experiments. Using the lymphoma cells, rather than the 
transgenic animals, allows better investigation of the effects of 
microenvironmental manipulation. The transgenic animals would potentially 
over-express Myc and Bcl2 in non-malignant lymphocytes, thus affecting the 
immune response to lymphoma. Transplantation of the lymphoma into C57BL/6 
mice enabled me to observe interactions with wild-type macrophages. 
Moreover, the ability to transplant allows me to introduce lymphoma in other 
mice, genetically manipulated in such ways as to specifically alter their immune 
response. This enables investigation of critical pathways of macrophage-
lymphoma interaction in, for example, tissue specific gene knockout mice.  
Transplantation of lymphoma by intravenous tail vein injection effectively 
constitutes an orthotopic tumour model, with early widespread haematogenous 
dissemination of malignant lymphocytes. Preliminary studies in our laboratory 
(Bossard M, unpublished data) suggested that the first signs of deterioration in 
overall condition would reliably occur from day 12 following the injection of 
2x105 Eµ-myc/bcl-2 cells. At sacrifice, transplanted mice exhibited widespread 
enlarged lymph nodes, and enlarged spleen and liver. Given our wish to avoid 
causing distress to the animals and work well within UK Home Office 
regulations regarding maximum allowable tumour volumes, we therefore 
planned elective sacrifice by day 12 post-injection. 
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9 Materials and methods. 
9.1 Immunohistochemistry of human tissues. 
9.1.1 Interrogating the human tissue bank. 
We were interested to explore whether there was any correlation between 
macrophage numbers and lymphoma growth rates at diagnosis. We felt this 
might provide a straightforward indication as to whether the growth dynamic of 
B-NHL is linked to the presence of macrophages. This approach was intended 
to shed light on the biology of B-NHL in the absence of the variable confounding 
effects of different treatment regimes, and provide a further basis for 
investigating the dynamic impact of macrophage ablation in a mouse model. To 
achieve this we interrogated a large number of diagnostic biopsies representing 
treatment-naïve DLBCL, and used the expected natural variation in tumour 
proliferation rates in this disease to act as an “experiment in nature,” allowing 
comparison of this variable with macrophage numbers. BL samples would have 
been unsuitable for this purpose owing to their lack of variation with almost 
universal proliferation rates of 98% and above. FL samples would be expected 
to show variation in proliferation, but over a narrower range than DLBCL.  
Principles and methods of assessing proliferation.  
Ki67 staining was used as a measure of tumour cell proliferation. Ki67 protein 
can be detected by the Ki67 antibody during all active phases of the cell cycle 
and not during the G0 resting phase (Gerdes et al., 1983). It is thought that the 
expression of no other protein is as tightly regulated in relation to proliferation 
as Ki67 (Scholzen and Gerdes, 2000). As such, measurement of the proportion 
of cells in a population expressing Ki67 enables the calculation of a proliferation 
fraction, or Ki67 labeling index, for any given tissue. This technique was 
optimised for NHL, and correlated very closely with classification in to high or 
low grade NHL as determined principally by cellular morphology as part of the 
Kiel classification of malignant lymphomas (Gerdes et al., 1984, Lennert, 1975).  
Macrophage assessment. 
Macrophage quantification of CD68 staining was less straightforward than with 
nuclear Ki67 staining. CD68 is a membrane/cytoplasmic stain. Owing to the 
large size and branching polydendritic shape of macrophages, thin tissue 
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sections contain multiple fragments of CD68 staining cytoplasm, extending 
between different sections. As such, it is impossible to determine which 
fragments belong to which individual cells, and so it is difficult to reliably count 
numbers of macrophages. In the figure below is a FFPE section of FL stained 
with anti-CD68 KP1 (brown) and haematoxylin (blue). A single large 
macrophage displays characteristic cytoplasmic staining with CD68, and long, 
branching cytoplasmic processes. 
 
 
 
Figure 11 - A tumour-associated macrophage in follicular lymphoma (original 
magnification (OM) x 60). 
However, working on the reasonable assumption that macrophage size and 
shape is the same in biopsies from the same tissue of the same diagnosis in 
different patients, then the area of a tissue section occupied by brown-staining 
CD68 positive cellular material will be proportional to the number of 
macrophages in that section, and allow comparison between biopsies on any 
given tissue microarray (TMA) slide. This technique was optimised on a TMA of 
Hodgkin lymphoma in my host laboratory and the technique and findings 
recently published (Greaves et al., 2012).  
9.1.2 Principles of immunohistochemistry. 
Immunohistochemistry (IHC) is the process of detecting proteins in tissues 
using the inherent avidity of antibody binding to specific antigens. Bound 
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antibodies are then visualised courtesy of prior conjugation to, or subsequent 
specific binding of, coloured or fluorescent dyes. 
We used an indirect enhanced polymer immunoperoxidase technique that is 
outlined in the figure below. An unlabelled primary antibody is selected with 
specificity for the target antigen. Tissue is exposed to the primary antibody and 
unbound antibody washed off after a period of incubation. Tissue is then 
exposed to a secondary antibody with species and IgG isotype specificity for 
the primary antibody. Multiple secondary antibodies bind the primary antibody, 
providing signal amplification. Further amplification is provided by the 
secondary antibody being conjugated to a polymer molecule, itself holding 
multiple molecules of the enzyme reporter, horseradish peroxidase (HRP). A 
chromogenic substrate, diaminobenzidine (DAB) is then exposed to the tissue. 
This binds to HRP molecules on the secondary antibody-polymer-HRP complex 
and is converted to a coloured substance, detectable by brightfield microscopy. !
!
Figure 12 - Principles of indirect polymer immunoperoxidase IHC. 
In our work the specific polymer reagent used was a proprietary compound 
manufactured by BioGenex and provided as a component of the 
SuperSensitive)Polymer-HRP IHC Detection System.  
9.1.3 Practical aspects of immunohistochemistry. 
Sample preparation, staining, and image capture was performed by A.Clear. I 
designed experiments in terms of choice of disease and markers to investigate, 
and performed subsequent data analysis. 
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Dako Autostainer. 
For efficiency and to standardise the protocol, all slides for any given 
experiment were stained at one time using an automated system. This 
consisted of a slide rack, with a robotic arm holding a nozzle to dispense 
common reagants from bulk reservoirs and specialised reagants as directed 
from a rack. Dako Autostainer Plus software facilitated bespoke programming of 
staining protocols.  
Protocol for immunohistochemical staining using Dako Autostainer. 
Removal of paraffin and dehydration. 
1. Place TMA slides overnight at 60oC. 
2. Remove paraffin using xylene in two stages: suspend slides in xylene for 
5 min then transfer to second xylene pot. 
3. Transfer to industrial methylated spirits (IMS) for 2 min. 
4. Transfer to hydrogen peroxide (2 ml reagent grade) in 100 ml IMS for 2 
min.. Transfer to a second  pot of hydrogen peroxide and IMS for 2 min. 
5. Transfer to a fresh IMS pot for 2 min (final dehydration step). 
Heat induced epitope retrieval. 
An epitope retrieval process was necessary as formalin fixatives cause protein 
cross-linking, resulting in compromised binding of certain antigens to their 
complementary antibodies. A variety of antigen retrieval methods can break the 
protein cross-links formed by formalin fixation and so better expose antigenic 
sites. Optimal conditions for antigen retrieval were determined for each antigen 
using whole tissue sections exposed to no antigen retrieval step, or an 
enzymatic protocol, or immersion in a heated solution. A heat induced epitope 
retrieval method produced the best results with the three antigen/antibody 
combinations of interest. 
Use of a domestic pressure cooker prevents changes in the buffer solute 
concentrations resulting from evaporation, and owing to positive pressure, 
allows temperatures of above 100°C without boiling (which can otherwise 
physically disrupt specimen integrity). 
6. Heat 3000 ml of antigen unmasking solution in a pressure cooker on low 
heat setting (100-110˚C). 
7. As soon as the solution is just beginning to boil, fully immerse slides in 
plastic racks.  
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8. Seal pressure cooker lid and increase the heat to high setting (120-
130˚C) and leave for 10-15 min. 
9. Remove from heat and cool pressure cooker under cold running tap 
water for 5-10 min. 
10. Retrieve slides and rinse in wash buffer. 
11. Ensure slides remain wet with wash buffer at all times during subsequent 
staining process. 
Antigen staining. 
The following antibodies were optimised and used at the stated dilutions. 
Antigen target Antibody Clone Manufacturer Dilution 
CD68 KP1 Dako 1:8000 
CD163 10D6 Leica 1:3000 
Ki67 MIB-1 Dako 1:1000 
Table 6 - Antibodies used for TMA IHC. 
12. Mark slides using hydrophobic marker pen around the edge of the array 
field: this is to retain liquid on the slide preventing drying, and to ensure 
exposure of the whole area of interest to dispensed solutions. 
13. Input directions using Autostainer control software, specifying number of 
slides to be stained, reagents and incubation times, rinse steps, non-
specific protein block steps (using casein-based commercial protein 
compound), primary antibodies to be used at optimal dilutions (in 
BSA/azide), polymer-conjugated secondary antibody, and chromogenic 
substrate (DAB).  
14. Start the Autostainer. The process takes 2-3 hours including incubation 
and wash steps. 
15. Replace all slides in plastic racks ready for counterstaining and and 
mounting. 
Counterstaining, rehydration and mounting. 
Counterstaining was performed with haematoxylin to provide an outline of 
cellular and tissue architecture, and highlight the presence of those cells not 
marked by the primary and secondary antibodies. Haematoxylin is a blue/purple 
dye that binds histone proteins, and so highlights nuclei. 
16. Rinse in tap water for 5 min. 
! (#N!
17. Suspend in haematoxylin solution for 5 min. 
18. Rinse for 2 min in tap water 
19. Perform five rapid dips in to acid alcohol solution. 
20. Wash immediately in tap water for 2 min. 
21. Rehydrate tissue using three 2 min suspensions in IMS. 
22. Remove residue and clarify tissue by suspending in two xylene baths, 
then suspend in final bath prior to mounting. 
23. Using distyrene, plasticizer and xylene (DPX) mountant apply cover slip 
removing trapped air bubbles. Air dry. 
9.1.4 Image analysis using the Ariol system. 
TMA slides were scanned using an Olympus BX 61 microscope with an 
automated platform. Chosen parameters were measured across all intact cores 
by automated image analysis system (Ariol) as previously described (Kleiner et 
al., 2009). This platform allows the standardised and rapid enumeration of a 
huge number of events from multiple images. The Ariol system was trained by 
an experienced operator (AC) to discriminate stained from unstained cells by 
contrasts in aspects of colour and shape. A pixel mask of positive events was 
constructed and refined in terms of shape and size, then tested to ensure its 
sensitivity and specificity, before being applied to all TMA sections.  
Different staining patterns require different training of Ariol. Ki67 is a nuclear 
stain and so the system is trained to count positive staining and non-staining 
nuclei, readily providing the number and proportion of positive nuclei per 
section. CD68 and CD163 are predominantly membrane and cytoplasmic 
stains. Macrophages are relatively large branching cells that commonly extend 
cytoplasmic processes across sequential tissue sections. As such, Ariol can be 
trained to measure the area of positive and negative staining per section, and 
with this proportional area of macrophage cytoplasm, so derive a proxy 
measure of macrophage number. Provided that macrophage volume and shape 
is, overall, consistent between patients, then this provides a reasonable relative 
measure of macrophage infiltration. 
Each case was entered into the subsequent analysis only if there were two or 
three high quality cores representing a total of 2-3 mm2. A mean count per 1 
mm2 core for lymphoid markers and mean percentage area for CD68 or CD163 
was then calculated. From the original cohort there was further attrition of cases 
based on these quality criteria. 
! (#(!
9.1.5 Tissue microarrays. 
A TMA of 218 diagnostic biopsies of DLBCL was constructed from high quality 
FFPE tissue blocks collected at our centre between 1977 and 2009 (Coutinho 
et al., 2011). The TMA included tissue from 128 males and 90 females, with a 
median age of 55 (18-94) years; 23.2% high-intermediate /high risk IPI; with a 
median follow up of 3.1 years. 33% of patients were treated with rituximab 
containing regimes. All patients had provided informed consent for excess 
biopsy tissue to be used for research purposes in accordance with the 
Declaration of Helsinki, and ethical approval was obtained from the North East 
London Research Board (05/Q0605/140).  
Use of this TMA enabled rapid, efficient and standardised staining and 
assessment of large numbers of biopsies on a small number of glass 
microscope slides. The TMA was constructed following previously described 
principles (Kononen et al., 1998). 1 mm2 cores were taken from 3 separate 
regions of biopsy material per block, having been marked by an expert 
histopathologist (MC) from sections stained with H&E. Acceptable regions were 
of high cellularity, containing malignant cells, without more than 10% by area of 
fibrosis or other cause of acellularity. Cores were arranged vertically in to a 
recipient paraffin block, sectioned and transferred onto glass slides. Control 
cores of tonsil were used to represent normal lymphoid tissue, and cores of 
myocardium or intenstine were placed as orientation markers. Subsequent 
quality control review by expert histopathologists excluded any sections that 
were damaged or of less than 90% cellularity.!
9.2 Liposomal clodronate and liposomal PBS. 
We obtained liposome preparations from Dr Nico van Rooijen, Department of 
Molecular Cell Biology, Vrije Universiteit, Amsterdam. Liposomes contained 
either clodronate at 7 mg/ml, or simply PBS as a vehicle control, which were 
manufactured as described (Van Rooijen and Sanders, 1996). Mice were 
injected into a lateral tail vein with 200 µl of LC or vehicle control, unless 
otherwise specified.  
9.3 Eµ-myc/bcl-2 tumour cells. 
Eµ-myc/bcl-2 cells were a kind gift of Leonie A Cluse, Cancer Immunology 
Program, The Peter MacCallum Cancer Institute, Trescowthick Research 
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Laboratories, East Melbourne, Australia. Eµ-myc/bcl-2 lymphomas had been 
engineered by retroviral transduction of freshly isolated Eµ-myc lymphoma cells 
as previously described (Schmitt et al., 2000, Lindemann et al., 2007). The 
tumour line was propagated by injection to normal healthy C57BL/6 mice. 
Brachial lymph nodes were harvested at day 10, mashed, and stored in solution 
with dimethyl sulphoxide (DMSO) under liquid nitrogen at a concentration of 3 x 
107 in 1 ml. For subsequent injection a single vial was thawed, washed twice in 
media, counted, resuspended in ice cold PBS, and injected immediately at 
room temperature (to avoid culture artefacts). For in vitro studies, tumour cells 
were maintained by incubating at 37°C in 5% CO2 at a starting concentration of 
1 x 106 cells per ml in a volume of 2 ml in 6-well plates.  
9.4 Collection of tumour conditioned media. 
TCM was collected and stored following a published schedule (Solinas et al., 
2010). Lymphoma cells were cultured in vitro to 90% confluence, assessed 
visually. Cells and media were transferred to a tube, an aliquot counted using 
trypan blue exclusion, and spun at 450 Xg for 4 min in an Eppendorf 5810R 
centrifuge. Supernatant was aspirated and discarded, and the cell pellet gently 
re-suspended in fresh warmed media. Cells in fresh media were plated in 6-well 
plate at identical cell density as before and incubated at 37°C in 5% CO2 for 24 
hours. Cells and media were collected and spun at 450 Xg for 4 min. 
Supernatant was collected, filtered through a 0.2 µm filter and stored at -20°C. 
9.5 Cell viability. 
Cell viability was determined by trypan blue exclusion assay using a Beckman 
Coulter Vi-CELL* XR cell viability analyser. 
9.6 Mice. 
Wild-type female C57BL/6 mice were purchased from Charles River and Harlan 
Laboratories. Male and female homozygote transgenic MaFIA mice were 
purchased from The Jackson Laboratory and paired for breeding. For all 
experimental protocols, mice were age matched between groups. For 
experiments with MaFIA mice, groups were balanced for biological sex. 
All mice were housed at a maximum of 6 per cage in a temperature-controlled 
pathogen-free animal facility. Water and food were freely available. Regulated 
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procedures on living animals were conducted within the scope of my personal 
licence (PIL 70/2249) awarded after satisfactory completion of accredited 
training and under the project licence of Professor F. Balkwill in accordance with 
the Home Office Animals (Scientific Procedures) Act 1986.  
9.7 Injections. 
Iv and ip injections were performed using a 1 ml capacity syringe and 25-gauge 
needle (BD Microlance). Iv injections were made into the lateral tail veins.  
9.8 Oral gavage. 
Gavage was performed with 20-gauge x 25 mm curved metal gavage needles 
(VetTech Solutions Ltd). 
9.9 Assessment of in vitro cytotoxicity. 
We administered three different agents to mice in order to specifically 
manipulate their macrophage populations, and then observe the impact on 
lymphoma progression. Namely, these were toxic liposomes, a dimerizer agent 
to trigger macrophage depletion in the MaFIA mouse, and a CSF-1R inhibitor. 
We wanted to assess whether any of these agents were directly toxic to Eµ-
myc/bcl-2 lymphoma cells. For this purpose we cultured Eµ-myc/bcl-2 
lymphoma cells in vitro and exposed identical cell numbers to a wide range of 
concentrations of these agents, separately, for the same length of time, and 
then measured the number of non-viable cells using the proxy measure of LDH 
release into the media (Korzeniewski and Callewaert, 1983, Decker and 
Lohmann-Matthes, 1988). Using the CytoTox-ONE*Homogeneous Membrane 
Integrity Assay (Promega Cat No G7890), we quantified LDH release through 
its conversion of administered resazurin to a fluorescent product, resofurin in 
the presence of excess supplemental diaphorase, pyruvate and nicotinamide 
adenine dinucleotide (NAD+). Generation of fluorescent resofurin is proportional 
to LDH release. Use of appropriate controls is absolutely critical to the reliable 
interpretation of results from this fluorometric technique. LDH is present in 
animal serum used in tissue culture media, and is elicited by human 
lymphomas. As such, acellular complete media and untreated lymphoma 
controls are required, in addition to a 100% cell lysis control. This is generated 
by the addition of a 9% solution of the detergent Triton( X-100 in water to 
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untreated Eµ-myc/bcl-2 lymphoma cells at the end-point of the assay. 
Concentrations of agents were calculated to span a very wide range 
encompassing the very peaks of concentrations that might be experienced in 
vivo.  
9.9.1 Experimental protocol for CytoTox-ONE*Homogeneous Membrane 
Integrity Assay.  
A 96-well plate was prepared with 5 replicates of each condition. The conditions 
studied were as below. The entire experiment was repeated once to confirm the 
results.  
A) Eµ-myc/bcl-2 lymphoma culture media alone.  
B) Eµ-myc/bcl-2 lymphoma cells with Eµ-myc/bcl-2 lymphoma culture media. 
C) Eµ-myc/bcl-2 lymphoma cells with Eµ-myc/bcl-2 lymphoma culture media to 
which 100% Cell Lysis Solution was added (maximum LDH release control). 
D) Eµ-myc/bcl-2 lymphoma cells with Eµ-myc/bcl-2 lymphoma culture media 
and 4 different concentrations, separately, of LC, CSF-1R inhibitor or MaFIA 
dimerizer.  
9.9.1.1 Experimental sequence. 
1)  Eµ-myc/bcl-2 lymphoma cells were plated at their optimal growth density 
of 1 x 106 per ml, giving 5 x 104 cells per well in 50 µl of media.  
2)  Agents or control media were added in 50 µl to make each well to 100 µl. 
There were 4 different concentrations of each agent starting in the mM range 
and reducing on a standard base 10 logarithmic scale. 
3)  The plate was covered and incubated for 18 hours at 37°C in 5% CO2. 
4)  The plate was removed to room temperature to equilibrate for 20 min. 
LDH enzymatic activity is influenced by temperature. 
5)  Substrate Mix and Assay Buffer were equilibrated to room temperature at 
22°C. 
6)  11 ml Assay Buffer was added to and gently mixed with each vial of 
Substrate Mix, protecting from bright light. 
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7)  2 µl of 100% Cell Lysis Solution was added to the maximum LDH release 
control wells. 
8)  100 µl Reagent Mix was added to each well and the plate agitated for 30 
sec. Resazurin dye in the Reagent Mix is light sensitive as is the resorufin 
product, so light exposure of the plate was minimized. 
9)  The plate was incubated at 22°C in the dark for 10 min. 
10)  50 µl Stop Solution was added to each well in the same sequence as 
Reagent Mix to standardise incubation times with active reagent. The plate was 
covered, kept out of bright light, and read with minimal delay. 
11) The plate was analysed using a POLARstar Optima (BMG Labtech) 
multidetection microplate reader with excitation at 560 nm and emission 590 
nm.  
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9.9.1.2 Calculation of percentage cytotoxity. 
The percentage cytotoxicity of each experimental condition was calculated 
using the following formula, incorporating units of fluorescence (FU) for each 
measured well. 
 
100 x!!!!
9.10 Preparation of stored Eµ-myc/bcl-2 lymphoma cells for in 
vivo use. 
Stored Eµ-myc/bcl-2 lymphoma cells were thawed at room temperature, 
washed twice and suspended in ice-cold PBS at a concentration of 2 x 106 
cells/ml. Mice were injected iv with 100 µl volume containing 2 x 105 Eµ-
myc/bcl-2 lymphoma cells. 
9.11 Cytokine analysis. 
Circulating cytokine levels were measured from healthy mice, mice with 
lymphoma, and those subjected to macrophage manipulations. Specifically, 
changes were assessed in circulating levels of CSF-1 and inflammatory 
cytokines. Given the small volumes of plasma available from sacrificed mice 
(approximately 500 µl per mouse), a multiplexed cytokine assay kit was used in 
addition to a specific CSF-1 assay kit, both purchased from Meso Scale 
Diagnostics(. Sample cytokines are measured using a sandwich 
immunoassay. Each well of a 96-well plate contains multiple spots, each with 
separate pre-coated specific capture antibodies bound to a base-plate that can 
act as an electrode. The sample is added and binds to the capture antibody. A 
detection antibody is then added and will bind any sample antigen held by the 
capture antibody. The detection antibody is linked to SULFO-TAG* (ruthenium 
(II) tris-bipyridine-(4-methylsulfonate) NHS ester) molecules. After incubation 
and washing steps, a read buffer is added and the plate loaded to a MSD 
FU of well – Mean FU of culture medium only 
______________________________________________________________ 
Mean FU of maximum LDH release control – Mean FU of culture medium only !
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SECTOR* Imager 6000 reader instrument. Here, a voltage is applied across 
the base plate electrode, causing any bound SULF-TAG molecules to emit light 
at an intensity proportional to the amount of bound sample. Multiple excitation 
cycles provide signal amplification, adding to the sensitivity of this technique.  
In addition to an individual kit to assay for mouse CSF-1, we used a mouse pro-
inflammatory 7-plex assay ultra-sensitive kit (Cat No. K11012C-2). The 
cytokines included, and their lower levels of detection (LLD) are detailed in the 
table below. 
Cytokine LLD (pg/ml) 
IFN-# 0.38 
IL-1" 0.75 
IL-6 4.5 
IL-10 11 
IL-12p70 35 
CXCL1 3.3 
TNF-! 0.85 
 
Table 7 - Sensitivity of cytokine detection in MSD pro-inflammatory 7-plex kit. 
9.11.1 Detailed experimental protocol. 
1) Reagent preparation. 
All reagents were brought to room temperature except the Calibrator 
stock, which was thawed on ice. 
In order that an 8-point standard curve could be constructed, 4-fold serial 
dilutions of Calibrator were made from a first standard point solution of 
10 µl of Mouse Proinflammatory 7-plex Calibrator Blend in 990 µl of 
Diluent 4. The final standard was Diluent 4 alone. This gave a range for 
the standard curve from 0 pg/ml to 10000 pg/ml. 
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The Detection Antibody Blend 50X stock solution was diluted 60 µl in to 
2.94 ml of Diluent 5. 
Equal volumes of 4X Read Buffer T and deionized water were mixed. 
2) Assay protocol. 
25 µl of Diluent 4 was dispensed to each well of the pre-coated plate. 
This was sealed with an adhesive film and agitated on a Dynatech 
microshaker plate-shaker for 30 min at room temperature. 
25 µl of sample plasma or Calibrator standard was dispensed to 
individual wells in duplicate. The plate was sealed and agitated as before 
at room temperature, for 2 hours.  
The plate was washed 3 times with PBS plus 0.05% Tween-20. 25 µl of 
1X Detection Antibody Solution was dispensed to each well, and the late 
sealed and agitated as before at room temperature for 2 hours. 
The plate was washed 3 times as before. 150 µl of 2X Read Buffer T was 
dispensed using careful reverse pipetting to each well and the plate. This 
was to ensure no fluid bubbles were formed that might interfere with the 
subsequent plate reading process. 
3) Plate reading using MSD SECTOR* Imager 6000. 
This imager uses a charge-coupled device (CCD) camera. This digital 
imaging technology allows high quality images to be constructed from 
emitted light by converting incoming photons into readable electric 
charges.  
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9.12 Lymphoma progression assessment. 
Whenever feasible, independent observers performed tissue quantification 
blinded to the therapy received by each group.  Initial assessments of 
lymphoma mass consisted of measurement of the long and perpendicular axes 
of spleens and lymph nodes using 0-200 mm electronic digital callipers with 
0.01 mm resolution (VWR). 
Organ volume was derived from the formula:  
Volume = 0.52 (short axis2 x long axis)  
It became apparent that this method was potentially fragile, with heavy reliance 
on observer judgment of the correct placing of the calliper arms, particularly with 
smaller nodes. To abolish this variability, and establish a more robust measure 
with no possibility of observer bias, we used organ weights alone as a proxy 
measure of lymphoma mass. Dissected lymph nodes and spleens were cleaned 
of adherent fat and connective tissues, and weighed on highly sensitive scales. 
To validate using organ weight as a proxy for lymphoma mass it was necessary 
to establish the relationship between organ weight and cross-sectional area of 
tissue infiltrated by lymphoma in histological sections. 
9.13 Quantification of liver cross-sectional tumour area. 
FFPE sections of liver were cut and stained with H&E. As is typical with 
intravenously transplanted lymphomas in mice, tumour cells appeared to 
congregate around hepatic sinusoids and veins. This is visible in the image 
overleaf as dark-staining areas that at higher magnification are revealed to be 
composed of cells with a high nuclear to cytoplasmic ratio. Using a low 
magnification lens, multiple images were photographed at random locations, 
obtained without looking through the viewfinder. The images were imported to 
Adobe+ Photoshop+ software and overlaid with a graticule. The number of 
whole and half squares occupied by lymphoma was counted for each image 
and expressed as units of area, corresponding to cm2 per low power field. The 
figure below indicates the principle of this approach. In practice, a finer graticule 
with more sub-divisions was used to enable more accurate quantification. An 
independent scientist, blinded to experimental groups and the aims of the 
project, repeated this process.!
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Figure 13 - FFPE section of liver stained with H&E with overlying graticule to 
demonstrate method of quantification of cross-sectional area of lymphoma  (OM 
x 2.5). 
9.14 Preparation of FFPE sections of bone and bone marrow.   
Femurs of sacrificed experimental mice were dissected, cleaned of soft tissues, 
and submerged in 4% formaldehyde for 24 hours at room temperature. Bones 
were then removed, washed in slow running tap water for 5 min before being 
placed in 10% formic acid for 24 hours and rotated slowly at room temperature. 
Decalcification was confirmed by the ability to bend a femur using forceps and 
minimal force. Decalcified bones were washed under slow running tap water for 
30 min prior to routine paraffin embedding. 
9.15 Embedding of tissues. 
1) A mould was filled with molten paraffin wax 
2) The tissue cassette was opened the tissue transferred to the mould with 
warmed forceps.  
3) Gentle pressure was applied to embed the tissue evenly in the mould. 
4) The mould was chilled on a cold plate with the tissue cassette base 
placed on top. 
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5) More molten paraffin was added to completely fill the mould and cassette 
base &] Once solid, the block with attached labelled cassette base was removed 
from the mould.!
9.16 Blood sampling by cardiac puncture. 
Blood was harvested by terminal cardiac puncture using a 1 ml syringe 
containing a drop of unfractionated heparin, and a 25-gauge needle (BD 
Microlance) under inhalational general anaesthesia with isoflurane and oxygen. 
Mice were placed supine exposing their ventrum, the needle inserted 
immediately caudal to the xiphoid process and advanced towards the left 
shoulder with continuous gentle suction until blood was freely aspirated. At 
completion, the needle was withdrawn and sacrifice performed by cervical 
dislocation. Blood was then stored on wet ice, spun in an Eppendorf 
Microcentrifuge (Cat. No. 5415D) at 1600 Xg for 2 min to separate the plasma 
from the cellular fraction. Plasma was frozen on dry ice and stored at -80°C. 
The cellular pellet was resuspended, and processed for analysis by flow 
cytometry. !
9.17 Sacrifice and organ removal. 
Mice were sacrificed by cervical dislocation. Organs were immediately weighed 
and then placed in appropriate storage depending upon subsequent intended 
use:  
FACS/ flow cytometry  –  Ice-cold PBS 
FFPE sections   –  4% Formaldehyde 
Frozen sections   –  OCT on dry ice 
RNA extraction   –  2 ml micro-centrifuge tube on dry ice 
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9.18 Preparation of MaFIA dimerizer AP20187. 
1) Lyophilized AP20187 was dissolved in 100% ethanol at a 
concentration of 13.75 mg/ml 
2) An injection solution was prepared in sterile water consisting of 10% 
PEG-400 and 1.7% TWEEN. 
3) AP20187 in 100% ethanol was diluted with injection solution in a ratio 
of 1:25 by volume. 
4) The final product in sterile water for injection consisted of: 
 0.55 mg/ml  AP20187 
 4%    ethanol 
 10%   polyethylene glycol (PEG-400) 
 1.7%   TWEEN 
This product was administered by ip injection within 30 min of preparation, with 
the volume injected adjusted by weight to deliver 10 mg AP20187 / kg per dose.  
9.19 Formation of single cell suspensions for flow cytometry. 
Organs in ice-cold Dulbecco’s modified eagle medium (DMEM) were macerated 
through 40 µm nylon cell strainers (BD falcon Ref 352340) using a 5 ml syringe 
plunger, spun and resuspended in red blood cell lysis buffer (BD Pharm Lyse) 
1x concentration), spun, washed and nucleated cells stained for analysis by 
flow cytometry. 
9.20 Flow cytometry antibody staining. 
Cells of interest were suspended at 1 x 107 per ml and 80 µl pipetted to each 
well in a 96-well plate with round-bottomed wells. The plate was spun at 950 Xg 
for 2 minutes using an Eppendorf 5810R centrifuge and the supernatant 
discarded. The pellet was re-suspended in 100 µl flow cytometry buffer and 
spun again at 950 Xg for 2 minutes, discarding the supernatant. The washed 
cell pellet was resuspended in 50 µl of CD16/CD32 Fc receptor block (diluted 
1:100 in flow cytometry buffer) to minimise non-specific binding to Fc receptor 
expressing cells. The plate was incubated at 4°C for 15 minutes before adding 
flow cytometry antibodies diluted at 1:100 in 50 µl of flow cytometry buffer. The 
plate was incubated at 4°C for 30 minutes in the dark before spinning at 950 Xg 
at 4°C for 5 minutes and discarding the supernatant. Two further washes with 
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flow cytometry buffer were performed, prior to resuspending the pellet in 50 µl 
2% formaldehyde to fix the stained cells. A table of flow cytometry antibodies, 
their manufacturer and optimal dilution is provided as an appendix.  
9.21 Analysis by flow cytometry. 
Samples were read using the BD FACSCalibur* and the BD Fortessa* 
platforms. Data was analysed using FlowJo 8.8.6 software. Accurate analysis of 
fluorochrome detection was achieved with unstained and isotype controls, and 
compensation performed with positively staining cellular samples and 
compensation beads.  
9.22 Collection of mouse peripheral blood for morphological 
review. 
A mouse was held within a restraining tube allowing its tail to protrude. The tail 
was held proximally, cleaned with an alcohol swab and sprayed with ethyl 
chloride to provide local anaesthesia, then 1-2 mm of the tip swiftly removed 
with a scalpel blade. Drops of blood were collected on individual glass slides 
and spread to allow subsequent clear visualisation of cellular morphology. 
Pressure was applied with clean gauze until haemostasis was achieved, and 
this was secured by painting the tip with a silver nitrate pencil. 
The project licence dictates that no mouse can be bled on more than 3 
occasions in its entire lifetime. Each bleed must be separated by at least 7 days 
from the next, and the total loss of blood must constitute less than 15% of 
circulating volume. In a protocol containing 10 mice per group, bleeding each 
mouse every 10 days on a staggered rota would allow a single representative 
blood smear from each group on every day for 30 days. 
9.23 Staining of mouse peripheral blood for morphological review. 
Each blood smear was dried, fixed and stained using the following rapid manual 
dip protocol. We chose to use a modified Wright’s stain (WS16 Sigma 
Aldrich+). This is a Romanowsky-type stain containing methylene blue, azure B 
and eosin Y dyes, allowing excellent discrimination between nucleus and 
cytoplasm in the interpretation of white blood cell morphology (Wright, 1902). It 
also contains methanol, acting as a solvent and fixative. 
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1) Slides were dried horizontally in still air at room temperature. Staining 
proceeded within one hour of drying. 
2) 50 ml modified Wright’s stain was placed in a Coplin jar. 
3) 50 ml deionised water was placed in another Coplin jar. 
4) Each slide was placed feather-edge down in modified Wright stain for 15 
seconds. 
5) Each stained slide was then placed feather-edge down in deionised 
water for 30 seconds. 
6) Each slide was rinsed by gently passing 5-10 ml of deionised water over 
its surface using a 5 ml plastic transfer pipette. 
7) Slides were dried horizontally in still air at room temperature before 
evaluation. 
9.24 Assessment of tumour proliferation by BrdU 
incorporation. 
We wished to assess the proliferative rate of Eµ-myc/bcl-2 lymphoma cells in 
different in vivo conditions. As a proxy measure, we determined the proportion 
of malignant cells entering and progressing through the S phase of the cell 
cycle. We used flow cytometry to measure cellular immunofluorescent staining 
of bromodeoxyuridine (BrdU) that had been incorporated in vivo. BrdU is a 
thymidine analogue, and is incorporated into newly synthesised DNA (Eidinoff 
et al., 1959, Hakala, 1959). Bolus ip injection of weight adjusted doses of BrdU 
allowed robust comparison between individual mice and groups. Equally 
important was ensuring identical time-intervals between injection of BrdU and 
storage at 4°C of harvested tissue from sacrificed mice. 
This was carried out using the BD Pharmingen* APC BrdU Flow Kit (Catalog 
No. 552598). The dose per mouse was 0.02 mg per kg  of a 10 mg/ml solution 
of BrdU in sterile PBS, delivered in a single ip injection (Rocha et al., 1990). 
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9.24.1 Immunofluorescent staining of blood and lymph nodes for 
assessment of BrdU by flow cytometry.  
Red cell lysis was performed with pharmlyse RBC lysis buffer as previously 
described. Lymph node single cell suspensions were formed as previously 
described.  
1) Staining cell-surface antigens. 
1 x 106 cells were resuspended in 50 µl staining buffer (PBS with 3% 
FCS) in individual 1.2 ml Linbro® Liquisystem polypropylene tubes (MP 
Biomedicals, Cat No. 61226C2).  
Fluorescent antibodies for all cell-surface antibodies were added in 50 µl 
of staining buffer, mixed well and incubated on ice in the dark for 15 min. 
1 ml of staining buffer was added to each tube and spun at 300 Xg for 5 
min, discarding the supernatant. 
2) Fixation and permeabilisation. 
The cell pellet was resuspended in 100 µl of BD Cytofix/Cytoperm Buffer 
and incubated on ice in the dark for 15 min. 1 ml of BD Perm/Wash 
Buffer was added to each tube, spun at 300 Xg for 5 min and the 
supernatant discarded.  
Cells were resuspended in 100 µl of BD Cytoperm Plus Buffer, incubated 
for 10 min in the dark on ice, then washed with 1 ml BD Perm/Wash 
Buffer, and spun as before. 
The cell pellet was resuspended in 100 µl of BD Cytofix/Cytoperm Buffer, 
incubated in the dark for 5 min on ice, washed once more with 1 ml BD 
Perm/Wash Buffer and spun as before. 
3) DNase treatment to expose incorporated BrdU. 
Cells were resupsended in 100 µl of DNase 300 µg/ml in PBS and 
incubated for 60 min at 37°C in the dark, before washing once more with 
1 ml of BD Perm/Wash Buffer and spinning as before. 
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4) Staining of BrdU and other intracellular antigens with fluorescent 
antibodies. 
Cells were resuspended in 50 µl of BD Perm/Wash Buffer containing 
anti-BrdU APC at a concentration of 1:50 then incubated at 22°C in the 
dark for 20 min before washing in 1 ml BD Perm/Wash Buffer and 
spinning as before. The fully stained and fixed cells were then 
resuspended in 1 ml of staining buffer and analysed by flow cytometry. 
9.25 Extraction of RNA with Qiagen kit. 
RNA was extracted according to tailored protocols from the RNeasy+ Mini and 
Micro Handbooks. Snap-frozen lymph nodes or spleen tissue were placed in 
gentleMACS* M Tubes (Miltenyi Biotec) with 0.5 ml of Buffer RLT (Qiagen) 
and homogenized for total RNA isolation using the gentleMACS Dissociator on 
the RNA-02 program for frozen tissues. The resultant foamy homogenate was 
spun at 2000 Xg for 1 minute in an Eppendorf 5810R centrifuge and 350 µl 
aspirated into a QIAshredder spin column placed in a 2 ml collection tube and 
spun for 2 minutes at 16000 Xg in an Eppendorf Microcentrifuge 5415D. The 
supernatant was transferred to a fresh 2 ml centrifuge tube. 350 µl of 70% 
Ethanol was added and thoroughly mixed by pipetting.  
700 µl of each sample was transferred to an RNeasy spin column placed in a 2 
ml collection tube and spun for 15 seconds at 16000 Xg. The flow through was 
discarded. On-column DNase digestion was then performed, as follows. 350 µl 
of Buffer RW1 was added to each sample and spun for 15 seconds at 16000 
Xg. The flow through was discarded and 80 µl of DNase solution in Buffer RDD 
was added directly to the RNeasy spin column and left at room temperature for 
15 minutes.  
350 µl Buffer RW1 was added to the RNeasy spin column and spun for 15 
seconds at 16000 Xg, with the flow through being discarded. 500 µl Buffer RPE 
was added to the RNeasy spin column and spun for 15 seconds at 16000 Xg, 
and the flow through discarded. This step was repeated but spinning for 2 
minutes to dry the RNeasy spin column membrane. The column was then 
carefully removed and placed in a fresh collection tube.  
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40 µl of RNase-free water was added directly to the column and spun for 1 
minute at 16000 Xg to elute the RNA. The flow through was aspirated and 
pipetted once more onto the column membrane before repeating this spin cycle. 
The flow through was collected and stored at -80°C. 
9.26 Counting macrophages in mouse tissue sections. 
This was performed manually rather than by using the automated Ariol system. 
Macrophages marked by the presence of brown stain were included in the 
count if they were clearly distinguishable as a discrete cell with a nucleus 
surrounded by positively staining cytoplasm and membrane. Positively staining 
fragments without a nucleus were not counted. High magnification images were 
taken from multiple areas of each section, selected randomly without looking 
through the microscope. A graticule was superimposed over each image using 
Adobe Photoshop software, to facilitate counting. Counting was performed by 
me, and then repeated by independent scientists, blinded to the purpose of the 
experiments and the treatment groups. The data included in this thesis derives 
from the independent observers.  
9.27 Cyclophosphamide. 
Cyclophosphamide was provided as 500 mg of white powder. It was 
reconstituted with 25 ml of sterile 0.9% saline, giving a 6 mg/ml concentration. 
This was given to mice with lymphoma as a single bolus ip injection, as detailed 
for each protocol. 
9.28 RNA analysis. 
Purity and quantity was analysed using the ND1000 Spectrophotometer, 
reading absorbance at 260/280 nm (NanoDrop, Wilmington, DE, US). 
9.29 RNA integrity. 
RNA integrity was measured using the Agilent RNA 6000 Nano Kit, using 
Agilent RNA 6000 Nano Assay Protocol – Edition April 2007 , Agilent 
Technologies.  
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9.30 Reverse transcription of RNA to yield cDNA. 
For each sample of RNA, 2 µl of RNA was added to a 2 ml centrifuge tube with 
10 µl DEPC H2O and 2 µl of Random Primers. Each tube was heated at 75°C 
for 5 minutes before cooling on wet ice for 5 minutes.  
To each centrifuge tube was added: 
5 µl  M-MLVT RT reaction buffer 
5 µl  Mixed Nucleotide Pool 
1 µl M-MLV RT enzyme 
0.6 µl  RNasin+ RNase inhibitor (Promega) 
 
After 10 minutes at room temperature, each tube was incubated at 40°C for 50 
minutes. Subsequently, 75 µl of DEPC H2O was added to each sample, which 
was stored at -20°C. 
9.31 Quantitative RT-PCR. 
Analyses were performed using the ABI Prism 7700 Sequence Detection 
System Instrument and software (PE Applied Biosystems). RT-PCR was 
performed using sample cDNA (FAM) and internal control 18sRNA (VIC) and 
specific TaqMan+ probes. 
qRT-PCR was carried out with the TaqMan+ Universal PCR Master Mix (PE 
Applied Biosytems) in a 96 well plate with optical film (ABI). Each well contained 
the following reagents: 
 10 µl  TaqMan+ Universal PCR Master Mix 
 6 µl   DEPC H20 
 2 µl   Sample cDNA 
 1 µl  Probe/primer set of gene of interest 
 1 µl   Primers and probes for 18s RNA 
The thermal cycling conditions, for a total of 60 cycles, were: 
 50°C  2 min 
 95°C  10 min 
 95°C  15 sec 
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 60°C  1 min 
Samples were tested in triplicate. Target mRNA was normalised ($CT) to 18s 
RNA by subtracting the cycle threshold (CT) of the 18s RNA sample from the 
cycle threshold (CT) of each sample.  
The expression level of each target gene in the intervention group samples was 
determined relative to the initial experimental controls (Livak and Schmittgen, 
2001): 
 $$CT = $CT intervention – $CT control group 
This was expressed as a fold change in gene expression using the formula: 
 Fold Change = 2-$$CT 
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9.32 Mouse bone marrow derived macrophages (BMDM). 
Mouse BMDM were prepared under sterile conditions by flushing bone marrow 
from the centre of femora and tibiae of healthy 6-12 week old female C57BL/6 
mice using a 5 ml syringe filled with ice cold DMEM and a 25 gauge needle (BD 
Microlance). A single cell suspension was created by maceration with the back 
of a syringe plunger through a 40 µm cell strainer, with cells spun and 
resuspended at 1 x 106/ml in DMEM with 10% FCS and 1 µl of recombinant 
CSF-1 (Miltenyi Biotec) per 1 ml of media at a final concentration of 10 ng/ml, 
then incubated at 37°C with 5% CO2, and re-stimulated with CSF-1 at day 3.  
In vitro polarisation of macrophage phenotype was performed by overnight 
stimulation on day 6 by replacing with fresh media supplemented with LPS 1 
µg/ml and IFN-# 20 ng/ml to derive classically activated M1 macrophages, IL-4 
20 ng/ml to derive alternatively activated M2 macrophages, and replacing with 
TCM for TAM polarised macrophages. 
Adherent macrophages were removed by incubation at 37°C for 30 minutes 
with 10 ml cell dissociation buffer (Gibco, Invitrogen), followed by gentle 
physical removal with a cell scraper (BD Falcon), washing and resuspension in 
appropriate media. 
!
Figure 14 - Preparation of phenotype-modulated bone marrow derived 
macrophages. 
To identify adoptively transferred macrophages, a red fluorescent dye (PKH26, 
Sigma-Aldrich) was incorporated into mouse BMDM in vitro as described by the 
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manufacturer (Product Information, PKH26 Red Fluorescent Cell Linker Kit for 
General Cell Membrane Labelling). Post mortem frozen tissue sections were 
visualized by fluorescent microscopy to identify labelled macrophages. BMDM 
purity was assessed by flow cytometry. !
9.33 Preparation of the small molecule CSF-1R tyrosine 
kinase inhibitor. 
The compound AZ268 was provided by AstraZeneca as a yellow powder. 
Diluent consisted of 0.1% Tween-80 and 0.5% methylcellulose in sterile water. 
Diluent was prepared by adding 100 µl of Tween-80 to 100 ml sterile water and 
placing on a stir plate. 0.5 g methylcellulose powder was added slowly and 
stirred overnight, before sterile filtering. The compound powder was added to 
this diluent to produce a final concentration of 20 mg/ml, and sterile filtered and 
injected within 2 hours of preparation. To deliver 100 mg/kg to 20g mice, 100 µl 
was administered to each mouse by oral gavage.  
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10 Statistical considerations. 
Statistical advice was kindly provided by Dr Donna Neuberg, Senior Lecturer on 
Biostatistics, Dana-Farber Cancer Institute, Massachusetts, USA, who is a long-
term collaborator of J. Gribben and receives funding from his Programme Grant. 
This included tuition in the use of power calculations to determine minimum 
numbers of mice required to achieve meaningful results for in vivo experiments. 
This input also facilitated the appropriate use of statistical tests and 
representation of data. The majority of mouse data showing weights or volumes 
of tissues and organs involved fairly small numbers of individual data points, 
relatively tightly clustered. As such, greatest clarity was achieved by 
representing the data with individual points for each measurement, and a line at 
the median, without crowding the figure with error bars. Our primary interest 
was to determine differences between groups. The most appropriate test for 
analysing differences between the groups was to perform a rank test. For this 
purpose we chose the Mann-Whitney test (Mann and Whitney, 1947). This is a 
non-parametric significance test requiring that observations in each group are 
independent of each other (not paired samples), responses are continuous 
measurements and that we are testing a null hypothesis that the independent 
groups are equally distributed. It does not require identical numbers in each 
group, unlike the otherwise similar Wilcoxon rank-sum test. The values from all 
the experimental samples, regardless of whether in the treatment or control 
group, are ranked according to the measured variable. This creates a single 
ranked series. The relative distribution of the rank values between the groups 
being compared is used to calculate the likelihood of a difference between the 
groups being due to chance alone.  
Particularly in relation to comparison of the weights of lymph nodes, many of 
the protocols produced very tightly clustered data points within each group, and 
obvious differences between groups. As such, a variety of different statistical 
tests would each have demonstrated statistical significance. A rank test was 
chosen as the most appropriate method of answering the question of whether 
differences existed between groups. It is prudent to consider the limitations of 
the p-values obtained from such tests. With small numbers of mice and clear 
differences in data values between two groups, the p-values from rank tests will 
not distinguish large magnitudes of difference in one experiment from small 
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magnitudes of difference in another, provided the rank positions of data points 
between groups are identical from one experiment to the next. This is 
demonstrated with example data below. There is clearly a greater magnitude 
difference in values between group A and group B, than between group A and 
group C. Although this can be appreciated from inspecting the data points on 
the dot plot, it is not reflected in the p-value for Mann-Whitney analysis. This is 
because the difference between the sums of the rank positions is the same in 
both instances. As such, several of the p-values were identical between our 
different experiments.  
!
Figure 15 - Example data demonstrating limitations of Mann-Whitney analysis. 
We believe that the Mann-Whitney analysis was appropriate for these 
experiments, and that the focus of future work should be establishing if there is 
biological significance for the observed statistically significant phenomena. 
The Mann-Whitney test is considered to be more robust that the Student’s t-test 
in situations such as here using small numbers of animals, in which the 
presence of a single extreme data point might otherwise result in the spurious 
attribution of significance. Furthermore, such a rank test is more appropriate in 
answering the question of whether a difference exists following an intervention, 
and in what direction. At this point, the magnitude of difference seen when 
manipulating macrophages in our model is perhaps less relevant until it has 
been established that a difference does indeed exist.  
Unless otherwise specified, the following conditions apply to our data: 
Dot Plots: Each dot represents a data point for an individual mouse. When 
depicting lymph node volume or weight, each dot is a cumulative value for 4 
lymph nodes per mouse; paired bilateral inguinal and brachial nodes. A single 
horizontal bar is at the median value. The p-value derives from Mann-Whitney 
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analysis. 
Bar Charts: Each bar represents combined data from several mice from one 
specified experimental group. The upper limit of the solid bar represents the 
mean value, and the up-going vertical arm with horizontal bar, the standard 
error of the mean (SEM). The p-value derives from Mann-Whitney analysis.  
Statistical significance corresponds to a p-value of less than 0.05.  
! (%%!
11 Protocols and results. 
We interrogated human biopsies of DLBCL to investigate whether there was 
correlative evidence supporting a relationship between macrophage numbers 
and lymphoma growth. !
11.1 Interrogating diagnostic human biopsies of DLBCL. 
We reviewed the diagnoses of the 218 cases included on the aggressive 
lymphoma TMA, as recorded in the clinical and histological databases at our 
centre. Given that the impact of TAM might be different in different types of 
lymphoma, we chose to exclude those aggressive B-NHL that are variants of 
DLBCL:  
 
Primary mediastinal B-cell lymphoma  19 cases 
T-cell/histiocyte rich B-cell lymphoma  16 cases 
HIV-related lymphoma     6 cases 
Primary CNS lymphoma    2 cases 
Lymphoplasmacytic lymphoma   1 case 
 
Additionally, 29 cases were excluded as technically inadequate. There 
remained 145 DLBCL with at least some data on staining for CD68, CD163 or 
Ki67. Of theses, 62 were female and 83 male. According to the Hans algorithm, 
95 were ABC phenotype, and 47 were GCB phenotype. 3 cases could not be 
assigned to either group. The median age at diagnosis was 60 years (18-88 
years). In each analysis were small numbers of cases without complete data 
from at least 2 cores for the markers of interest so these cases were excluded 
from analysis. 
Example sections are shown overleaf of cores on the DLBCL TMA stained with 
CD68, and separately with Ki67. These demonstrate high and low scores for 
both markers. 
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Figure 16 - Representative sections of DLBCL TMA stained with CD68 (top) and 
Ki67 (bottom). 
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In the following plots, each dot represents a score for that marker in an 
individual patient. This figure is an average of at least 2 cores from each patient 
biopsy.  
!
Figure 17 - Distribution of scores for CD68 and CD163 staining by area (above) 
and Ki67 staining by percentage of positive nuclei (below). !
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We plotted the percentage area of CD68 and CD163 staining for paired 
samples, the data for each individual biopsy linked by a straight line, as shown 
in the figure below. These data derive from sequential sections of the same 
patient cores for each paired set. Although there are individual exceptions, in 
the majority of cases the percentage area staining for CD163 was less than the 
percentage area staining for CD68, and this was statistically significant using a 
two-tailed Mann-Whitney rank analysis. 
 
!
Figure 18 – Comparison of areas of CD68 and CD163 staining across the whole 
TMA, with each patient biopsy average score represented by a dot for each 
marker, joined by a straight line (n=136). 
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We investigated correlations between the 3 different markers in the following 
dot plots.  
!
Figure 19 - Correlations between CD68 and CD163 staining (above) and each 
macrophage marker and Ki67 (below). A regression line is depicted in red. 
 
Comparison Number 
of cases 
Probability  of 
non-zero slope 
of regression 
line 
Spearman 
rank 
coefficient 
CD163 / CD68 136 p= <0.0001 0.6485 
p= <0.0001 
CD68 / Ki67 130 p= 0.0036 0.3155 
p= 0.0003 
CD163 / Ki67 129 p= 0.0195 0.2287 
p= 0.0094 
Table 8. - Statistical outcomes of data analysis. 
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CD163 and CD68 staining areas were very closely and positively correlated. 
Both CD68 and CD163 areas were independently positively correlated with the 
percentage of Ki67 positive nuclei. Overall, tissues with more abundant 
macrophages exhibited higher proliferation fractions. There were individual 
cases that did not appear fit this pattern, but the correlation over the whole 
group was statistically significant. 
When analysed separately, GCB and ABC phenotypes of DLBCL maintained 
the same relationships as in the whole data set (data not shown).  
These data were consistent with published data that tissue sections of more 
proliferative lymphoma subtypes had more frequent macrophages (Hermann et 
al., 1998). Our data supplements this by demonstrating a clear correlation 
within a lymphoma subtype, among a much larger number of cases of DLBCL, 
and by indicating that TAM in DLBCL have features of alternative activation by 
virtue of expression of CD163. As such, this work further supported the need to 
investigate the nature of TAM-lymphoma interactions in a living system. !
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11.2 Investigating macrophage-lymphoma interactions in a 
living system – the Eµ-myc/bcl-2 mouse lymphoma. 
11.2.1 Characterisation of Eµ-myc/bcl-2 lymphoma. 
Experimental protocol: 
The original Eµ-myc/bcl-2 transgenic mice exhibit variability in the stage of B-
cell maturity at which malignant clones are generated. As such, it was important 
to determine the exact phenotype of the dominant malignant population in any 
given batch of cells derived from these mice. For this reason, and for 
subsequent quantification of B-cell populations, we thawed an aliquot of Eµ-
myc/bcl-2 cells stored in liquid nitrogen, and incubated them for 3 passages 
over 12 days. Cells were mixed with panels of flow cytometry antibodies at a 
concentration of 1:50 and fixed in 2% formaldehyde. Controls included 
unstained cells, isotype controls, and positive controls for each fluorochrome. 
This enabled purity of the cell population to be assessed. We attempted to 
corroborate these in vitro findings by flow cytometry of enlarged lymph nodes 
from C57BL/6 mice 10 days following iv transplant of 2 x 105 Eµ-myc/bcl-2 cells.  
Data: 
After 3 passages over 12 days, Eµ-myc/bcl-2 cells exhibited 84% viability (by 
Trypan blue dye-exclusion) at a concentration of 3.5 x 106 /ml. The vast majority 
of cells (>85%) were of one phenotype, indicating that this was the dominant 
population. These cells displayed the immunophenotype CD19+, B220+, IgM+, 
IgD+ consistent with a mature B-cell phenotype. A minority population had weak 
or absent expression of surface IgD. All cells were negative for T-cell markers 
including CD3, CD8 and CD5, and were negative for CSF-1R. Flow cytometry 
of fresh lymph nodes harvested from mice with advanced lymphoma confirmed 
these findings, as shown overleaf. 
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Figure 20 – Gating of live, CD19 positive cells from whole fresh lymph nodes. 
The CD19 positive portion was selected, and assessed below for expression of 
surface immunoglobulin. 
!
!
Figure 21 - Histograms depicting surface IgM and IgD expression of live, CD19 
positive cells from the fresh lymph nodes of mice with lymphoma. 
! (&#!
There was almost totally mutually exclusive expression of CSF-1R and B220, in 
the lymph nodes of mice with lymphoma, strongly indicating that malignant B-
cells do not express CSF-1R in this model. The low frequency of dual positive 
cells may represent a subset of DC.  
!
Figure 22 - Mutually exclusive expression of CSF-1R and B220 in fresh lymph 
nodes of mice with lymphoma. 64.4% = B220+/CSF-1R-, 6.7% = CSF-1R+/B220-, 
0.18% = B220+/CSF-1R+, 28.7% = B220-/CSF-1R-. 
We were satisfied with these data and so propagated and used the same 
population of Eµ-myc/bcl-2 lymphoma cells in all subsequent experiments. 
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11.3 Effects of intravenous liposomal clodronate on normal 
healthy C57BL/6 mice. 
We planned to investigate the effects of macrophage ablation on the 
progression of lymphoma, using liposomal clodronate (LC). This initial 
experiment investigated the effects of an intensive regime of LC on normal 
healthy mice without lymphoma. 
Experimental protocol: 
Healthy mice without lymphoma were repeatedly injected with 200 µl of LC on 
days 1, 3, 6 and 10 and sacrificed on day 12. 
!
Figure 23 - Protocol investigating the effects of liposomal clodronate in healthy 
mice. 
! (&%!
Data: 
Mice given iv LC had significantly less overall weight gain than untreated mice 
after 11 days of the above schedule.  
 
 
Figure 24 - Body weight of mice treated with iv LC (n=5) or untreated (n=4). Plot 
shows mean values with standard error of the mean (SEM) for each group at 
each time point. 
As demonstrated in the following two figures, there was no statistically 
significant difference observed in the weights of livers, or volume of lymph 
nodes.  
!
Figure 25 - Liver weights. 
! (&&!
 
 
Figure 26 - Lymph node volumes.  
 
However, spleens were significantly smaller in mice treated with iv LC. 
!
Figure 27 - Spleen volumes. 
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Flow cytometry analysis of spleen and lymph nodes demonstrated a reduced 
proportion of live cells in the spleens of mice receiving LC, but no difference in 
the lymph nodes. This is shown in the following two figures. The percentage of 
live cells was measured by displaying the characteristics of single cell 
suspensions in terms of forward scatter and side-scatter, and constructing a 
gate to exclude cells with features of being non-viable.  
 
Figure 28 - Percentage of live cells in the spleen. 
 
Figure 29 - Percentage of live cells in lymph nodes. 
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As shown below, mice receiving LC had fewer F4/80 staining macrophages in 
the lymph nodes than un-manipulated mice, as measured by flow cytometry. 
 
!
Figure 30 - Flow cytometric measurement of macrophages in lymph nodes of 
healthy mice with no manipulation (n=4) or iv LC (n=5), percentage of all node 
cells. 
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There was no difference in the percentage of B-lymphocytes and T-
lymphocytes in the lymph nodes or spleens of treated mice and un-manipulated 
controls. !
!
Figure 31 - Percentage of CD3 positive T-lymphocytes in lymph nodes of normal 
healthy mice (n=4) or those receiving iv LC (n=5). 
 
!
Figure 32 - Percentage of CD19 positive and B220 positive B-lymphocytes in 
lymph nodes of normal healthy mice (n=4) or those receiving iv LC (n=5). 
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!
Figure 33 - Percentage of CD3 positive T-lymphocytes in the spleen of normal 
healthy mice (n=4) or mice with iv LC (n=5). 
!
Figure 34 - Percentage of CD19 positive and B220 positive B-lymphocytes in the 
spleen of normal healthy mice (n=4) or mice with iv LC (n=5). 
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Immunohistochemical staining of FFPE sections of spleen, liver, lymph node, 
and bone marrow clearly demonstrated macrophage depletion in the organs of 
mice treated with liposomal clodronate.  
Normal spleen   Treated with iv LC 
 
Figure 35 - Spleen stained with F4/80 and haematoxylin (OM x 40). 
Normal liver    Treated with iv LC 
 
Figure 36 – Liver stained with F4/80 and haematoxylin (OM x 40).                                                                                                                                                                                                                                                                                                             
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   Normal lymph node   Treated with iv LC 
 
Figure 37 – Lymph Node stained with F4/80 and haematoxylin (OM x 40). 
Normal bone marrow   Treated with iv LC 
 
Figure 38 - Bone marrow stained with F4/80 and haematoxylin (OM x 20). 
In summary, an intensive regime of iv LC depletes macrophages from the bone 
marrow, lymph nodes, liver, and spleen of otherwise healthy female C57BL/6 
mice. This is associated with a substantial degree of cell death within the 
spleen, and impairment of general wellbeing as evidenced by retardation of 
normal weight gain over 15 days. B-lymphocyte and T-lymphocyte numbers 
appear unaffected by this intervention. 
Having confirmed macrophage depletion with this regime of LC in healthy mice, 
we planned to investigate its effects in mice with transplanted Eµ-myc/bcl-2 
lymphoma. Firstly we conducted in vitro experiments that would reveal whether 
or not LC was directly toxic to Eµ-myc/bcl-2 cells. 
! ('#!
11.4 The impact on lymphoma progression of macrophage 
depletion with liposomal clodronate.  
11.4.1 Liposomal clodronate versus Eµ-myc/bcl-2 cells in vitro. 
Experimental protocol: 
Eµ-myc/bcl-2 lymphoma cells were exposed to LC at varying concentrations in 
a 96 well plate, and cytotoxicity measured as previously described. Controls 
were media alone, lymphoma cells with no LC, lymphoma cells with a range of 
concentrations of liposomal PBS, and a positive control of fully lysed lymphoma 
cells. In this assay, fluorescence is proportional to cell injury and death. 
Data: 
Eµ-myc/bcl-2 lymphoma cells cultured in vitro were not killed by direct exposure 
to a wide range of concentrations of LC.  
!
Figure 39 - Eµ-myc/bcl2 cells in vitro exposed to LC. 
Having established that LC was not directly toxic to Eµ-myc/bcl-2 cells, we were 
able to investigate its effects on Eµ-myc/bcl-2 growth in vivo, with the 
reasonable assumption that any impact would be indirect, possibly owing to 
macrophage depletion. 
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11.4.2 Effects of liposomal clodronate mediated 
macrophage depletion on the progression of transplanted 
Eµ-myc/bcl-2 lymphoma. 
11.4.2.1 An intensive regime of liposomal clodronate reduces lymph 
node volume. 
Macrophage depletion with LC was commenced prior to lymphoma 
transplantation, and repeated throughout the experiment, in an attempt to 
maximise its impact. 
Experimental protocol: 
Mice received either iv LC or a vehicle control of liposomal PBS on days -1, 3, 6 
and 10, in addition to injection of Eµ-myc/bcl-2 lymphoma cells at day 0. Age-
matched mice with transplanted lymphoma acted as an untreated control group. 
!
Figure 40 - Protocol investigating liposomal clodronate in mice with lymphoma. 
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Data: 
By day 12, a reduced total body weight relative to normal healthy mice was 
seen in all groups that had been injected with lymphoma. Similarly, all mice 
injected with lymphoma displayed early signs of ill health by Day 12, with 
slightly reduced spontaneous activity levels, a hunched posture and shallower, 
more rapid breathing than the normal controls.  
 
Figure 41 - Body weight of mice, untreated (n=4) or transplanted with 2x105 Eµ-
myc/bcl-2 lymphoma cells, then given iv LC (Lymphoma + LC, n=5) or liposomal 
PBS (Lymphoma + LP, n=5) or no further injections (Lymphoma only, n=5). 
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At necropsy it was clear that gross differences were present, and consistent, 
between the groups. Those injected with lymphoma and no further treatment, or 
treatment with liposomal PBS, had massive splenomegaly extending to the 
pelvis, massive hepatomegaly, and widespread lymph node enlargement in all 
areas. Inguinal, brachial and cervical nodes were highly conspicuous, with intra-
abdominal and intra-thoracic node enlargement evident on further dissection. 
Those mice injected with lymphoma who received LC had spleens and livers of 
approximately normal size. This group did display widespread lymph node 
enlargement, but clearly to a lesser degree than those with lymphoma not 
treated with LC.  
  Lymphoma                   Lymphoma + LC 
 
 
Figure 42 – Macroscopic appearance of partially dissected mice on day 12 
following iv injection with Eµ-myc/bcl-2 lymphoma cells demonstrating smaller 
spleen and lymph nodes in the mice treated with LC.  
! (''!
 
Figure 43 - Spleen volumes. 
 
Figure 44 - Lymph node volumes. 
 
Figure 45 - Liver weights. 
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In the liver, lymphoma infiltration, as shown in the figure below when stained 
with H&E, consisted of conspicuous confluent areas of small to medium sized 
dark-blue staining cells with a high nuclear to cytoplasmic ratio, congregating 
around hepatic sinusoids and veins. 
 
Figure 46 - FFPE section of liver 10 days after iv lymphoma, stained with H&E 
(OM x 20). 
F4/80 staining revealed macrophages within areas of lymphoma infiltration. 
 
Figure 47 - FFPE section of liver, 10 days after iv lymphoma stained with F4/80 
(OM x 40). 
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Livers of mice treated with LC clearly showed a reduced cross sectional area of 
lymphoma, suggesting that reduced organ size was contributed to by reduced 
lymphoma volume, and could not simply be attributed to a loss of macrophages. 
The reduction in cross-sectional area of lymphoma was quantified using a 
graticule overlying low magnification images of FFPE sections, as detailed in 
my methods, and represented in the bar chart below. 
 
Figure 48 - Area of liver infiltrated by lymphoma in FFPE sections stained with 
H&E. Number of infiltrated squares was counted for 5 randomly selected LPF per 
section, one section per mouse and 5 mice per group. Units = cm2 per 
unmanipulated LPF image using Adobe+  Photoshop+  software.  
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     Low magnification (OM x2.5) High magnification (OM x 40) 
!
Figure 49 - Normal mouse liver stained with H&E, FFPE section.  !       Low magnification   High magnification 
!
Figure 50 - Liver 10 days following  iv lymphoma, FFPE section. !       Low magnification   High magnification 
 
Figure 51 - Liver 10 days following iv lymphoma and intensive iv LC, FFPE 
section. 
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Lymphoma transplantation produced complete effacement of normal splenic 
architecture by malignant lymphocytes. Macrophage depletion with LC 
produced dramatic reductions in spleen size. Normal splenic architecture was 
not restored, with high magnification images demonstrating widespread areas 
of necrosis and small islands of remaining lymphocytes. Splenic necrosis with 
LC was supported by data from flow cytometry, depicted below. 
!
Figure 52 - Percentage of live cells in the spleen, measured by flow cytometry 
(n=5 per group). “Untreated” refers to unmanipulated normal healthy mice.  
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Low magnification (OM x 2.5)     High magnification (OM x 40) 
Figure 53 - Normal spleen stained with H&E. 
Low magnification    High magnification 
Figure 54 – Spleen stained with H&E  day 12 after iv injection of lymphoma. !
Low magnification    High magnification !
Figure 55 - Spleen stained with H&E day 12 after iv injection of lymphoma and 
intensive regime of iv LC. 
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Bone marrow sections from mice with transplanted lymphoma demonstrated 
increased overall cellularity. F4/80 staining highlighted plentiful macrophages. 
     H&E (OM x 2.5)    F4/80 & haematoxylin (OM x 40)!
!
Figure 56 - Normal bone marrow. 
 
!
Figure 57 - Bone marrow day 12 following iv lymphoma. 
 
 
Figure 58 - Bone marrow day 12 following iv lymphoma and intensive iv LC. 
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An intensive regime of LC induced almost total macrophage depletion, 
associated with obviously decreased overall bone marrow cellularity.  
!
Figure 59 - Bone marrow macrophage frequency, measured by counting of FFPE 
sections. 5 HPF per mouse, 4 mice per group. 
! (C%!
Flow cytometry of blood demonstrated monocyte depletion in mice with 
lymphoma given LC, compared to vehicle and lymphoma only controls. The 
figures below show that this was associated with an increase in circulating 
granulocytes. 
!
Figure 60 - Measurement by flow cytometry of blood monocytes (n=6 per group). 
!
Figure 61 - Blood granulocytes (n=6 per group). 
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LC did not reduce the macrophage frequency in lymph node samples to a 
statistically significant degree.  
!
Figure 62 – Nodal macrophage frequency by flow cytometry (n=5 per group). 
However, an overall reduced number of macrophages in lymph nodes of mice 
with lymphoma given LC is revealed when the macrophage frequency is 
factored by lymph node volume.  
!
Figure 63 - Nodal macrophage population (n=5 per group).
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Splenic macrophage frequency was reduced by LC.  
 
Figure 64 - Splenic macrophage frequency by flow cytometry (n=5 per group). 
In summary, LC depletes circulating monocytes and bone marrow and tissue 
macrophages in all organs studied. In mice injected with Eµ-myc/bcl-2 
lymphoma, this correlates with significant, consistent and reproducible 
reductions in overall lymphoma mass.  
To further test whether LC-mediated macrophage depletion might be 
responsible for attenuated lymphoma growth in this model, we investigated in 
the following protocol whether this phenomenon operated with a dose effect.  !
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11.4.2.2 The effects of liposomal clodronate on lymph node volume 
operates with a dose-response relationship. 
Experimental protocol: 
Healthy female C57BL/6 mice were transplanted with lymphoma on day 0. One 
group received only a single injection of LC, on Day 6. The extent of 
macrophage depletion, and lymphoma progression, was compared, in the same 
experiment, with mice receiving the previous intensive schedule, including LC 
prior to lymphoma transplantation, and also with those receiving no LC.  
!
Figure 65 - Protocol investigating dose effects of liposomal clodronate in mice 
with lymphoma. 
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Data:  
Lymph node volumes of mice receiving a single dose of LC occupied an 
intermediate position between untreated mice, and those receiving an intensive 
schedule of LC. 
!
Figure 66 - Lymph node volumes. 
This intermediate effect on organ size was clearer for spleens. 
 
Figure 67 - Spleen volumes. 
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Liver weights were significantly reduced following a single injection of LC, 
apparently to the same degree as following an intensive regime of LC. 
!
Figure 68 - Liver weights. 
Liver macrophage numbers were reduced by a single dose of iv LC. 
!
Figure 69 - Liver macrophage frequency, measured by counting of FFPE 
sections. 5 HPF per mouse, 5 mice per group. 
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Consistent with reductions in liver weight, there was a reduction in cross-
sectional lymphoma area to the same degree as in mice receiving the intensive 
regime of iv LC. 
!
Figure 70 - Liver area infiltrated by lymphoma, measured in FFPE tissue 
sections. 5 LPF per mouse, 5 mice per group. Units = cm2 per unmanipulated 
LPF image using Adobe+  Photoshop+  software.  
A single injection of LC, delivered 5 days after transplantation of lymphoma, 
was effective in depleting tissue macrophages and retarding lymphoma 
progression. Both effects were, overall, less than observed with intensive LC, 
strongly indicating a dose response between LC and extent of macrophage 
depletion and lymphoma retardation. These data also add to this body of work 
by indicating that LC-mediated macrophage depletion impacts on Eµ-myc/bcl-2 
lymphoma that has become established in vivo. In the following protocol we 
investigated whether the apparent attenuation of lymphoma growth with this 
strategy translated in to a survival benefit.  
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11.4.2.3 Liposomal clodronate treatment does not measurably 
prolong “survival” in this model. 
Experimental protocol: 
!
Figure 71 - Protocol investigating the survival impact of liposomal clodronate in 
mice with lymphoma. 
Mice injected with lymphoma with or without an intensive LC injection schedule 
were assessed, at twelve hourly intervals, for signs of illness. Individual mice 
were sacrificed as soon as they experienced 20% weight loss from the start of 
the experiment, or decreased spontaneous activity, or any other signs of 
distress. UK Home Office guidelines were strictly adhered to regarding humane 
end points in animal experiments, and were enforced by an independent 
observer, blinded to the experimental design and treatment groups.  
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Data: 
No difference in time to end point was observed between those mice that 
received intensive LC and those that received no LC.  
 
Figure 72 – Time to reach UK Home Office limits of survival (n=12 per group). 
We will assess the implications of these data in the discussion. We proceeded 
to use an alternative, well-validated model to further investigate the impact on 
macrophage depletion on the progression of Eµ-myc/bcl-2 lymphoma. By using 
a different approach to achieve macrophage depletion we determined to test 
whether the effects we have reported with LC-mediated macrophage depletion 
might be widely applicable rather than idiosyncratic.  
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11.5 Investigating macrophage depletion and lymphoma 
progression in the MaFIA mouse model. 
We conducted in vitro experiments that would reveal whether or not AP20187, 
the dimerizer agent triggering macrophage depletion in MaFIA mice, was 
directly toxic to Eµ-myc/bcl-2 lymphoma cells.!
11.5.1 Investigating the effects of the MaFIA dimerizer AP20187 on Eµ-
myc/bcl-2 lymphoma cells in vitro. 
Experimental protocol: 
Eµ-myc/bcl-2 lymphoma cells were exposed to AP20187 at varying 
concentrations in a 96 well plate, and cytotoxicity measured as previously 
described. Controls were media alone, lymphoma cells with no AP20187, and a 
positive control of fully lysed lymphoma cells.  
Data: 
Eµ-myc/bcl-2 lymphoma cells cultured in vitro did not appear to be killed by 
prolonged direct exposure to AP20187 until concentrations of over 1 mM were 
reached.  
!
Figure 73 - Eµ-myc/bcl2 cells in vitro exposed to MaFIA dimerizer AP20187. 
These data indicate that AP20187 is not directly toxic to Eµ-myc/bcl-2 cells at 
the concentrations that would be achieved in vivo. Product literature states that 
a complete dose response profile can be obtained with a concentration range of 
0.01-100 nM in vitro, corresponding to in vivo doses in mice of 0.005-10 mg/kg 
(Clontech, 2012).!
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11.5.2 Investigating the effects of macrophage depletion on Eµ-myc/bcl-2 
lymphoma progression in the MaFIA mouse.  
In the light of the in vitro data, we investigated the impact of macrophage 
depletion in MaFIA mice on the progression of transplanted Eµ-myc/bcl-2 
lymphoma. 
Experimental protocol: 
10-week-old MaFIA mice were injected with lymphoma, and then received 5 
consecutive once-daily ip injections of either AP20187 dimerizer or its vehicle 
control, as outlined below.  
!
Figure 74 - Protocol investigating lymphoma progression in MaFIA mice. 
Data: 
MaFIA mice with lymphoma treated with ip injections of dimerizer had lymph 
nodes of less weight at sacrifice on day 9 than did sex matched control MaFIA 
mice with lymphoma given vehicle injections ip for the same schedule. Data 
were collected from 2 separate experiments with identical protocols.  !
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Macrophage ablation resulted in lower lymph node weights at sacrifice. 
!
Figure 75 - Lymph node weights. 
Lymph node CD19+ percentage was unchanged by macrophage ablation. 
!
Figure 76 - Lymph node CD19+ frequency by flow cytometry (vehicle n=10, 
dimerizer n=8). 
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The CD19- population was selected and the frequency of CD11b+Ly6G- cells 
measured, as a reliable indicator of tissue macrophage numbers. There was a 
substantial and significant reduction in lymph node macrophages.  
!
Figure 77 - Whole fresh lymph node single cell suspensions assessed for 
macrophages by selecting the CD19- population, then the CD11b+ Ly6G- 
population. 
!
Figure 78 – Lymph node macrophage ablation in MaFIA mice with lymphoma 
(vehicle n=10, dimerizer n=8). 
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Blood was stained and analysed by flow cytometry to assess the expression of 
Ly6G and Ly6C among the CD19- CD11b+ population, using the following 
gating schedule)!!
!
Figure 79 - CD19+ CD11b+ cells were selected as shown. 
!
Figure 80 - Monocyte subsets were assessed by Ly6G and Ly6C expression. !!!!
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There was a reduction in the overall number of circulating monocytes and of 
Ly6C- “patrolling” monocytes, and a rise in Ly6C+ “inflammatory” monocytes.  
!
 
Figure 81 - Overall blood monocytes (top chart) expressed as a percentage of all 
CD19-CD11b+ cells. Monocyte subsets (middle and lower chart) expressed also 
as a percentage of all CD19-CD11b+ cells (vehicle n=10, dimerizer n=8). 
These data from the MaFIA model are in agreement with those from using LC; 
namely that macrophage depletion results in reduced lymphoma growth. To 
further investigate whether this phenomenon represented a causal relationship, 
and one that might crucially depend on macrophage phenotype, we performed 
experiments assessing the impact of supplementing macrophages in the 
transplantable Eµ-myc/bcl-2 lymphoma.  
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11.6 Adoptive transfer of bone marrow derived macrophages. 
11.6.1 Assessment of purity of bone marrow derived macrophages and in 
vitro phenotype manipulation. 
BMDM were prepared from the hind legs of 5 healthy female C57BL/6 mice. 
3.58 x 108 bone marrow cells generated a total of 1.71 x 108 viable 
macrophages by day 7. BMDM viability was 91%. BMDM purity and the impact 
of in vitro phenotype modulation were assessed by flow cytometry.  
BMDM were of high purity, with almost all cells being CD11b+ and Ly6G-. The 
only exception to this was a conspicuous small minority population of M1 
polarised BMDM that expressed Ly6G. 
!
Figure 82 - Percentage of all cultured bone marrow cells that were CD11b+Ly6G- 
BMDM on Day7: M0 = 98.1%, M1 = 96.4%, TAM = 98.8%. 
 
! "N(!
BMDM universally expressed CSF-1R and F4/80. There was a slightly higher 
level of F4/80 expression in M1 polarised BMDM than other phenotypes.  
 
!
Figure 83 - Histograms of CSF-1R and F4/80 expression. X-axis depicts the 
percentage of maximum cells expressing marker. Unstained BMDM are in red. 
There was slightly increased expression of MR in TAM than in M1 BMDM. 
 
Figure 84 - Mannose receptor staining of BMDM. 
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TAM had decreased intracellular staining of IFN-#. M1 BMDM demonstrated 
increased surface expression of MHCII. 
 
Figure 85 - Histograms of BMDM staining by flow cytometry. X-axis depicts 
percentage of maximum cell staining. 
In M0 BMDM and TAM, an LPS boost 6 hours before harvest increased the 
expression of MHCII, an M1 phenotype marker. Absence of such an increase in 
M1 BMDM suggested they were already maximally polarised to this phenotype.  
 
Figure 86 - Flow cytometry histograms illustrating the impact on MHCII 
expression of an LPS boost 6 hr prior to BMDM harvest. 
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These data show that our protocol generated BMDM of very high purity and that 
in vitro polarised BMDM displayed features typical of their intended phenotypes. 
The following in vivo protocols investigated the impact on lymphoma growth of 
adoptive transfer of different phenotypes and doses of BMDM. If macrophages 
do support the growth of lymphoma, then AT of TAM or M2 BMDM might 
promote lymphoma growth, and AT of M1 polarised BMDM might attenuate it. 
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11.6.2 Adoptive transfer of bone marrow derived macrophages. 
Adoptive transfer experimental protocol 1: 
This protocol aimed to establish the tolerability of AT, whether BMDM reached 
target tissues, and whether there was a gross effect on lymphoma progression 
of M1 or M2 BMDM. 
!
Figure 87 - Protocol investigating adoptive transfer of macrophages in mice with 
lymphoma. 
As described in our methods, samples of BMDM were stained in vitro with a red 
fluorescent dye prior to AT, to enable visual confirmation of their infiltration of 
target tissues. 
Data: 
Iv adoptive transfer of syngeneic BMDM was well tolerated, with no immediate 
adverse reactions observed. Red fluorescent cells were seen in frozen tissue 
sections of lymph node and spleen, as shown overleaf. 
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  Lymph node (OM x60) 
  Lymph node (OM x60)!
  Spleen (OM x20)!
Figure 88 - Immunofluorescent images of 4 µm tissue sections from mice 
transplanted with Eµ-myc/bcl-2 lymphoma and adoptively transferred red 
fluorescent bone marrow-derived macrophages, counterstained with DAPI. 
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AT of M1 polarised BMDM was associated with reduced lymph node volume 
compared to untreated controls. AT of M2 polarised BMDM was not associated 
with any statistically significant change in lymph node volume. 
!
Figure 89 - Lymph node volumes. 
There was no significant difference in liver cross-sectional area of lymphoma. 
!
Figure 90 - Liver area infiltrated by lymphoma, measured in FFPE tissue 
sections. 5 LPF per mouse, 5 mice per group (lymphoma n=6, M1 n=5, M2 n=5). 
Units = cm2 per unmanipulated LPF image using Adobe+  Photoshop+  software.  
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Adoptive transfer experimental protocol 2: 
Having seen no effect of M2 BMDM we subsequently explored whether 
macrophage depletion prior to AT might increase their impact, as they might 
then constitute a higher proportion of the lymphoma-populating macrophages. 
Partial macrophage depletion with 100 µl of LC 48 hours before AT of 1 x 106 
M2 BMDM was conducted as outlined in the figure below.  
!
Figure 91 - Protocol investigating adoptive transfer of M2 macrophages following 
liposomal clodronate. 
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Data: 
LC macrophage depletion prior to AT of M2 BMDM did not produce a 
statistically significant difference in lymphoma progression, in terms of lymph 
node volume or cross-sectional area of lymphoma in liver sections. 
!
Figure 92 - Lymph node volume. 
!
Figure 93 - Liver area infiltrated by lymphoma, measured in FFPE tissue sections 
(lymphoma n=6, M2 n=5, LC + M2 n=5). Units = cm2 per unmanipulated LPF 
image using Adobe+  Photoshop+  software.  
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Adoptive transfer experimental protocol 3: 
The dose of M2 polarised BMDM was increased 10-fold to 1 x 107 cells, 
delivered over 2 consequetive days. 
!
Figure 94 - Protocol investigating adoptive transfer of an increased dose of M2 
macrophages following liposomal clodronate. 
Data: 
 An increased dose of M2 polarised BMDM did not result in any difference in 
lymph node weights compared to controls.  
!
Figure 95 - Lymph node weights. 
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Adoptive transfer experimental protocol 4: 
On the basis that potentially pro-tumoural TAM in this model might not strictly 
conform to an IL-4 stimulated M2 phenotype, we assessed the impact of AT of 
Eµ-myc/bcl-2 specific TAM. BMDM were polarised with TCM from Eµ-myc/bcl-2 
lymphoma cells to generate a TAM BMDM as previously described. AT of 1 x 
107 TAM BMDM was compared to M1 BMDM and lymphoma-only control mice.  
!
Figure 96 - Protocol investigating adoptive transfer of M1 macrophages and TAM 
in mice with lymphoma. 
Data: 
AT of 1 x 107 TAM BMDM resulted in significantly greater lymph node weights 
than those receiving 1 x 107 M1 polarised BMDM. This was a consistent and 
statistically significant phenomenon. These differences remained when lymph 
node weight was corrected for total body weight, and when it was multiplied by 
the percentage of lymph node CD19 positive cells as determined by flow 
cytometry, to give an alternative and perhaps even more accurate reflection of 
lymphoma burden.  
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!
Figure 97 - Lymph node weights. 
!
Figure 98 - Lymph node CD19+ cell frequency, measured by flow cytometry 
(lymphoma n=8, M1 n=8, TAM n=7). 
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!
Figure 99 - Lymphoma burden displayed as a function of lymph node weight and 
CD19+ percentage (lymphoma n=8, M1 n=8, TAM n=7). 
!
Figure 100 - Lymphoma burden as a function of lymph node weight and 
percentage of CD19+ cells, normalised to untreated lymphoma at 100%. 
Horizontal dashed line represents mean value of untreated mice with lymphoma. 
These data suggest an impact of AT on the progression of lymphoma, and that 
phenotype can influence the direction of this effect. The magnitudes of impact 
are small but consistent and statistically significant. Following this we were keen 
to use transplanted Eµ-myc/bcl-2 lymphoma as a pre-clinical model to 
investigate the feasibility and efficacy of a novel therapeutic agent that might 
reduce TAM populations.  
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11.7 Investigating CSF-1R inhibition in lymphoma. 
11.7.1 Investigating the in vitro effects of AZ268 CSF-1R inhibitor on Eµ-
myc/bcl-2 cells. 
Unpublished data provided by AstraZeneca show that AZ268, a small molecule 
CSF-1R tyrosine kinase inhibitor, reduces circulating monocyte numbers in 
healthy mice with a dose response such that 100 mg/kg gives approximately a 
50% reduction. In an orthotopic xenograft of a breast cancer cell line (MDA-MB-
231), the CSF-1R inhibitor (CSF-1Ri) given twice daily at 75 mg/kg for 18-20 
days reduced tissue macrophages by 94%. This was associated with tumour 
growth inhibition, and 100 mg/kg produced 32% tumour retardation. Other 
tumour xenograft models were less responsive, even though TAM reduction 
was seen. There is no published data concerning CSF-1R inhibition in 
lymphoma models. We explored whether the CSF-1Ri might reduce TAM 
populations and attenuate lymphoma growth in the transplantable Eµ-myc/bcl-2 
lymphoma. 
Experimental protocol: 
Eµ-myc/bcl-2 lymphoma cells were exposed to CSF-1R inhibitor (referred to in 
figures as CSF-1Ri) at varying concentrations in a 96 well plate, and cytotoxicity 
measured as previously described. Controls were media alone, lymphoma cells 
with no CSF-1R inhibitor, and a positive control of fully lysed lymphoma cells.  
Data: 
Eµ-myc/bcl-2 lymphoma cells cultured in vitro were not killed by direct 
prolonged exposure to a wide range of concentrations of CSF-1Ri.  
!
Figure 101 - Eµ-myc/bcl2 cells in vitro exposed to CSF-1R inhibitor. 
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11.7.2 Investigating the in vivo effects of CSF-1R inhibitor at 50 mg/kg for 
5 days in mice with lymphoma. 
As the CSF-1Ri had no direct effect on the survival of Eµ-myc/bcl-2 lymphoma 
cells in vitro, we proceeded to administer it to mice with lymphoma, with the 
reasonable expectation that any subsequent impact on lymphoma growth might 
be indirectly mediated, possibly by macrophage depletion, should this occur.  
Experimental protocol: 
Initial experiments used a 50 mg/kg dose of CSF-1Ri, given twice daily by oral 
gavage for 5 consecutive days following the establishment of transplanted Eµ-
myc/bcl-2 lymphoma. 
!
Figure 102 - Protocol investigating low dose CSF-1R inhibition in mice with 
lymphoma. 
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Treatment was well tolerated. There was a statistically significant reduction in 
lymph node and liver weights in mice with lymphoma treated with CSF-1Ri, 
compared to vehicle and untreated control mice with lymphoma. Administration 
of vehicle by twice daily oral gavage resulted in a reduced lymph node weight 
compared to untreated controls. 
!
Figure 103 - Lymph node weights. 
!
Figure 104 - Liver weights. 
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FFPE sections of lymph node were stained with the macrophage marker F4/80 
and haematoxylin.!
!
Figure 105 - Lymph node stained with F4/80 and haematoxylin on day 10 
following iv lymphoma and 2x daily oral gavage of control vehicle (OM x 40). 
!
Figure 106 - Lymph node stained with F4/80 and haematoxylin on day 10 
following iv lymphoma and 2x daily oral gavage of CSF-1R inhibitor (OM x 40). 
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There was a quantifiable reduction in the number of macrophages in tissue 
sections of lymph nodes of CSF-1R inhibited mice with lymphoma. 
!
Figure 107 – Lymph node macrophage frequency measured in FFPE sections 
stained with F4/80. Data represents 5x HPF per mouse and 4 mice per group. 
There was a reduced cross-sectional area of lymphoma infiltrating the liver. 
!
Figure 108 – Liver area infiltrated with lymphoma in FFPE tissue sections. Data 
represents 5x HPF per mouse and 4 mice per group. Units = cm2 per 
unmanipulated LPF image using Adobe+  Photoshop+  software.  
In summary, we observed a reduction in macrophage numbers and the mass of 
lymphoma bearing organs with CSF-1Ri compared to untreated or vehicle 
treated mice. The vehicle alone produced a reduction in lymph node weight, 
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with no significant effect on macrophage numbers, liver weight, or cross-
sectional lymphoma area. 
Expression of inflammatory genes in whole lymph nodes.  
RNA was extracted from whole, unsorted lymph nodes of mice treated with 
CSF-1Ri and vehicle treated controls. qRT-PCR was performed for a panel of 
genes chosen to reflect different infiltrating immune cell populations and the 
cytokines typically associated with inflammatory responses. 
Gene group by cell/function Specific genes assessed 
Monocyte/macrophage F4/80, CSF-1R, CD14 
DC CD208 
T-cell CD2, CD8a 
Treg FOXP3 
NK cell NK1.1 
Th1 cytokines IL-12b 
Th2 cytokines IL-10, IL-6 
Chemokine receptors CXCR1, CCR3, CCR1 
 
Table 9 - Genes selected for measurement by qRT-PCR. 
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Data: 
There was reduced gene expression, of CSF-1R and F4/80, and increased 
expression of CD14 and FOXP3 within the lymph nodes, with CSF-1R inhibition 
compared to vehicle. All other alterations in gene expression were less than 2-
fold changes. 
!
Figure 109 - Fold changes in gene expression at day 10 in lymph nodes of mice 
with lymphoma given 50 mg/kg twice daily CSF-1Ri for 5 days (n=5), compared to 
vehicle controls (n=5). 
These data suggest that AZ268 CSF-1Ri is well tolerated and produces a 
degree of macrophage depletion in lymph nodes. Gene expression data are 
consistent with these findings, with a reduction in the macrophage specific 
genes F4/80 and CSF-1R. Subsequently we investigated the impact of 
delivering a higher dose of AZ268 CSF-1Ri for a prolonged period of time. The 
unexpected, small, but statistically significant reduction in lymph node weight 
with gavage of the vehicle will be considered further in the discussion. 
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11.7.3 Investigating the in vivo effects of AZ268 CSF-1R inhibitor at 100 
mg/kg for 10 days in mice with lymphoma. 
Experimental protocol: 
In subsequent experiments, the dose of CSF-1R inhibitor was doubled to 100 
mg/kg, and the duration of therapy increased, starting with the transplantation of 
Eµ-myc/bcl-2 lymphoma cells, and with a final dose 1 hour before sacrifice. 
!
Figure 110 - Protocol investigating prolonged higher dose CSF-1R inhibition in 
mice with lymphoma. 
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Data: 
The lymph node weight was recorded for each mouse, combining bilateral 
inguinal and brachial nodes. 
CSF-1Ri treated  Vehicle control 
Body weight 
(g) 
Lymph node 
weight (g) 
 Body weight 
(g) 
Lymph node 
weight (g) 
19.99 0.0439  19.73 0.0761 
20.76 0.0578  18.42 0.0722 
14.38 0.0374  19.90 0.0622 
18.03 0.0538  19.67 0.0723 
18.73 0.0572  18.93 0.0596 
18.03 0.0547  20.31 0.0778 
19.25 0.0583  20.30 0.0704 
   20.96 0.0823 
 
Table 10 - Data from a representative experiment of prolonged CSF-1R inhibition 
in lymphoma. 
There was a substantial reduction in lymph node weight in mice treated with this 
prolonged higher dose schedule of CSF-1R inhibitor. This was a consistent 
finding in 4 separate protocols. Data, represented graphically overleaf, is from a 
representative experiment. 
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!
Figure 111 - Lymph node weights. 
There was no significant difference in total body weight. 
!
Figure 112 - Total body weight at sacrifice. 
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A substantial difference was maintained when lymph node weight was 
corrected for body weight. 
!
Figure 113 - Lymph node weight corrected for total body weight. 
The frequency of lymph node CD19 positive B-lymphocytes was identical. 
!
Figure 114 - Lymph node frequency of CD19 positive cells. 
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Lymphoma burden, expressed in different ways, remained statistically 
significantly different. 
!
Figure 115 - Lymphoma burden expressed as a function of lymph node weight 
and frequency of CD19 positive cells. 
!
Figure 116 - Lymphoma burden expressed as function of lymph node weight 
corrected for total body weight, and frequency of CD19 positive cells. 
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Lymph node macrophage frequency was reduced in mice with lymphoma 
receiving CSF-1R inhibition, on the basis of CD11b+Ly6G- cells, and also F4/80 
positive cells. 
!
Figure 117 - Lymph node CD11b+Ly6G- macrophages frequency of all lymph 
node cells, measured by flow cytometry (vehicle n=8, CSF-1Ri n = 7). 
!
Figure 118 - Frequency of F4/80 positive macrophages in lymph nodes, by flow 
cytometry, percentage of CD19- cells (vehicle n=8, CSF-1Ri n = 7). !
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The overall lymph node macrophage population was markedly reduced, as 
estimated by multiplying macrophage frequency by measures of lymph node 
weight.  
!
Figure 119 - Macrophage burden expressed as a function of lymph node weight 
and frequency of F4/80 positive cells (vehicle n=8, CSF-1Ri n = 7). 
 
!
Figure 120 - Macrophage burden, expressed as a function of lymph node weight 
and frequency of CD11b+Ly6G- macrophages by flow cytometry. 
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!
Figure 121 - Macrophage burden expressed as a function of node weight 
corrected for body weight, and frequency of CD11b+Ly6G- macrophages by flow 
cytometry. 
There was clearly a statistically significant reduction in TAM and lymphoma 
burden in mice with lymphoma treated with 10 days of CSF-1R inhibition with 
AZ268 at 100 mg/kg, compared to vehicle controls. This was a consistent 
finding in repeated experiments, and appeared to be of greater magnitude than 
with the previous lower dose and duration schedule.  
Blood cells, plasma and lymph nodes were analysed in a series of protocols to 
elucidate some of the cellular and biochemical consequences of 10 days of 
CSF-1R inhibition at 100 mg/kg in this model. !
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11.7.4 Investigating the consequences of CSF-1R inhibition in 
transplantable Eµ-myc/bl2 lymphoma. 
In an attempt to elucidate the consequences of CSF-1R inhibition, and the 
mechanisms that might be responsible for such consequences, the following 
investigations were undertaken: 
1) Further flow cytometry of blood cells and lymph nodes. 
2) Assessment of lymphoma cell proliferation. 
3) Measurement of circulating inflammatory cytokines. !
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11.7.4.1 Flow cytometry of blood cells and lymph nodes. 
Multiple protocols were repeated, administering CSF-1R inhibition at 100 mg/kg 
or vehicle twice daily for 10 days to normal healthy mice, and mice with 
lymphoma. A variety of multi-colour fluorescent antibody panels were optimised 
and used to determine changes in the cellular composition of blood and lymph 
nodes, allowing estimation of malignant B-cell and immune-infiltrating cell 
populations. I investigated markers in addition to F4/80, whose expression is 
CSF-1 dependent (Hume et al., 1988) and so may not a reliable indicator of 
total macrophage numbers following administration of a CSF-1R inhibitor.   
Mice without lymphoma. 
In the blood of normal healthy mice, prolonged CSF-1R inhibition had no 
substantial effect on the frequency of B220+ cells.  
!
Figure 122 - Flow cytometry plot of live-gated blood cells stained for B220 and 
CSF-1R. Data represents pooled samples from 4 mice per group. 
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In the lymph nodes of normal healthy mice, prolonged CSF-1R inhibition 
resulted in a reduced CSF-1R+ population, but no substantial change in the 
B220+ population. 
 
Reduced  
 
 
 
Figure 122 - Flow cytometry plot of live-gated lymph node cells stained for 
B220 and CSF-1R. Data represents pooled samples from 4 mice per group. 
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Mice with lymphoma. 
The blood of mice with lymphoma contained a greatly increased frequency of 
B220+ cells. This fell slightly with CSF-1R inhibition. The frequency of CSF-1R+ 
cells also rose substantially with advanced lymphoma, but did not appear to fall 
significantly with CSF-1R inhibition in this pooled data.  
!
Figure 123 - Flow cytometry plot of live-gated blood cells stained for B220 and 
CSF-1R. Data represents pooled samples from 5 mice per group. 
This is likely to reflect a large increase in the proportion of both malignant B-
cells and monocyte/macrophages with the transplantation and progression of 
lymphoma. We investigated the increase in circulating lymphocytes in later 
experiments by inspecting the morphology of serial blood films during 
lymphoma progression. The more subtle possible decrease in circulating 
malignant B-cells and lack of change in monocyte/macrophages shown by this 
data from pooled samples warranted further examination with repeated 
measurement in a larger sample size. The data that follows derives from such 
experiments.!
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In mice with lymphoma treated with CSF-1Ri, compared to vehicle control, there 
was no change in the frequency of CD3+ T-lymphocytes in the blood. 
 
Figure 124 - Frequency of blood CD3+ cells by flow cytometry (n=8 per group). 
There was a reduced CD19 positive B-lymphocyte frequency in the blood. 
!
Figure 125 - Frequency of blood CD19+ cells by flow cytometry (n=8 per group). 
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There was a clear shift in the relative balance of CD11b+ myelo-monocytic 
cells. CSF-1R inhibition resulted in an increased population of granulocytes 
(CD11b+Ly6G+) and a reduced population of monocytes (CD11b+Ly6G-). 
!
Figure 126 - Frequency of granulocytes and monocytes in the blood by flow 
cytometry, expressed as a percentage of CD19- live cells (n=8 per group). 
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F4/80 staining confirmed that CD11b+Ly6G- monocytes expressed this 
monocyte-macrophage surface marker, and CD11b+Ly6G+ cells did not. This 
finding supported the statement that CSF-1Ri resulted in a true reduction in 
monocytes in the blood, and is displayed in the figure below. 
!
Figure 127 - Histogram displaying relative expression of F4/80 by blood 
monocytes and granulocytes, representative data. 
The impact of prolonged CSF-1R inhibition on monocyte subsets in the blood 
was studied using the following flow cytometry gating procedure. 
!
Figure 128 - Selection of blood CD19-CD11b+Ly6G- monocytes (black box) for 
expression of Ly6C (red box) or not (orange box), representative data. 
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No significant difference was seen in monocyte subsets in the blood. 
!
Figure 129 – “Patrolling” monocyte frequency as a percentage of CD19-
CD11b+Ly6G- cells in the blood (n=8 per group). 
 
!
Figure 130 – “Inflammatory” monocyte frequency as a percentage of CD19-
CD11b+Ly6G- cells in the blood (n=8 per group). 
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11.7.4.2 Assessment of lymphoma cell proliferation in vivo. 
Experimental protocol: 
The proliferation of lymphoma cells was assessed in mice at the end of the 
protocol for prolonged CSF-1R inhibition. As described in the methods section, 
ip injections of BrdU were given to all mice 2 hours before sacrifice. The 
proportion of cells incorporating BrdU was measured by flow cytometry. 
Data: 
A significantly smaller percentage of CD19+ B-cells incorporated BrdU in the 
lymph nodes of CSF-1R inhibited mice with lymphoma than in the lymph nodes 
of vehicle controls with lymphoma.     
!
Figure 131 – Lymph node frequency of proliferating lymphoma cells expressed 
as percentage of CD19+ cells incorporating BrdU (n=7 per group). 
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There was no such difference detected in the blood.!
!
Figure 132 - Blood frequency of proliferating lymphoma cells expressed as 
percentage of CD19+ cells incorporating BrdU (n=7 per group). 
These data show that within the lymph nodes, but not in the blood, CSF-1Ri is 
associated with decreased B-cell proliferation.  
We proceeded to measure changes in the levels of circulating inflammatory 
cytokines, comparing normal healthy mice to mice with advanced lymphoma, to 
mice with lymphoma treated with CSF-1Ri. The intention was to reveal aspects 
of mechanisms that might link CSF-1Ri, reductions in monocyte and 
macrophage numbers, and reductions in lymphoma burden and B-cell 
proliferation. 
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11.7.4.3 Measurement of circulating inflammatory cytokines. 
Experimental protocol: 
Plasma cytokines were measured in the blood of healthy mice, and mice in both 
the treatment and control groups at the end of the protocol for prolonged CSF-
1R inhibition. The following cytokines were measured, as detailed in the 
methods section: 
Cytokine Lower limit of detection (pg/ml) 
IFN-# 0.38 
IL-1" 0.75 
IL-6 4.5 
IL-10 11 
IL-12p70 35 
CXCL1 3.3 
TNF-! 0.85 
Table 11 - Measured cytokines and their lower limits of detection (LLD). 
In addition, plasma levels of CSF-1 were measured in healthy MaFIA mice, 
those with advanced lymphoma, and MaFIA mice with advanced lymphoma 
treated with macrophage depleting dimerizer injections. 
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Data: 
Plasma CSF-1 levels were higher in mice transplanted with lymphoma 10 days 
previously, than in healthy mice. Macrophage depletion with dimerizer in MaFIA 
mice did not have any significant effect on these raised levels.  
!
Figure 133 - Plasma CSF-1 levels in normal healthy MaFIA mice (n=6), MaFIA with 
advanced lymphoma (n=4) and MaFIA with lymphoma and macrophage depleting 
dimerizer injections (n=3). 
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IL-6 levels were undetectable in healthy mice, and rose substantially with 
lymphoma progression, and fell with CSF-1R inhibition. 
!
Figure 134 - Plasma IL-6 concentrations in C57BL/6 mice with no manipulation 
(n=5), with lymphoma (n=5) and with lymphoma and CSF-1R inhibition (n=6). 
IL-10 levels rose substantially with lymphoma and were unaffected by CSF-1R 
inhibition. 
!
Figure 135 - Plasma IL-10 concentrations in C57BL/6 mice with no manipulation 
(n=5), with lymphoma (n=5) and with lymphoma and CSF-1R inhibition (n=6). 
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CXCL1, which is expressed by macrophages, neutrophils and epithelial cells 
and has neutrophil chemoattractant properties, rose substantially with CSF-1R 
inhibition in mice with lymphoma. 
!
Figure 136 - Plasma CXCL1 concentrations in mice with no manipulation (n=5), 
with lymphoma (n=5) and with lymphoma and CSF-1R inhibition (n=6). 
 
IL-12p70 levels did not change with statistical significance. 
!
Figure 137 - Plasma IL-12p70 concentrations in C57BL/6 mice with no 
manipulation (n=5), with lymphoma (n=5) and with lymphoma and CSF-1R 
inhibition (n=6). 
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TNF-! levels rose with lymphoma and were unaffected by CSF-1R inhibition. 
Absolute levels were low but above the LLD for the assay. 
!
Figure 138 - Plasma TNF-!  concentrations in mice with no manipulation (n=5), 
with lymphoma (n=5) and with lymphoma and CSF-1R inhibition (n=6). 
IL-1" readings were mostly below the LLD, although a statistically significant 
rise was detected with lymphoma, and fall with CSF-1R inhibition. 
!
Figure 139 - Plasma IL-1"  concentrations in mice with no manipulation (n=5), 
with lymphoma (n=5) and with lymphoma and CSF-1R inhibition (n=6). 
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IFN-# levels rose with with CSF-1R inhibition. The absolute levels were low, but 
above the LLD for the assay. 
!
Figure 140 - Plasma IFN-#  concentrations in C57BL/6 mice with no manipulation 
(n=5), with lymphoma (n=5) and with lymphoma and CSF-1R inhibition (n=6). 
We will interpret these data in the discussion. 
In the light of our data indicating a potentially beneficial effect of CSF-1R 
inhibition with AZ268 in this model of lymphoma, we were interested to explore 
any additional benefit when used in combination with traditional cytotoxic 
chemotherapy. The following two protocols investigated the impact of 
macrophage depletion following chemotherapy, and before chemotherapy.!
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11.1 Combination with chemotherapy. 
11.1.1 Macrophage depletion following cyclophosphamide. 
Experimental protocol: 
According to the protocol below, C57BL/6 mice with transplanted and 
established lymphoma were given a single 300 mg/kg ip dose of 
cyclophosphamide on day 8, followed by CSF1-R inhibitor or vehicle until 
survival end point was reached. CSF-1R inhibitor 100 mg/kg or vehicle was 
given twice daily by oral gavage. The aim was to assess impact on time to 
relapse, and time to reach survival end point as defined by Home Office limits.  
!
Figure 141 - Protocol investigating chemotherapy followed by CSF-1R inhibition 
in mice with lymphoma. 
Lymphoma progression prior to cyclophosphamide, and in relapse, was 
assessed subjectively by palpation of inguinal lymph nodes and spleen, and 
objectively by analysing peripheral blood smears taken from one mouse in each 
group each day. 
Data: 
All mice became acutely unwell approximately 1 hour after the injection of 300 
mg/kg of cyclophosphamide, They developed a hunched posture with reduced 
spontaneous movement, and so were observed carefully as they appeared to 
recover fully over the next 2 hours. Consequently, it was decided that in future 
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protocols the maximum single dose of cyclophosphamide should be reduced to 
200 mg/kg. 
Blood film analysis, shown overleaf, revealed an increasing number of large 
irregular lymphoid cells, reaching a peak by day 7, immediately prior to 
cyclophosphamide. Pancytopaenia was evident from day 11 to day 13. A small 
number of irregular lymphoid cells, as well as some immature myeloid cells, 
were seen on day 14. The number of large irregular lymphoid cells increased by 
day 17. Once daily blood film analysis did not reveal any difference in time to 
leukaemic relapse between the treatment groups. Daily palpation of spleens 
and inguinal lymph nodes failed to demonstrate any difference in time to 
macroscopic relapse between the groups. 
! "$&!
Day 0      Day 4 
 
Day 7      Day 11 
 
Day 14     Day 17 
!
Figure 142 – Representative blood smears stained with modified Wright's stain 
(OM x 2.5). 
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Total body weights of 4 mice dropped by more than 20% during this 
pancytopaenic phase, and so they were culled. These mice, 2 from the CSF-1R 
inhibition group and 2 from the vehicle control group, had no organomegaly or 
lymph node enlargement at this time.  On day 15, total body weights rose in all 
mice except one, which recorded weight gain on day 16. Nucleated blood cell 
numbers started to rise in the peripheral blood at the same time.  
One mouse in the CSF-1R inhibition group became unwell on day 17 and was 
culled, with evidence of lymphoma relapse. The majority of mice in both groups 
became unwell and were culled on days 18 and 19, with none surviving beyond 
day 20. 
!
Figure 143 - Average body weights of mice in each group (n= 10 per group). 
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There was no statistically significant difference in time to survival end-point 
between the groups.  
!
Figure 144 - Time taken to reach Home Office guidelines limits of survival (n=10 
per group). 
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11.1.2 Macrophage depletion prior to cyclophosphamide. 
Experimental protocol: 
As depicted in the protocol below, mice with lymphoma were subjected to 
macrophage depletion either with 5 days of oral CSF-1R inhibition or a single 
200 µl iv dose of LC on day 3, followed by cyclophosphamide ip on day 5. 
Control mice received CSF-1R inhibitor vehicle for 5 days followed by 
cyclophosphamide on day 5. A relapse end-point for the whole protocol was 
declared when one mouse had easily palpable splenic and lymph node 
enlargement. At this point, all mice in all groups were sacrificed, and lymphoma 
progression assessed.  
!
Figure 145 - Protocol investigating cyclophosphamide after macrophage 
depletion in mice with lymphoma. 
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Data: 
All mice in all groups had macroscopic evidence of relapse with splenic and 
lymph node enlargement. There were no statistically significant differences 
between the groups with respect to lymph node weight or lymph node cell 
count. 
!
Figure 146 - Lymph node weights of mice exposed to macrophage depletion or 
vehicle prior to cyclophosphamide. 
 
Figure 147 - Lymph node cell counts. 
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Flow cytometry of lymph nodes did not detect any difference between the 
groups with respect to the size of the CD19 positive population in the lymph 
nodes, and no difference emerged when factoring this figure by lymph node cell 
count or weight.  
!
Figure 148 - Frequency of lymph node CD19 positive cells by flow cytometry 
(Vehicle n=7, CSF-1Ri n=7, LC n=8). No statistically significant differences 
detected. 
!
Figure 149 – Lymphoma burden in lymph nodes expressed as function of lymph 
node total cell count (by Trypan-blue exclusion assay) and frequency of CD19 
positive cells. 
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!
Figure 150 - Lymphoma burden in lymph nodes expressed as function of lymph 
node weight and frequency of CD19 positive cells. 
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There was no significant difference in B-cell BrdU incorporation between the 
groups.  
!
Figure 151 - Frequency of proliferating CD19+ cells expressed as percentage of 
CD19+ cells incorporating BrdU (Vehicle n=7, CSF-1Ri n=7, LC n=8). 
All groups had low percentages of myelo-monocytic cells in the lymph nodes, 
as measured using CD11b staining. There was a statistically significant, but low 
magnitude, reduction in CD11b+ cells in the lymph nodes of mice treated with 
CSF-1R inhibition prior to cyclophosphamide, compared to other groups. 
!
Figure 152 - Frequency of CD19-CD11b+ cells in whole lymph nodes by flow 
cytometry (Vehicle n=7, CSF-1Ri n=7, LC n=8).  
These data will be interpreted in the following discussion. 
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12 Discussion. 
12.1 Critical interpretation of data. 
12.1.1 Interrogation of human DLBCL biopsies.  
Interrogation of a large number of diagnostic, treatment naïve DLBCL biopsies 
contributed to existing evidence that TAM in lymphoma might be alternatively 
activated and are associated with the promotion of lymphoma growth. The tight 
correlation between the area of tissue staining with the universal human 
macrophage marker CD68 and the area staining with CD163, a macrophage 
specific marker of alternative activation and the M2 phenotype, suggests that 
nearly all macrophages in DLBCL have features of alternative activation in 
keeping with an M2-like phenotype. It seems reasonable to have made the 
assumption that macrophage area is directly proportional to macrophage 
number. Expert histopathologist review (AL) could discern no difference in 
macrophage size between different patient samples. As such, numbers of CD68 
staining macrophages, and numbers of CD163 staining macrophages, both 
positively correlated with tumour proliferation, as defined by Ki67 staining. This 
is contrary to earlier published findings of no correlation between CD68 and 
Ki67 staining in 176 cases of DLBCL (Hasselblom et al., 2008). Referring back 
to our introduction, CD163 is not only considered a marker of alternative 
activation in non-lymphoid cancers (Mantovani et al., 2004b). CD163 staining 
macrophages were associated with increased angiogenesis in FL (Clear et al., 
2010) and the promotion of malignant B-cell survival through the secretion of 
APRIL in gastric MALT lymphoma (Munari et al., 2011), as well as in recent 
months, with a poor outcome in DLBCL, via unknown mechanisms (Wada et al., 
2012). It is therefore entirely plausible, and consistent with our data, that similar 
processes are occurring in DLBCL, such that CD163 positive macrophages 
promote the proliferation of DLBCL.  
This correlative data reinforced the need to use an animal model in an attempt 
to reveal whether this might reflect an important functional relationship between 
TAM and lymphoma. Additionally, such work might give an indication as to the 
direction and strength of such a relationship, and reveal the molecular and 
genetic mechanisms responsible. The statistically significantly smaller area 
represented by CD163 than by CD68 staining in most cores and overall might 
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represent the fact that CD163 staining macrophages with features of alternative 
activation are a subset of CD68 positive macrophages. This is biologically 
plausible, and the acquisition of CD163 expression may represent the 
acquisition of an alternatively activated phenotype that may be dependant upon 
maturity or location within the lymphoma microenvironment. A caveat to this is 
the recognition that although CD163 and CD68 are both membrane bound 
antigens, it is possible that an unidentified artefact of the IHC process results in 
reduced areas of CD163 compared to CD68 positivity for any given cell.  
It is interesting to speculate how these data relate to the clinical outcomes of 
the patients included in this TMA by Coutinho et al., who reported in abstract 
form that abundant CD68+ cells correlated with an improved prognosis 
following treatment (Coutinho et al., 2011). It may be that more proliferative 
cases, although more aggressive in their natural history, are more sensitive to 
cytotoxic chemotherapy. Inconsistent with this suggestion is that the number of 
CD163+ cells appeared to have no correlation with survival, yet in our analysis 
correlated with proliferation. A variety of different therapies were used in these 
patients, some being first treated in the 1970’s, and 33% of all patients 
receiving rituximab. We speculate that subsequent analysis might reveal that 
the direction and strength of association between macrophage numbers and 
survival in this cohort is related to the specific treatment received.!
12.1.2 Interpretation of Liposomal Clodronate data. 
Our data indicate that LC depletes monocytes and macrophages in all tissues 
studied. In the blood, the percentage of CD11b+Ly6G+ granulocytes rises 
significantly in concert with monocyte depletion. These changes are associated 
with reduced volume and weight of lymphoma bearing tissues at a set time 
point. Several findings strongly suggest that this reflects a true reduction in 
lymphoma at this time point. Firstly, there is a greatly reduced cross-sectional 
area of lymphoma infiltrating sections of liver. Secondly, lymph nodes appear 
heavily and diffusely infiltrated with lymphoma in all mice with lymphoma, 
regardless of whether or not they were exposed to LC. As such, lymph node 
volume and weight will be related to the number of infiltrating lymphoma cells. 
Of note, administration of iv LC appeared to cause a greater degree of 
macrophage depletion and reduction in lymphoma growth in the liver, spleen 
and bone marrow than in the lymph nodes. It seems reasonable to speculate 
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that this might reflect respective differences in tissue penetration of liposomes; 
being far greater in more vascular tissues and less in lymph nodes. 
Administration of liposomal PBS in vivo neither depletes macrophages, nor is 
associated with a reduction in the volume or weight of lymphoma bearing 
tissues, nor a reduction in cross-sectional area of lymphoma in liver or lymph 
nodes. 
In vitro LDH release assays indicate that lymphoma cells in isolation are not 
damaged or killed by even very high concentrations of LC. This supports the 
notion that LC might mediate attenuation of lymphoma proliferation via indirect 
means, potentially via macrophage depletion. 
An intensive regime of iv LC did not prolong the survival of mice with 
transplanted lymphoma. We postulate several potential reasons for this. These 
are outlined below: 
1) The dynamic of the disease and assessment of end-point. 
The transplanted lymphoma is highly proliferative, growing rapidly and causing 
obvious signs of sickness only 12 days following initial injection. As such, 
although we observed a consistent and statistically significant reduction in 
lymphoma growth by day 10 or day 11, this difference may not have been 
sufficient to prolong survival to an extent that was measurable given our 
experimental protocol. The end-point was not actually death from lymphoma, 
rather, and appropriately for animal experiments, signs of any deterioration and 
suffering, as dictated by UK Home Office regulations. This was assessed every 
12 hours, and no difference was discernable. It may be that with a more 
indolent model of lymphoma, and greater numbers of mice, a “survival” 
difference might be seen.  
2) Tissue penetration of LC. 
Iv LC will not have penetrated the CNS, being unable to cross an intact blood-
brain barrier (Bauer et al., 1995). We have no evidence to suggest that this is a 
critical site for lymphoma progression in this model, but it is possible that 
although lymphoma growth was retarded in the lymph nodes, liver and possibly 
spleen, it may have continued to progress unhindered in the CNS, contributing 
to the signs of ill health that determined the “survival” end point.  
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3) Depletion of physiological monocytes and macrophages. 
LC depletes physiological monocytes and macrophages, and therefore must 
impact on important homeostatic processes, and also potentially on any 
adaptive and beneficial elements of the response to disseminated lymphoma. 
For instance, phagocytosis of apoptotic bodies, acute responses to pathogens, 
coordinating innate and adaptive immune responses to pathogens, and iron 
homeostasis will all be compromised. We speculate that an intensive regime of 
LC with widespread and profound macrophage depletion contributes to signs of 
illness, that in conjunction with an albeit more slowly progressing lymphoma, 
results in the attainment of “survival” end point at the same time as control mice 
with lymphoma. This does not necessarily argue against our hypothesis that 
TAM promote lymphoma, but does suggest that an intensive regime of iv LC 
would not be a safe therapeutic strategy. 
Nonetheless, experiments with LC were consistent with the theory that 
macrophages support the growth of lymphoma.!
12.1.3  Interpretation of MaFIA mouse data. 
Our data from the MaFIA mouse model are broadly supportive of our 
hypothesis, and of the findings with LC. The LDH release assay found 
progressive lymphoma cell cytotoxicity in vitro above I mM concentration of 
dimerizer AP20187. This certainly suggests that direct lymphoma cell killing is a 
consequence of prolonged very high dose AP20187, yet such concentrations 
are unlikely to be achieved or maintained in vivo, and are far in excess of the 
nanomolar concentrations required to effect macrophage cell death.  
According to the data of Burnett et al., our schedule will have begun to deplete 
macrophages from 24 hours after the third injection of dimerizer, this being day 
4 of the in vivo protocol. Monocyte and macrophage re-population of bone 
marrow and spleen would not be expected to begin until 7 days after the last 
injection of dimerizer, this being day 12 of the in vivo protocol, and after the day 
of elective sacrifice. We saw partial monocyte and macrophage depletion in the 
blood and lymph nodes at sacrifice on day 9.  
Monocyte depletion in the blood of MaFIA mice with lymphoma treated with 
dimerizer was almost entirely due to loss of Ly6C- “patrolling” monocytes, with a 
relative increase in Ly6C+ “inflammatory” monocytes. This finding might support 
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the theory that monocyte subsets are a maturation series. If we assume that all 
monocytes and macrophages were killed in equal proportions by dimerizer 
induction, then the less mature, shorter lived and so higher turnover, 
“inflammatory” monocytes might be expected to be the first to repopulate the 
blood on recovery.   
Monocyte and macrophage depletion was associated with a significantly 
reduced lymph node weight and CD19 positive population by flow cytometry. 
This is supportive of the hypothesis that TAM promote the growth of lymphoma. 
By demonstrating this using the MaFIA mouse, we have provided further 
evidence that the effects seen with LC-mediated macrophage depletion were 
neither idiosyncratic nor an artefact.  
Of note, Burnett et al. found that an identical schedule of dimerizer 
administration failed to deplete macrophages in the lymph nodes of healthy 
MaFIA mice, whilst depleting most macrophages in the bone marrow and 
spleen (Burnett et al., 2004). The partial but consistent and statistically 
significant macrophage depletion we observed might itself provide insights 
regarding the accumulation of TAM in growing lymphoma. For this to have 
occurred, we speculate that either or both of two phenomena may have 
occurred: 
1) Changes in the vascularity of lymph nodes occurred with the 
dissemination and growth of lymphoma, such that the dimerizer was able 
to penetrate to a far greater extent than in healthy lymph nodes, thus 
effecting macrophage cell death. 
2) The dimerizer was still unable to penetrate lymph nodes during 
lymphoma dissemination and spread. Rather, the partial macrophage 
depletion in lymph nodes during lymphoma progression can be 
accounted for by the profound loss of monocytes in the bone marrow and 
spleen, so reducing the circulating pool from which new TAM can be 
recruited. If this were so, it also suggests that monocyte recruitment 
plays a significant role in the increase in numbers of TAM seen in lymph 
nodes with growing lymphoma. By inference, this suggests that local 
macrophage proliferation can only play a partial role in the increase in 
TAM numbers in this model.  
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12.1.4 Interpretation of adoptive transfer data. 
Analysis by flow cytometry demonstrated that the protocol we used generated 
BMDM of very high purity, with almost all cells expressing CD11b, F4/80 and 
CSF-1R. Phenotype modulation appeared consistent with the literature, with M1 
BMDM having relatively higher expression of MHCII (Movahedi et al., 2010) and 
IFN-#, suggestive of an antigen-presenting and pro-inflammatory phenotype. 
TAM BMDM had relatively increased expression of MR and decreased 
expression of IFN-#, consistent with an alternatively activated phenotype.  
AT BMDM labelled in vitro with a red fluorescent dye were visualised in post-
mortem specimens of lymph nodes and spleen. Having been stained in vitro 
and repeatedly washed to prevent injection of dye into recipient mice, these red 
fluorescent cells likely represent successful adoptive transfer, and not in vivo 
staining of resident macrophages. The main differential explanation for these 
images is that AT BMDM containing red fluorescent dye reached tissues but did 
not survive, with their cell debris being phagocytosed by resident tissue 
macrophages.  
In vivo AT data suggest that supplemental M1 macrophages slow the growth of 
lymphoma and M2 macrophages do not. Supplemental BMDM polarised with 
TCM (TAM polarised) appeared to invigorate the growth of lymphoma in vivo.  
Together, these findings suggest that: 
1) Macrophage phenotype influences lymphoma progression. 
2) M1 phenotype attenuates lymphoma progression. 
3) M2 phenotype has no discernable gross effect on lymphoma progression. 
4) TAM phenotype is pro-tumoural and distinct from either the M1 or M2 
phenotype. 
This would appear to support the hypothesis that TAM promote lymphoma 
growth in this model. This may well be the case. These experiments were 
repeated on several occasions and the differences between the groups are 
consistent, reproducible and although small magnitude, statistically significant. 
It is conceptually attractive to embrace such conclusions. However, it is 
absolutely necessary to consider several caveats when interpreting these data: 
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1) The proportion of injected BMDM that reach the lymph nodes is small; the 
majority accumulate within the pulmonary vasculature (Andreesen et al., 1998).  
2) The proportion of TAM in lymph nodes that derive from injected BMDM is 
likely to be small in our experiments. 
3) Macrophage phenotype is plastic and may well be modified further in vivo. 
These three points imply that it might be unlikely that such a relatively small 
number of AT BMDM could cause a difference in lymphoma growth that would 
be discernable in such an aggressive model of lymphoma. In other words, there 
is an issue as to whether it is biologically feasible that such a small number of 
supplemental macrophages reaching the lymph nodes could have such an 
impact. We suggest that there are several reasons why they might: 
1) BMDM are strongly polarised and so disproportionately influential. 
2) BMDM influence lymphoma growth significantly, albeit briefly, and the timing 
of AT and sacrifice might have been optimal to discern this impact. 
3) The lymphoma is disseminated and so BMDM, even lodged in pulmonary 
capillaries, are able to influence the systemic proliferation of lymphoma and so 
the growth of lymph nodes, perhaps through secreting high levels of key 
cytokines. In this way AT BMDM could also act to modulate or recruit other 
immune effector cells in a pro- or anti-lymphoma response, thus amplifying the 
effect. 
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12.1.5 Interpretation of CSF-1R inhibitor data. 
CSF-1R inhibition in healthy mice reduced the number of macrophages in 
lymph nodes and had no effect on the numbers of normal B-cells and T-cells in 
lymph nodes or blood. We speculate that the slight reduction in macrophages in 
normal lymph nodes may be multifactorial. The literature reviewed earlier would 
suggest that CSF-1R inhibition might have the following effects: 
1) Reduced formation of CMP and GMP in the bone marrow. 
2) Reduced differentiation of MDP from GMP. 
3) Compensatory increased differentiation of granulocytes from GMP. 
4) Reduced differentiation of GMP to monocytes. 
5) Reduced differentiation to patrolling versus inflammatory monocytes. 
6) Reduced trafficking of monocytes to tissues. 
7) Reduced maturation of monocytes to macrophages. 
8) Reduced survival of macrophages. 
9) Reduced in situ proliferation of macrophage precursors. 
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Figure 153 - CSF-1R ligation in monocyte production in the bone marrow. 
These same effects could also be responsible for the clear reduction in blood 
monocytes and lymph node macrophages seen in mice with lymphoma treated 
with CSF-1R inhibition. The relative importance of these different mechanisms 
might well be different between situations of health and of lymphoma.  
Prolonged use of a higher dose of CSF-1R inhibitor produced a greater degree 
of blood monocyte and lymph node macrophage depletion and greater relative 
reduction in lymph node weight, strongly implying a dose effect. The fact that 
the only populations we found that were depleted by CSF-1R inhibition were 
monocytes, macrophages and malignant B-lymphocytes, and that a dose 
response relationship appears to exist, suggests a causal link. CSF-1R 
inhibition is associated with monocyte and macrophage depletion that is 
associated with a reduced lymph node weight and reduced lymph node CD19 
positive population. Given that the lymphoma cells do not express CSF-1R, nor 
are directly killed by even very high doses of CSF-1R inhibitor over 18 hours of 
exposure in vitro, this strongly suggests that CSF-1R inhibition attenuates 
overall lymphoma growth via intermediary mechanisms. Given that 
macrophages express CSF-1R, and that the CSF-1Ri used has been shown by 
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the manufacturer to reduce tissue infiltrating macrophage numbers in other 
models, it seems reasonable to interpret our data as supporting the following 
statement: 
‘CSF-1R inhibition reduces monocyte and TAM numbers in the transplantable 
Eµ-myc/bcl2 model of lymphoma, and this is associated with decreased 
lymphoma growth.’ 
 According to our experiments, CSF-1R inhibition only causes a partial 
reduction in monocyte and TAM numbers, and a partial reduction in lymphoma 
burden and proliferation. There are several plausible reasons for this: 
1) CSF-1R ligation is only one of the events responsible for the recruitment, 
maturation, or proliferation of monocytes and TAM. As such, even with 
maximal CSF-1R inhibition, only partial effects will be seen. As IL-34 also 
acts at the CSF-1R, and we used a small molecule tyrosine kinase 
inhibitor, it is unlikely that IL-34 could compensate for CSF-1R inhibition. 
As mentioned in the introduction, CCL2 can act as a monocyte chemo-
attractant, and acts via CCR2 and CCR4, not the CSF-1R. We have not 
investigated the role of CCL2 and its receptors in this project. 
2) Even with maximal specific reduction in TAM numbers, the impact on 
lymphoma proliferation will be limited. Lymphoma may not be entirely 
dependent on its microenvironment for survival and proliferation, and 
certainly is unlikely to be entirely dependent on TAM. Other cells of the 
immune microenvironment are likely to contribute survival and growth 
signals, and these other cells may even partially compensate for the 
reduction in TAM. 
3) Only partial CSF-1R inhibition was achieved in our experiments. Twice 
daily oral dosing is likely to result in peaks and troughs of CSF-1R 
inhibitor levels in blood and target tissues. This might allow monocyte 
maturation and trafficking, and possibly even TAM proliferation, to 
proceed during these troughs.  
Effects of CSF-1R inhibition on monocyte subsets, and on granulocyte 
numbers, are discussed in the following chapters. 
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The vehicle alone produced a reduction in lymph node weight in mice with 
lymphoma. This did not correlate with statistically significant lymph node 
macrophage depletion. This phenomenon was restricted to the lymph nodes, 
with no reduction in liver weight. There was no reduction in liver cross-sectional 
area of lymphoma in those receiving the vehicle. When the duration of therapy 
was increased from 5 to 10 days, this effect on lymph node weight did not 
appear to increase with a dose effect and became proportionally smaller as the 
treatment group displayed an even greater reduction in lymph node weight than 
with the lower dose. We can only speculate as to the cause of this effect of 
vehicle gavage. Certainly, twice daily gavage appears to be a physically and 
possibly emotionally traumatic event for the mice, and it seems possible that 
such episodes of acute stress might result in increased endogenous 
corticosteroid release, thus reducing lymphoma growth. It is not at all clear, 
however, how this could be a phenomenon restricted to the lymph nodes. A 
literature review reveals a sound evidence basis for this theory of gavage-
induced stress. The stress induced by oral gavage is considered to be a 
confounding variable in many studies, and one that can be partially abrogated 
by pre-coating the gavage needle with sucrose to induce the cooperation of the 
subjects (Hoggatt et al., 2010). Nonetheless, the firm “scruffing” restraint 
technique required for safe gavage itself causes a rise in plasma corticosteroid 
levels in rodents (Dobrakovova and Jurcovicova, 1984), and high viscosity 
gavage liquids, such as the CSF-1R inhibitor vehicle, containing 
methylcellulose, also contribute to increased corticosteroid release (Brown et 
al., 2000).  
Our investigations into a biologically plausible mechanism that might link these 
elements of CSF-1R inhibition, reduction in TAM numbers, and decreased 
lymphoma growth, are thus far incomplete. However, they do provide some 
clues and help to shape new hypotheses to guide further work. We will discuss 
these in the following four sections.!
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12.1.6 Interpretation of gene expression data. 
Gene expression analysis of whole lymph nodes indicated reduced expression 
of F4/80 and increased expression of CD14 in treated versus untreated mice 
with lymphoma. CD14 expression is strongest in monocytes and is 
progressively lost during maturation to lymph node resident macrophages, both 
in the context of health and in the presence of most lymphomas (Marmey et al., 
2006). F4/80 is absent on monocytes, expressed only on mature resident tissue 
macrophages. This is consistent with our understanding of the expected effects 
of CSF-1R inhibition in monocyte maturation. As such there might be inhibition 
of maturation to mature resident macrophages, and so an accumulation of 
CD14+ monocytes and immature macrophages, and a reduction in F4/80+ 
mature tissue macrophages. Of potential relevance is that this work was 
conducted using tissues from an early protocol using only 50 mg/kg CSF-1R 
inhibitor for only 5 days. As such, it would be interesting to repeat this 
experiment with prolonged higher dose CSF-1R inhibition. 
 !!
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12.1.7 Interpretation of flow cytometry data. 
Prolonged CSF-1R inhibition in mice with advanced lymphoma produced a 
substantial reduction in the total number of monocytes in the blood when 
measured using a combination of the surface markers CD11b and Ly6G. There 
was a substantial increase in the number of circulating CD11b+Ly6G+ 
granulocytes. F4/80 staining of these two populations, distinguished by Ly6G 
staining, confirmed differentiation of only the Ly6G- cells towards a macrophage 
fate. Possible explanations for this shift include: 
1) CSF-1R inhibition alters the balance between monocyte and granulocyte 
differentiation at the bone marrow GMP stage. 
2) CSF-1R inhibition reduces the egress of CD11b+Ly6G- monocytes from 
the bone marrow. 
3) CSF-1R inhibition reduces the survival of monocytes in the blood, with no 
such effect on granulocytes, which do not express CSF-1R. 
4) Other changes consequent on CSF-1R inhibition cause a relative 
prolongation of survival of granulocytes compared to monocytes. 
Plasma cytokine data support this concept, as increased levels of 
IFN-# extend the life of granulocytes by decreasing their apoptosis 
(Simon et al., 1997, Colotta et al., 1992, Whyte et al., 1997).  
There was no discernable shift in the balance between monocyte subsets, 
however. As such, there was no evidence that CSF-1R inhibition with this drug 
in this model of lymphoma, had any effect on the relative balance between 
“inflammatory” and “patrolling” monocyte numbers in the blood, although with 
reduced overall CD11b+Ly6G- numbers, the absolute numbers of both 
inflammatory and patrolling monocytes were both reduced by CSF-1R 
inhibition. CSF-1R inhibition was associated with a reduced number of lymph 
node TAM in the model we used. A block at any stage in monocyte lineage 
maturation would reduce the number of monocytes capable of being recruited 
from the blood and maturing further into tissue resident macrophages. This 
block could have occurred at several different stages to different extents. 
Without specifically investigating the bone marrow for numbers of precursors, it 
is impossible to be certain, however, our data suggest that in particular, 
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differentiation in to either monocytes or granulocytes at the GMP stage might be 
exquisitely sensitive to CSF-1R inhibition.  
In the blood we found there was a reduction in the malignant B-cell population. 
However, there was not a reduction in BrdU incorporation amongst this 
malignant population. It is necessary to pursue this finding further to investigate 
why this should be so. Several explanations are possible, including: 
1) The burden of circulating disease simply reflects overspill from lymph 
nodes and other tissues such as the bone marrow and spleen. As such, 
if there is primarily less lymphoma in these tissues, this will simply be 
reflected in the amount of circulating disease. Supporting this is the 
observation that total monocyte/macrophage numbers are reduced in the 
blood yet there is no change in their incorporation of Brdu in this 
compartment, implying that lymphoma cell biology in the blood is not 
affected in the same way as in the lymph nodes; it operates in a very 
different microenvironment. "] There is a clear shift in the balance in numbers between monocytes and 
granulocytes in the blood with CSF-1R inhibition. As such, it is plausible 
that lymphoma within the blood is subject to a very altered 
microenvironment with CSF-1R inhibition, and its dynamic might also be 
altered. I have not measured rates of lymphoma cell apoptosis in this 
model, and it is conceivable that although rates of proliferation might not 
be altered, rates of apoptosis might be, and so could explain the reduced 
lymphoma burden in the blood even though proliferation rates are 
unchanged. The function and impact of the increased number of 
circulating granulocytes is certainly worthy of future investigation but was 
considered beyond the scope of this project.!
In lymph nodes, there was a clear and substantial reduction in macrophages, as 
measured using a variety of surface markers including CSF-1R, CD11b, CD11b 
and Ly6G and F4/80. Unlike in the blood, we did not investigate the relative 
proportions of CD11b+Ly6G-Ly6C+ and CD11b+Ly6G-Ly6C- cells as this 
schema applies to circulating monocytes, rather than resident tissue 
macrophages. There was no percentage change in the malignant B-cell 
population in lymph nodes, as measured by CD19 or B220 expression. When 
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combined with lymph node weight, the pattern is consistent and very clear; that 
there is a reduction in the total number of lymph node resident malignant B-cells 
in mice subjected to CSF-1R inhibition.    
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12.1.8 Interpretation of plasma cytokine data. 
CSF-1 levels rose with the presence of advanced lymphoma. This is consistent 
with published data for other malignancies and models, but has not been 
reported in lymphoma models before. This is also consistent with the 
hypothesis that lymphoma promotes the generation, survival, trafficking, and 
maturation of monocytes through producing and secreting CSF-1. Macrophage 
depletion in MaFIA mice with lymphoma had no effect on these raised levels. 
We speculate that this might be the net result of opposing factors. Firstly, a 
reduction in lymphoma mass with macrophage depletion reduces the number of 
malignant B-cells present and so able to produce CSF-1. Secondly and 
opposing this, macrophage depletion in MaFIA mice reduces the number of 
CSF-1R expressing cells and so reduces the rate at which circulating CSF-1 is 
consumed by ligation with its receptor. We have no data from our own 
experiments to support this suggestion. 
The substantial rise in circulating levels of IL-10 that occurs in advanced 
lymphoma supports the notion that the lymphoma environment is one 
dominated by immune-suppression, entirely in keeping with an abundance of 
alternatively activated TAM.  
The rise in CXCL1 levels with CSF-1Ri is of unclear significance. This may 
reflect its role as a leukocyte chemoattractant, perhaps being produced at 
increased levels in an attempt to compensate for CSF-1R inhibition. 
Alternatively, this rise may reflect the increased number of circulating 
granulocytes that may be producing this ligand.  
IL-6 levels change significantly with the presence of advanced lymphoma, and 
then again with CSF-1R inhibition. IFN-# levels rise significantly when mice with 
lymphoma are treated with CSF-1Ri. The plasma concentrations of these two 
cytokines appear to change with CSF-1R inhibition in a way that might indicate 
a more favourable immune response. IFN-# is the archetypal Th1 cytokine, high 
levels favouring the direction of macrophages towards a pro-inflammatory and 
potentially tumouricidal M1 phenotype. Levels of IFN-# rise with CSF-1R 
inhibition. This could reflect the shift in circulating myelo-monocytic cells with a 
relative abundance of inflammatory Ly6G+ granulocytes, as well as a reduced 
acquisition of CSF-1R dependent features of an alternatively activated / M2 
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phenotype by tissue macrophages. Although the absolute levels of IFN-# 
recorded in the plasma were low, they may reflect larger magnitude changes in 
other critical sites such as the bone marrow or lymph nodes. The rise with 
progression of lymphoma and then fall in circulating IL-6 levels with CSF-1R 
inhibition is the most prominent change recorded, and may be of great 
significance. We discuss the potential roles of IL-6 in a later chapter. Our data 
do not allow reasonable inference as to whether the fall in IL-6 levels is in any 
way responsible for the reduced proliferation of lymphoma, or if it simply reflects 
a decreased number of lymphoma cells, arising through IL-6 independent 
mechanisms.    
One significant limitation of this approach is that plasma cytokine levels are 
likely to be different from cytokine levels within tissues, such as lymph nodes. It 
is within such tissues that we hypothesise the most critical TAM-lymphoma 
interactions occur, and where this relationship might be most vulnerable to local 
changes in the cytokine milieu.  
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12.1.9 Interpretation of data from combination with chemotherapy. 
Combination of macrophage depletion strategies with cyclophosphamide did 
not provide evidence for any added benefit of this approach over 
cyclophosphamide alone. There may be several reasons for this. It might be 
that the model is too aggressive to allow detection of subtle benefits.  It may be 
that cyclophosphamide was not the ideal choice of agent to combine with 
macrophage depletion strategies. In fact, in addition to being cytotoxic to 
dividing malignant cells, cyclophosphamide itself causes macrophage depletion. 
A principal side effect of this agent is leukopaenia. In guinea pigs, deficiencies 
in resident tissue macrophages (Hunninghake and Fauci, 1977) and 
inflammatory macrophage numbers (Winkelstein, 1973) were seen following 
cyclophosphamide therapy. This was subsequently confirmed in human tissues 
(Santosuosso et al., 2002). As such, macrophage depletion therapies following 
cyclophosphamide would need to be sustained beyond the normal period of 
monocyte/macrophage recovery following chemotherapy to conceivably have 
additional impact. It would be interesting to study combination with agents that 
do not cause significant macrophage depletion themselves, so as to determine 
if any additive or summative benefit could be achieved.  
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12.2 Discussion of methods. 
12.2.1 Measuring tumour burden. 
Lymph node dimensions and weight appear to be reasonable proxy measures 
of lymphoma mass, with histological sections showing diffuse and uniform 
infiltration with lymphocytes in mice with lymphoma, regardless of therapy. Flow 
cytometry data is consistent with this, with the proportion of malignant cells 
unchanged between treatment groups, and so lymph node dimensions/weight 
being proportional to the overall number of malignant lymphocytes. For the liver 
and spleen, this is probable less robust. Intensive treatment of normal mice with 
LC is known to lead to a degree of splenic shrinkage that is out of proportion to 
simply the loss of macrophages, and has been associated with apoptosis of 
non-phagocytic lymphocytes, possibly damaged by enzyme release from dying 
macrophages (van Rooijen et al., 1985). This idiosyncratic effect may explain 
the dramatically reduced spleen size in mice with lymphoma treated with LC. 
This reduction in spleen size is out of proportion to the changes in lymph node 
and liver size. Sections of liver show that despite lymphoma only occupying a 
minority of the overall liver mass, the cross-sectional area of lymphoma 
changes with treatment in the same direction as does liver weight and so is in 
itself a valid measure of changes in hepatic lymphoma mass. In the light of 
these observations, we were reluctant to consider spleen weights as a measure 
of overall lymphoma mass, preferring to pay most attention to the most robust 
measure, lymph node weight, and then quantify B-lymphocytes by flow 
cytometry. 
Flow cytometry for CD19+ cells provides a somewhat indirect but nonetheless 
accurate relative measure for comparing malignant B-cell populations between 
experimental groups. In support of this strategy, separation of malignant from 
non-malignant lymph node cells is commonly performed on the basis of CD19 
expression, including in publications in the most highly regarded scientific 
journals (Dave et al., 2004). Experiments in healthy mice demonstrated that 
neither LC nor CSF-1R inhibition altered the proportion or total number of 
normal healthy CD19 expressing B-lymphocytes in lymph nodes or blood. In 
mice with lymphoma, the proportion and number of CD19 expressing cells is 
greatly increased. Given that treatment with LC or CSF-1R inhibition do not alter 
the normal B-cell population, it seems reasonable to assume that differences in 
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CD19 expressing cells in mice with lymphoma subjected to different therapies 
are entirely, or almost entirely, consequent on reductions in malignant B-cells.  
A further point to reinforce is that flow cytometry measures relative proportions 
of different cells, often expressed as percentages of gated populations. Aiming 
to provide a measure of total lymph node tumour burden, it was imperative that 
the proportion of CD19 positive cells was factored by the lymph node weight or 
total cell number, so as to derive a measure that truly reflected tumour burden. 
Similarly, when measuring macrophage numbers, it is important to consider the 
total number of macrophages present in lymph nodes by also factoring the 
proportion of cells by the total cell number or lymph node weight. !
12.2.2 Criticisms of the transplantable Eµ-myc/bcl-2 lymphoma model.  
We believe this model proved to be excellent for the specific purposes of our 
project. Owing to its highly proliferative biology it was easily transplantable, and 
enabled rapid collection of data, and repetition of protocols to confirm findings 
and collect further samples. The model was highly reproducible, with lymphoma 
progression being consistent within and between protocols. In keeping with 
expectations, it proved to be chemoresistant. As such, the observed impact of 
macrophage manipulation is particularly encouraging. We discuss some of the 
limitations of this model below. 
i) Differences between human and mouse macrophages. 
Macrophages are an ancient and evolutionarily conserved cell with 
many functional similarities between mice and humans. TAM 
expression signatures in mouse models of cancer are represented in 
human tumour datasets, and can even be of prognostic value (Ojalvo 
et al., 2009, Zabuawala et al.). Monocyte subsets, as reviewed in the 
introduction to this thesis, provide an example of comparable 
functional attributes of equivalent subsets distinguished by different 
surface markers in mice and humans.  The validity of our project 
relies upon there being a similar comparability between mice and 
humans with respect to the functional relationship between TAM and 
malignant B-lymphocytes. Detailed comparisons of mouse and 
human macrophage genomes indicate overlap as well as particular 
differences. However, exact duplication of genetic and molecular 
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events is not as critical to the demonstration of proof-of-principle as 
the faithful representation of the functional consequences of cellular 
interactions between these two cell types in man and mouse.     
ii) Use of Eµ-myc/bcl-2 lymphoma transplantation. 
We identified many advantages to using this lymphoma as a 
transplant to alternative hosts rather than using the transgenic Eµ-
myc mice themselves. The nature of the original transgenic model is 
that malignant clones can potentially arise at a number of different 
stages of maturation of lymphoid cells. As such, T-lymphomas as well 
as B-lymphomas were reported, as well as varieties of pre-B, pro-B 
and mature B-cell clones. We set out to work with a mature B-cell 
malignancy and so by characterizing a large mature B-cell population 
we were able to keep this as a constant between and within 
experiments, and propagate the population in immune-competent 
hosts. Critically, we were intent on studying the innate immune 
response to lymphoma. Within the original Eµ-myc transgenic host, 
the non-malignant immune cells (in particular the lymphocytes) may 
not be entirely normal in number and function. Transplantation has 
allowed me to investigate the interactions between lymphoma and a 
competent immune system that we were able to manipulate 
subsequently, and also between lymphoma and genetically altered 
hosts, such as MaFIA mice.  
However, although the Eµ-myc/bcl-2 lymphoma was generated upon 
a C57BL/6 background, the potential for antigraft immune reactions 
must be considered. Use of immunocompromised mice might 
attenuate such reactions, but would prove an even less satisfactory 
means of studying lymphoma-macrophage interactions.   The ideal 
situation for some of our experiments might be to study 
spontaneously arising mature B-lymphomas in fully immune 
competent mice. This is not readily available in sufficient numbers 
and would not provide the same opportunities for using genetically 
modified hosts.  
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12.3 Consideration of the role of IL-6. 
A unifying hypothesis that could be generated from this work, and tested by 
future studies, is that macrophage derived IL-6 drives lymphoma proliferation. 
Reflecting on the literature, this seems plausible. Becker et al. provided 
evidence that myeloid cell orchestration of IL-6 production was critical in tumour 
progression (Becker et al., 2004). Gilbert and Hemann reported that IL-6 
promoted the survival of a variant of Eµ-myc lymphoma cells during exposure to 
doxorubicin in vivo and in vitro, with IL-6 genetic knockout mice with 
transplanted lymphoma having prolonged survival (Gilbert and Hemann, 2010). 
As summarised in the figure below, chemotherapy caused genotoxic stress to 
thymic endothelial cells which, via Janus associated kinase 2 (JAK2) signalling 
and p38 MAPK activation caused ataxia telangiectasia-mutated (ATM) 
independent IL-6 release and so acute induction of anti-apoptotic BcXL in 
lymphoma cells within this chemoresistant thymic endothelial cell niche.  
!
Figure 154 - Summary of mechanisms proposed by Gilbert and Hemann. 
Given that we also used a variant of the Eµ-myc lymphoma, the question arises 
as to how far their findings are relevant to our model. Perhaps of significance is 
that the different variant Eµ-myc lymphoma we used already constitutively over-
expresses anti-apoptotic Bcl2, causing widespread, perhaps non-niche 
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dependent relative chemo-resistance. We measured high levels of circulating 
IL-6 in mice with Eµ-myc/bcl-2 lymphoma. Perhaps, in the model we studied, 
constitutive BCL2-mediated chemoresistance is further augmented by 
advanced disease and rising IL-6 levels, and this element of chemoresistance 
might be amenable to therapeutic intervention.  
It remains to be demonstrated how much IL-6 is macrophage derived and so 
potentially providing a mechanism whereby CSF-1R inhibition might reduce IL-6 
production by reducing TAM numbers, and so maybe increase constitutive or 
chemotherapy-induced apoptosis. Additionally, the CSF-1Ri used is a small 
molecule tyrosine kinase inhibitor, and in line with the work of Gilbert and 
Hemann, it seems sensible to wonder to what extent it also produces a degree 
of JAK2/3 inhibition, thus potentially giving a mechanism for reduced IL-6 
production, other than simply a reduction in the number of TAM. Looking 
beyond apoptosis it is necessary to consider what role IL-6 has with regards 
lymphoma cell proliferation in the model we used. Does IL-6 directly promote 
the proliferation of Eµ-myc/bcl-2 lymphoma cells? IL-6 certainly appears to 
promote a tumour permissive immune response (Kortylewski et al., 2005) 
including an M2 phenotype (Duluc et al., 2007, Jeannin et al., 2011) via STAT3 
activation so providing an indirect mechanism for influencing lymphoma 
progression. In a mouse model of breast cancer, Fra-1, a transcription factor 
upstream of STAT3, is both overexpressed in TAM and can also stimulate IL-6 
production, itself further activating STAT3 (Luo et al., 2010). In the light of the 
work by Roca et al. it seems logical that future work investigates the impact of 
macrophage manipulation on CCL2 levels in mice with lymphoma, and whether 
levels of this chemotactic cytokine are affected by CSF-1R inhibition and 
macrophage ablation (Roca et al., 2009b).  
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13 Summary. 
The following positive statements can be made regarding the experimental 
results of this project:  
1) In treatment naïve diagnostic specimens of DLBCL, macrophages 
express CD163, a marker of alternative activation, and their number is 
positively correlated with the lymphoma proliferation rate. 
2) LC depletes macrophages in mice and is associated with less Eµ-
myc/bcl-2 lymphoma at sacrifice. 
3) Activating the macrophage death construct in transgenic MaFIA mice 
results in macrophage depletion and attenuated Eµ-myc/bcl-2 lymphoma 
growth. 
4) AT of M1 macrophages in mice is associated with less Eµ-myc/bcl-2  
lymphoma at sacrifice than is AT with TAM. 
5) Established Eµ-myc/bcl-2 lymphoma is associated with a rise in 
circulating concentrations of IL-10 and IL-6. 
6) CSF-1R inhibition in mice causes a reduction in total circulating 
monocyte numbers, an increase in circulating granulocytes, and a 
reduction in TAM numbers. This is associated with decreased Eµ-
myc/bcl-2 lymphoma in lymph nodes and blood at sacrifice. In the blood 
this is associated with reduced IL-6 and increased IFN-# levels. In lymph 
nodes it is associated with decreased lymphoma cell proliferation.  
Having used CSF-1R inhibition and observed a reduction in monocyte numbers 
in the blood and a reduced number of TAM, it seems most obvious to infer that 
this reflects attenuated production and recruitment of monocytes from the blood 
to tissues. However, this is not necessarily the entire picture, and it might be 
that CSF-1R inhibition impacts on the already resident TAM by reducing their 
survival and the in situ proliferation of their precursors. 
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13.1 Implications for future research. 
Several key questions are raised by our data. We will outline those questions 
below, before exploring how they might be addressed in the laboratory. 
1) Not only do macrophages appear to promote lymphoma in this 
model, but the TAM phenotype appears to be specifically pro-
tumoural, as opposed to either the M1 or M2 phenotypes. What is 
the TAM phenotype in this model? What are the key features of the 
TAM phenotype that promote lymphoma in this model? 
Future work will focus on isolation and comparison of macrophage populations 
from lymph nodes of normal mice, compared with those from mice injected with 
lymphoma. Comparison will be made by flow cytometry analysis, to determine 
macrophage phenotype and subpopulations, as well by RNA extraction and 
gene expression analysis. Macrophages would ideally be isolated without delay 
from fresh tissue, selected by as few steps and as little processing as possible, 
so as to minimise alterations to viability, gene expression and surface markers. 
We propose to use FACS to isolate lymph node infiltrating macrophages from 
normal healthy C57BL/6 mice and from such mice 10 days after the 
transplantation of Eµ-myc/bcl-2 lymphoma cells. Single cell suspensions will be 
created from freshly harvested lymph nodes and stained with fluorescent 
antibodies. 
Tissue macrophages will be sorted using the following profile: 
1) CD19 negative 
2) CD11b positive 
3) Ly6G negative 
Characterization of these cells will be performed by analyzing the selected 
population for expression of F4/80 and CFS-1R. 
All stages of the process will carried out simultaneously for each group of mice 
and macrophages, under identical conditions at the same time, from purchasing 
and housing the mice to sorting the macrophages by FACS. This will be critical 
in minimising potential artefact differences between the groups. This approach 
will produce a sufficient number and purity of macrophages that RNA extraction 
for whole genome expression analysis should be feasible.  
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2) How is the TAM phenotype acquired? Is it driven by lymphoma 
cells, and if so, what are the relative contributions of secreted 
substances versus cell-cell contact? Can key elements in this 
process be identified, and potentially targeted? 
Once key elements of the TAM phenotype have been established on a gene 
expression level, we will interrogate macrophages in the in vivo setting of 
transplantable Eµ-myc/bcl-2 lymphoma for their expression as proteins. This will 
then herald in vitro co-culture of Eµ-myc/bcl-2 lymphoma cells and BMDM to 
investigate the acquisition of the TAM phenotype, and mechanisms responsible 
for it. We will perform co-culture with direct cell-cell contact and also using 
Transwell( (Corning() chambers to prevent cell-cell contact and allow only 
diffusible substances. Blocking and stimulation experiments will allow 
investigation of the role of candidate molecules in the polarization of BMDM 
towards a pro-tumoural TAM phenotype. 
3) The relationship between lymphoma and its microenvironment 
appears to be bidirectional. In what way do changes to the number 
of phenotype of macrophages impact on lymphoma biology? More 
specifically, and perhaps more relevant to the clinic, what changes 
occur to lymphoma cells with CSF-1R inhibition and the resultant 
reduction in monocyte and TAM numbers? 
Similarly to the approaches outlined in the 2 points above, malignant B-
lymphocyte biology will be studied by FACS isolation and gene expression 
analysis from different in vivo scenarios of Eµ-myc/bcl-2 lymphoma, including 
untreated and macrophage deplete and CSF-1R inhibited. Co-culture 
experiments can also be employed to investigate key molecular and genetic 
events. 
4) Why does the consistent reduction in lymphoma mass at sacrifice 
seen with macrophage depletion not translate in to a survival 
benefit? If this is because the model used is too aggressive to allow 
us to measure a potential benefit, then what is the impact of 
macrophage depletion and/or CSF-1R inhibition on more indolent 
models of lymphoma, that one might speculate are more vulnerable 
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to changes in the microenvironment than aggressive MYC-driven 
lymphomas? 
An aggressive model of lymphoma has allowed me to perform transplantation of 
lymphoma to immunocompetent mice, and also to make and repeat these initial 
observations in a relatively short period of time. With evidence having been 
collected supporting proof-of-principle, it is attractive to further investigate such 
strategies in a more indolent model of lymphoma. It is the most common 
indolent lymphoma, FL, for which there is the largest and most persuasive body 
of evidence supporting a role for TAM. Relapsing repeatedly and being 
ultimately incurable, FL is perhaps more likely than DLBCL or BL to present 
frequent opportunities for the introduction of novel agents in early stage clinical 
trials.  
5) Can the potential benefits of CSF-1R inhibition be translated into 
the clinic? 
There is a limit to how far any mouse model can be used to usefully derive 
insights into human disease. Having found evidence that CSF-1R expressing 
TAM and the progression of B-NHL are related in our model, possibly involving 
IL-6 and rates of lymphoma cell proliferation, we are further interrogating our 
extensive bank of human tissue for correlative evidence regarding IL-6, the 
CSF-1R and IFN-#.   
Since the beginning of this project, the number of publications exploring CSF-
1R inhibition has greatly increased, with critical reviews by opinion leaders in 
macrophage biology adding support to the translation of laboratory studies into 
the clinic (Hume and Macdonald, 2012). An orally available small molecule 
CSF-1R inhibitor, PLX3397 (Plexxikon) has entered phase 1 clinical trials in 
metastatic cancers and phase 2 trials in Hodgkin lymphoma. It is reported to 
have additional inhibitory effects on other type III receptor tyrosine kinase 
molecules, KIT and FLT3. It will be interesting to follow these trials as they 
report. It would be fascinating to use this compound in mouse models of B-NHL 
to provide pre-clinical evidence in support of clinical trials. 
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6) Is macrophage derived IL-6 a key cytokine driving lymphoma 
proliferation in this model, as suggested by plasma IL-6 
measurements? 
As described earlier, IL-6 appears to have many and varied roles in the 
formation and progression of cancers. In regard to B-cell malignancies, IL-6 is 
extensively documented to be critical in the formation (Hilbert et al., 1995), 
survival and progression of multiple myeloma, a plasma cell neoplasm. Further 
laboratory studies are necessary to elucidate the role for IL-6 in this model. 
Gene expression analysis of sorted macrophages and lymphoma cells will 
inform whether the genes for IL-6 or the IL-6 receptor are upregulated in 
macrophages and lymphoma cells respectively. Supplementing or blocking IL-6, 
over-expressing or knocking out the IL-6 gene in vitro and in vivo, will be 
important initial steps. Therapeutic anti IL-6 antibodies and anti IL-6 receptor 
antibodies have been manufactured and are at various stages of development 
in inflammatory diseases and cancers, including multiple myeloma. The effects 
of such antibodies could be studied in relation to TAM-lymphoma interactions in 
the Eµ-myc/bcl-2 and other mouse models of B-NHL. 
7) What cytokine changes occur within lymph nodes with CSF-1R 
inhibition and the subsequent reduction in TAM numbers? 
We have found changes in circulating cytokine levels that provide clues as to 
important biological mechanisms during lymphoma progression and resulting 
from CSF-1R inhibition. Focusing on such changes within lymph nodes might 
provide more relevant information regarding the specific interactions between 
malignant B-lymphocytes and their immediate microenvironment. We are 
currently optimising techniques to measure cytokines from mouse lymph nodes.  
8) In the light of failing to demonstrate any additional benefit of 
combining macrophage depletion with cyclophosphamide, can 
benefit be demonstrated with alternative treatment schedules, or 
alternative cytotoxic or immunomodulatory agents?  
Additive and possibly synergistic impacts might be gained by targeting different 
aspects of the lymphoma microenvironment simultaneously. Reducing TAM 
numbers by CSF-1R inhibition might be most efficacious when combined with 
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other immunomodulatory drugs such as Lenalidomide, perhaps also in addition 
to traditional cytotoxic chemotherapy. This raises the prospect of improved 
responses in terms of lymphoma growth, and might translate to survival benefits 
in this or more indolent models. 
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13.2 Concluding statement. 
In this project we have critically reviewed the relevant literature relating to TAM 
and lymphoma. We have conducted a series of related laboratory experiments 
that provide support for a relationship between the presence and function of 
TAM and the progression of B-cell lymphoma. This thesis includes the first 
reports of whole organism functional data supporting the strategy of CSF-1R 
inhibition in the treatment of B-cell lymphoma. Future pre-clinical work in this 
field will define more precisely the critical cellular, molecular and genetic events 
responsible for monocyte-macrophage depletion and retardation of lymphoma 
growth that we have observed with this promising strategy. We speculate that 
defining the optimal timing and delivery of CSF-1R inhibition in relation to other 
therapies will be crucial in deriving benefit from this novel approach to the 
treatment of B-NHL.  
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Buffers and Solutions !
Flow cytometry staining buffer 
PBS with 3% foetal calf serum (FCS) 
 
Eµ-myc/bcl-2 lymphoma culture media 
400 ml  Dulbecco’s modified eagle medium (DMEM) 
10%    FCS 
1%   Penicillin-Streptomycin 
4 ml  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) 
7 µl  of 50 mM "-mercaptoethanol  
12 ml  of 10 mM  L-Asparaginase  
 
Vehicle for CSF-1Ri (*requires sterile filtration with 0.22 µm filter) 
Sterile water 
0.1%    Tween( 80 
0.5%    methylcellulose 
 
Vehicle for AP2087 dimerizer (*requires sterile filtration with 0.22 µm filter) 
   Sterile water 
4%    ethanol 
10%    polyethylene glycol (PEG-400) 
1.7%    Tween( 80 
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Flow cytometry antibody reference table 
All flow cytometry antibodies were raised in rats and diluted 1:100. 
P34-Q&C/+ =.5&%&$(%&6*+ "#35;#$45%*%+ ?*;*%*3$*+ R2&4/'*+
!""#$ %&'$ ()*+,-*(.-($ /01#23"$ 456$789"5:$;$
'<//)$ (=>?+@23#$ ()*+,-*(.-($ 2A1#//"$ 456$789"5:$;$
'</BCD"$ &E$ ()*+,-*(.-($ /"1#/B/$ 456$789"5:$F$
'</G$ &E$ ()*+,-*(.-($ /"1#/GD$ 456$789"5:$;$
'<D$ %>(H5$=>?+@$0##$ ()*+,-*(.-($ 3B1##D"$ 456$789"):$;$
'I=4/$
&(@'&1
(=>?+@0/#$ ()*+,-*(.-($ 2B1//3"$ 456$789"5:$;$
'I=4/$ &E$ ()*+,-*(.-($ /"1//3"$ 456$789"5:$;$
=2CA#$ =7J'$ ()*+,-*(.-($ //12A#/$ 456$789"5:$;$
=2CA#$ &E$ ()*+,-*(.-($ /"12A#/$ 456$789"5:$;$
=2CA#$ &E1'K0$ ()*+,-*(.-($ "312A#/$ 456$789"5:$;$
7=L8$ 'K3$ ()*+,-*(.-($ /G10D//$ 456$789/:$;$
78<$ %&'$ ()*+,-*(.-($ /013GGD$ 456$789"5:$;$
78M$ (=>?+@0/#$ ()*+,-*(.-($ 2B130G#$ 456$789"5:$;$
FKB'$ %&'$ ()*+,-*(.-($ /013GD"$ 456$789"-$
FKB9$ %>(H5$=>?+@$0##$ ()*+,-*(.-($ 3B13GD/$ 456$789"):$;$
FKB9$ =7J'$ ()*+,-*(.-($ //13GD/$ 456$789"):$;$
MN'$77$ %&'1(=>?+@0A#$ ()*+,-*(.-($ 2013D"/$ 456$789"):$;$
MN'77$ =7J'$ ()*+,-*(.-($ //13D""$ 456$789")$
M4$$ &E$ )*+>(8(.O$ 141706 789"5$
Table 12 - Flow cytometry antibodies. 
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